# REPORT TO THE NEW YORK STATE DEPARTMENT OF HEALTH

# New York State Medical Indemnity Fund 2<sup>nd</sup> Quarter 2020 Actuarial Analysis As of June 30, 2020 REVISED

June 2021



3109 Cornelius Drive Bloomington, IL 61704 309.807.2300

pinnacleactuaries.com

**Commitment Beyond Numbers** 

# **Table of Contents**

SECTION	PAGE
PURPOSE & SCOPE	1
EXECUTIVE SUMMARY	2
BACKGROUND	4
DATA, METHODS & ASSUMPTIONS	6
PARTICIPANTS WITH \$0 IN BENEFIT PAYMENTS	8
PARTICIPANTS WITH LESS THAN \$25,000 IN ANNUAL BENEFIT PAYMENTS	8
PARTICIPANTS WITH MORE THAN \$400,000 IN ANNUAL BENEFIT PAYMENTS	9
DISCUSSION AND ANALYSIS	10
NUMBER OF QUALIFYING PARTICIPANTS	10
MORTALITY EXPERIENCE/LIFE EXPECTANCY	11
ACTUARIAL CALCULATION OF ESTIMATED FUND LIABILITIES	12
AMOUNT OF BENEFITS PAID	14
PATTERNS OF UTILIZATION	14
BENEFIT PAYMENTS AND INJURY TYPE	17
INFLATIONARY PATTERNS OF TYPES OF SERVICES	21
ADMINISTRATIVE EXPENSES	22
IMPACT OF AVAILABLE HEALTH INSURANCE	23
INVESTMENT EARNINGS	23
DISTRIBUTION & USE	24
RELIANCES & LIMITATIONS	25

**EXHIBITS** 

**APPENDICIES** 

# New York State Medical Indemnity Fund

2<sup>nd</sup> Quarter 2020 Actuarial Analysis

As of June 30, 2020

# Purpose & Scope

Pinnacle Actuarial Resources, Inc. ("Pinnacle") has been retained by the New York State Department of Health (NYS DOH or "the Department") to provide quarterly actuarial reports regarding the experience of the New York State Medical Indemnity Fund (MIF or the Fund). Previously, Pinnacle performed this service for the New York State Department of Financial Services (NYS DFS). This analysis evaluates data for the Fund as of June 30, 2020.

§69-10.19 of the New York State Department of Health Regulation states that the quarterly reports should "include a review of the various elements contributing to the amount of benefits paid by the Fund and to the expenses of administration of the Fund, including:"

- The number of qualifying plaintiffs
- The mortality experience of the qualified plaintiffs
- The amount of benefits paid by the Fund
- The patterns of utilization of types of services provided
- Inflationary patterns by types of services provided
- The expenses of administration of the Fund
- The impact of available health insurance on benefits paid by the Fund, and
- Investment earnings of the Fund

§69-10.20 of the New York State Department of Health Regulation also requires an actuarial calculation of the estimated liabilities of the Fund for the coming year resulting from the qualified plaintiffs enrolled in the Fund.

### **Executive Summary**

Based on our review of available information regarding the New York State Medical Indemnity Fund as of June 30, 2020, Pinnacle has arrived at a number of key conclusions:

- As of June 30, 2020, the Fund has accepted 731 participants (719 living) with expected future benefit payments of approximately \$2.078 billion and future administrative expenses of \$230.2 million, assuming a discount rate of 2.0% and future medical inflation of 3.0%. With a Fund balance as of June 30, 2020 of approximately \$231.0 million, this results in an unfunded liability for the Fund of approximately \$2.077 billion. The increase in unfunded liability from our analysis as of March 31, 2020 is due to the addition of 23 new participants over the past quarter as well as the removal of the sunset for the current benefit payment rates. As of June 30, 2020, the Fund's current liabilities for the upcoming 2021-2022 fiscal year of \$74.6 million are 32.3% of the Fund's current assets of \$231.0 million. We expect this ratio to increase to 93.2% by fiscal year-end 2023-24.
  - For the fiscal year prior to the impact of legislation signed on December 31, 2016 (4/1/16-3/31/17, the 2016-17 fiscal year), the average benefit payments per participant were \$12,310 per quarter for a total of \$21.100 million paid in benefits during this fiscal year. Living participant counts increased from 400 to 455 over this period (an increase of 55 participants). See the Payments Per Participant Summary for more detail regarding these numbers.
  - o On December 31, 2016, new legislation was signed expanding eligibility for the Fund to non-hospital births and significantly raising reimbursement rates for the period from July 1, 2017 through December 31, 2019. The period for these increased reimbursement rates was later extended to December 31, 2020 as part of the New York State budget. These increased rates are now in effect until December 31, 2021, and for this analysis we have been asked by the NYS DOH to assume that the increased rates will continue in perpetuity. For the most recent four quarters of the Fund (7/1/2019-6/30/2020), average benefit payments per participant were \$18,864 per quarter, representing a 53.2% increase over the average payments in the 2016-17 fiscal year. Total benefits paid were \$51.179 million for these four quarters, representing a 142.6% increase in payments over the 2016-17 fiscal period, while living participant counts increased from 628 to 719 over this period (an increase of 91 participants). Total annual benefit payments are anticipated to increase annually as more participants are added to the Fund. See the Payments Per Participant Summary for more detail regarding these numbers.
  - Previous analyses contemplated the "sunset" of the 2016 legislation expected to occur on December 31, 2021. The Department has requested that we remove this assumption

from the current analysis and our exhibits reflect this removal. With this assumption removed, the Fund is expected to surpass the 80% threshold for current liabilities to assets by year-end 2023-24 and this analysis contemplates no new participants added after that time.

- o Total future lifetime benefits for the 719 living Fund participants without discounting is estimated to be \$4.212 billion. See Exhibit 2, Page 2.
- The current present value of future benefit payments of \$2.078 billion does <u>not</u> consider any additional enrollees that may be admitted to the Fund in the future.
- Prior to the beginning of the fiscal year, the Fund was expected to have approximately eighty-seven (86.6) additional participants accepted between March 31, 2020 and March 31, 2021. Historically, more participants are admitted in the first quarter of the fiscal year than in successive quarters of the fiscal year; we have incorporated this observation into our expected participant counts per quarter (see Exhibit 3).
  - There were twenty-three (23) new participants to the Fund in the first quarter of fiscal year 2020-21, approximately five (5) less than expected for this period at the beginning of the fiscal year. It's possible that court closures due to the COVID-19 pandemic may have slowed new participant enrollment in the Fund.
  - The 2019 budget legislation eliminated the Fund administrator's discretion in determining whether plaintiffs are qualified for the Fund. It's possible we will see higher participation rates in the future due to this change.
- Actual benefit payments in the first quarter of the 2020-21 fiscal year (4/1/20-6/30/20) as of 6/30/20 were \$13.122 million. This amount is \$1.404 million lower than expected at the prior quarterly analysis. Benefits payments may appear low for the current quarter due to the waiver of timely filing requirements in light of the COVID-19 pandemic. Based on modeled severities and an expected 58.89 additional participants, expected benefit payments in the remaining three quarters of the 2020-21 fiscal year are \$45.910 million. Estimated total benefit payments for the 2020-21 fiscal year (4/1/20 3/31/21) are therefore \$59.032 million, compared to \$52.816 million estimated at the March 31, 2020 analysis. See Exhibit 3 for more detail regarding these numbers. It is important to recognize that these amounts can vary significantly each quarter due to the inherent uncertainty in benefit payments and the effect of the legislative changes on payments. In particular, these amounts contemplate no sunset for the increased reimbursement rates which is a change from prior reports.

- As of September 1, 2018, both the Fund's claims handling and enrollment services are now provided by Public Consulting Group (PCG) instead of Alicare. This change is ultimately expected to decrease the administrative expenses of the Fund on a per month per member basis. Based on information from the NYS DFS, at the March 31, 2020 analysis we projected that \$5.788 million would be spent in administrative costs for the 2020-21 fiscal year (see Exhibit 2, Page 1 of our report for 2020 Q1). This number was based on expected, not actual, participant counts and excludes Department expenses allocated to the Fund. We have included Department expenses in the current analysis. We expect the annual administrative expense to decrease on a per member basis over the next few years due to economies of scale.
- Exhibit 1 summarizes Fund payments by benefit type since 4<sup>th</sup> quarter of 2012. Compared to
  the Virginia Birth Related Neurological Injury Compensation Fund, another state-run birth injury
  fund serviced by Pinnacle, the Fund is having a substantially higher percentage of overall costs
  in medical and hospital costs, medical equipment and prescription drug costs, and
  corresponding lower percentages in nursing and long term care costs.
- As of June 30, 2020, fifty (50) participants have received more than \$1 million in benefit payments, with fifteen (15) of these participants receiving more than \$2 million in benefit payments. Based on current annual severities by individual member, we expect seven (7) more members to cross the \$1 million threshold in the next twelve months. These benefit payments do not include prescription amounts handled in bulk by vendors; see Exhibit 7, page 10 for total prescription drug payments handled in bulk.
- In response to the COVID-19 pandemic, two changes were made to Fund benefits payments. Benefits were temporarily expanded to include cleaning and disinfectant products in certain cases. In addition, timely filing requirements were temporarily waived. These changes remain in effect as of June 30, 2020.
- The \$52 million annual funding for the Fund will not be received for the 2019-20 fiscal year. We have removed this funding amount from our calculations.

# **Background**

"The Medical Indemnity Fund was established in 2011 to provide a funding source for future health care costs associated with birth-related neurological injuries. Enrollees of the Fund are plaintiffs in medical malpractice actions who have received either court-approved settlements or judgments deeming the plaintiffs' neurological impairments to be birth-related." More specifically, a "birth-related neurological injury" is "an injury to the brain or spinal cord...that occurred in the course of

<sup>&</sup>lt;sup>1</sup> Provided by NYS DFS

labor, delivery or resuscitation, or by the provision or non-provision of other medical services during the delivery admission."<sup>2</sup> These injuries must result in a physical impairment, a developmental disability, or both.

Benefits provided by the Fund include:

- Medical, Dental, Surgical and Hospital Care
- Nursing and Custodial Care
- Prescription and Non-Prescription Drugs
- Rehabilitation Services
- Durable Medical Equipment and Assistive Technology
- Certain Home and Vehicle Modifications
- Other Health Care Costs for Medical Services and Supplies for Participants

The NYS DOH serves as the administrator of the Fund. Beginning on October 1, 2019 the New York State Department of Health (NYS DOH) replaced the NYS DFS as the Fund's administrators. For the first year of the MIF's operations, Sedgwick CMS served as the Fund's third party administrators (TPA). For the second year of operations, they were replaced by Alicare. As of September 1, 2017, claims are now handled by PCG while Alicare continued to work with Fund enrollment and case management until September 1, 2018. PCG now handles enrollment services as well as claims. Pinnacle serves as the actuarial advisors to the Fund as well as the only other two state-run birth injury funds in the U.S., the Virginia Birth Related Neurological Injury Compensation Fund and the Florida Neurological Injury Compensation Association.

The Fund currently is financed through a budget allocation from the state of New York. Any party to a medical professional liability claim can request for the judgment to reflect eligibility for participation in the Fund. Upon this judgment, the participant is eligible to receive covered benefits from the Fund.

According to part 6(a) of section §2999-i of the New York Public Health Law Title 4:

"the superintendent of financial services shall conduct an actuarial calculation of the estimated liabilities of the fund for the coming year resulting from the qualified plaintiffs enrolled in the fund....If the total of all estimates of current liabilities equals or exceeds eighty percent of the fund's assets, then the fund shall not accept any new enrollments until a new deposit has been made pursuant to subdivision five of this section. When, as a result of such new deposit, the fund's liabilities no longer exceed eighty percent of the fund's assets, the fund administrator shall enroll new qualified plaintiffs in the order that an application for enrollment has been submitted in accordance with subdivision seven of section twenty-nine hundred ninety-nine-j of this title."

<sup>&</sup>lt;sup>2</sup> http://www.dfs.ny.gov/insurance/mif/mif faqs.htm

In addition, part 6(d) states that "suspension of enrollment....shall not impact payment under the fund for any qualified plaintiffs already enrolled in the fund."

### **Data, Methods & Assumptions**

Given that the Fund has been in operation for less than ten years, a number of sources of information are still in the formative stages. Pinnacle has worked with Alicare and is working with PCG to ensure that their claims databases are sufficient to support these ongoing quarterly reports and to enhance the ongoing management of the Fund.

Early in the Fund's operations, some health care benefits that should have been paid by the Fund were erroneously paid by New York Medicaid. Pinnacle was provided detailed benefit payment information on these costs by the NYS DOH and they are reflected in the exhibits.

Some of the long-term forecasts and industry benchmarks used in the analysis are based on data for the birth injury funds in Virginia and Florida, as well as medical professional liability insurers in the state of New York. These have been significantly modified based on data from the Fund as it becomes more credible.

Assumptions that we are currently monitoring include:

- Benefit payment patterns
- The lag between a participant's birth and joining the Fund
- Participant mortality rates
- The rate of medical inflation in the state of New York
- Appropriate rates for discounting benefit payments
- Projected administrative expenses over a participant's lifetime

One significant area of ongoing review of assumptions relates to the expected number of claims per 10,000 live births. Initially, 1.10 participants per 10,000 births were assumed based on data from Virginia and Florida. After the first year, the frequency rate was increased to 2.90 participants per 10,000 births. In the first quarter 2014 report, the expected number of eligible Fund participants was increased from 2.90 per 10,000 live births to 3.48 to be more consistent with the first two full fiscal years of experience and present more realistic financial projections for the next five years. In late 2016, we increased the assumption to 4.50 participants per 10,000 births to better reflect ongoing frequency data. It should be recognized that this is over four times the number of participants per 10,000 live births experienced by the birth funds in Florida and Virginia. Starting with the March 31, 2018 analysis, we reduced this assumption to 4.00 participants per 10,000 births to acknowledge lower than expected Fund participation rates. Due to recent changes in the Fund and the admittance of

participants with less severe diagnoses such as ADHD and autism, we may find it necessary to revisit these frequency assumptions.

As we are accumulating more credible amounts of benefit payments data, several differences are emerging from Virginia's birth fund experience. To illustrate, we show the annual benefit payments during calendar years 2017, 2018 and 2019 to Fund participants that were admitted to the program prior to the beginning of each year and were living at the conclusion of the calendar year (i.e. participants that have a full year of benefit payments) on the following graph and compare the Fund's data to data from Virginia. Additional severity information is contained in Exhibit 1, Page 2 and Exhibit  $6^3$ .




Chart 1: Calendar Year Payments Received by Participants

This comparison raises three key issues. We will pose each issue as a question, then offer more comments below.

1) The Fund has significantly more participants with \$0 of benefit payments during the year. Will these participants have benefit payments at some point?

<sup>&</sup>lt;sup>3</sup> The remaining portion of the *Data, Methods and Assumptions* section has been updated for the MIF 2019 Q4 report. This section is updated annually as another calendar year of data emerges.

- 2) The Fund has substantially more participants with less than \$25,000 in annual benefit payments. Is there something about the Fund's enabling legislation that is causing this or will their costs increase over time?
- 3) The Fund had eight participants in 2017, twenty-two participants in 2018, and twenty-six participants in 2019 with annual benefit payments totaling over \$400,000. Virginia's birth fund has only one participant that breached this threshold. Admittedly, there are sample size issues, but will this phenomenon continue to persist?

# Participants with \$0 in Benefit Payments

To address the first issue, we analyzed the participants that had been in the Fund for more than one year as of December 31, 2019. We found that of these participants, 8% showed \$0 in benefit payments as of December 31, 2019. Approximately 3% of participants showed only prescription drug payments through vendors based on schedules provided by PCG. We also grouped participants based on number of years in the Fund and found that these percentages are similar to those in our 2018 year-end analysis:

		Number of	Percentage of
	Number of	<b>Participants</b>	Participants
Time in Fund	<u>Participants</u>	With Payments	With Payments
3 years or longer	456	430	94.3%
2 years or longer	529	493	93.2%
Longer than 1 year	583	538	92.3%

Table 2: Participants with Payments (in the Fund longer than 1 year)

Based on the data collected so far and assuming no significant changes in health insurance, we believe it is reasonable to assume that 6% of Fund participants will not receive any benefit payments over their lifetimes. Hence while 22% of the participants in the graph above showed \$0 in payments for calendar year 2019, we expect that over the long run only 6% of participants will receive \$0 in benefit payments.

# Participants with Less than \$25,000 in Annual Benefit Payments

The second issue, a higher number of participants with less than \$25K in annual payments, may be related to the difference in the definition of "birth-related injury" between the Fund and Virginia. In Virginia, participants must be "permanently motorically disabled <u>and</u> developmentally disabled or cognitively disabled (emphasis added)" as well as "need assistance with all daily living activities." The New York Fund requires either a physical <u>or</u> mental disability (emphasis added); both types are not required. Several of the Fund's patients have injury diagnoses that tend to be physical-only injuries, particularly Brachial Plexus and Erb's Palsy. These injury types show significantly lower severities than

<sup>&</sup>lt;sup>4</sup> From vabirthinjury.com/eligibility-benefits-claims

other types (see Exhibit 1, Page 2); while 12.0% of Fund participants have one of these diagnoses, they have accounted for just over 0.5% of the Fund's total payments. However, physical-only or mental-only disabilities classified within other injury categories may also be contributing to the low severities. We do not have the detailed diagnosis information to further explore this hypothesis.

Over the long term, we show that nearly 60% of participants will receive more than \$25K in benefit payments:

		Number of	Percentage of
	Number of	Participants	Participants
Time in Fund	<u>Participants</u>	With >\$25K Paid	With >\$25K Paid
3 years or longer	456	271	59.4%
2 years or longer	529	304	57.5%
Longer than 1 year	583	323	55.4%

Table 3: Participants with At Least \$25K Paid (in the Fund longer than 1 year)

Previously, long term benefit payments shown in this table did not include prescription/non-prescription drug payments currently handled in bulk by Fund vendors. This exclusion made a significant difference; in the third quarter of the 2019-20 fiscal year, 94% of prescription/non-prescription drug costs were handled in bulk (compare current quarter vendor payments at the bottom of Exhibit 7 to total prescription payments on Exhibit 1, page 1). We are now regularly provided with vendor schedules by PCG which allows us to approximate prescription drug payments by member. We therefore include these payments when reviewing Fund utilization by member, but for accuracy we do not include these values when calculating average severities or calendar year payments by member.

### Participants with More than \$400,000 in Annual Benefit Payments

The phenomenon mentioned in the third issue, participants with very large annual payments, has continued to grow since 2016. In calendar year 2017, eight participants received more than \$400K in benefit payments. In calendar year 2018, this number increased to twenty-two with one member receiving over \$1 million in benefit payments. Most recently in calendar year 2019, twenty-six participants received more than \$400K in benefit payments with three members receiving over \$1M in benefit payments. Taking a long-term view, ten of the twenty-six participants show an average annual benefit cost of over \$400,000 per year of membership in the Fund. These numbers are also prior to any allocation of prescription/non-prescription drug payments processed in bulk by Fund vendors. We reviewed payments by category (other than prescription/non-prescription drugs) for these twenty-six participants in order to determine whether large one-time payments (such as hospitalizations or home modifications) could be responsible for this increase. We found that nearly 80% of payments in 2019 for these members were due to nursing costs, a similar result to our 2018 analysis. Two members received more than \$1 million in nursing costs in 2019. Since nursing costs are expected to result in

regular, ongoing benefits (and quarterly payments) over time as opposed to one-time expenses, it is likely that these high payment levels will continue, and continue to increase, for these participants and others in the future.

We are continuing to monitor these phenomena and will continue to add additional analysis as appropriate and as more information emerges.

As frequency and severity patterns were observed over time, changes to the assumptions regarding the expected frequency and severity of claims were made to the 4th quarter 2014 analysis and again in the second quarter of 2016 due to observed frequencies and severities differing from original assumptions. These assumptions are detailed above in this report. Furthermore, we expect to continue monitoring participation frequency and re-visit our selections regularly.

# **Discussion and Analysis**

# Number of Qualifying Participants

Based on the loss runs provided by Sedgwick CMS, Alicare, PCG and DOH, valued as of June 30, 2020, there are seven hundred and thirty-one (731) participants that have qualified for the Program as of this date; seven hundred and nineteen (719) were still living as of June 30, 2020. This information is summarized in Exhibit 6, Page 2.

There were twenty-three (23) new participants to the Fund in the first quarter of fiscal year 2020-21, approximately five (5) fewer than expected for the quarter. Instead of assuming uniform admittance throughout the year, we now incorporate the apparent pattern of a higher admittance rate near the beginning of a fiscal year. This change was first introduced in the June 30, 2019 analysis.

In 2019, legislation passed as part of the New York State budget included procedural amendments for the Fund. One particular change removes the Fund administrator's role in determining if a plaintiff is a "qualified plaintiff" and therefore eligible for the Fund. Since this change became effective on October 1, 2019, ninety-two (92) participants have been admitted into the Fund.

The number of Fund participants and the distribution of participants by age warrants continued monitoring. The average age of a Fund participant at the time of admission is about 8.9 which is approximately four years older than the age of a Virginia Birth Fund participant at admission. Since the 2015-16 fiscal year, average age of admittance is higher at 9.2 years. Average admittance age for the most recent quarter is 9.4 years.

Based on the Fund's statutory limitations, we expect that the 80% threshold of current assets to liabilities will be breached by year-end 2023-24, resulting in no new participants added after that time[NC1].




Chart 4: Average Entry Age of Fund Participants Since 2015-16 Fiscal Year

# Mortality Experience/Life Expectancy

It is reasonable to expect that average life expectancies for Fund participants will average in the high twenties as a group, unless the different admission standards materially change life expectancies relative to the Virginia and Florida birth funds. The current life expectancies of the Virginia birth fund are 28.4 years from birth and 29.1 years for participants that reach the age of three (3). As of June 30, 2020, the Fund has experienced the death of twelve (12) of its participants. Furthermore, only eighteen (18) Fund participants were admitted prior to the age of three. The following graph shows the distribution of current Fund participants by age.




Chart 5: Age Distribution of Fund Participants

Due to the low number of Fund participant deaths (1.6% of admitted participants are deceased), we still do not yet have enough credible data to compare Fund participant life expectancies with Virginia life expectancies. However, we have revised initial mortality assumptions to reflect lower than expected mortality thus far. We hypothesize that the inclusion of physical-only and mental-only injuries may lead to higher Fund life expectancies than Virginia life expectancies, but we require more data to support or refute this hypothesis.

# <u>Actuarial Calculation of Estimated Fund Liabilities</u>

We have been asked to project expected fund liabilities for the next ten fiscal years of the MIF. To do this, we have estimated the ultimate benefit payments for the participants admitted to the Fund each quarter on both a nominal and discounted basis. Three methods were used as a reasonability check for estimating ultimate benefit payments by the year in which a participant was accepted to the Fund.

A <u>loss development</u> method was used in which actual benefit payments to date were divided by the expected percentage of ultimate benefits as of each participant-quarter's maturity. These percentages were developed based on information for the Virginia Birth Fund and modified to reflect the older average age of the Fund participants upon admittance and the Fund's actual payments. An <u>expected loss</u> method was also used in which expected ultimate benefit payments by quarter were also estimated using a weighted average of expected average ultimate benefit payments per Fund participant overall and by quarter of eligibility. Finally, a <u>Bornhuetter-Ferguson (B-F)</u> technique estimates ultimate losses using a combination of expected losses and loss development techniques. See Exhibit 6, page 1 for the application of these three techniques. The resulting selected severities are shown on Exhibit 6, page 2.

On December 31, 2016, legislation was signed expanding eligibility for the Fund to non-hospital births and significantly raising reimbursement rates for the period from July 1, 2017 through December 31, 2019. This period was extended to December 31, 2020 then again to December 31, 2021 in 2020 as part of the New York State budget legislation. The Department has requested that we now assume the increased reimbursement rates continue indefinitely, and we have reflected this assumption in the current analysis. We prepared an extensive costing study in March 2017 estimating the impact of this change on participant severities based on the expected increased participation and reimbursement rates. Since that time we have relied primarily on these severities, modifying them as actual experience emerges for living participants and using the other three methods as a reasonability check. The current selected severities can be seen in Exhibit 6, Page 2.

For the March 31, 2018 analysis, the March 31, 2019 analysis, and the March 31 2020 analysis, we adjusted the severity assumptions for participants already admitted into the Fund based on Fund experience. These severities vary based on the participant's admittance year to the Fund. The timing of the payments used in our severity estimates also reflect the amount of time a participant is expected to live, so that these severities take participant mortality into account. See Exhibit 6, Page 2 for more detail on these numbers.

Based on this approach and the current legislation, we estimate that the 719 living admitted Fund participants will ultimately receive benefit payments on the order of \$4.396 billion (including the \$184.6 million in benefits already paid and \$4.212 billion in expected future payments). Adjusting for the time value of money at a 2.0% discount rate results in a present value for these benefits of \$2.263 billion. See Exhibit 5, Pages 3 and 6 for more detail on these numbers.

Actual benefit payments in the first quarter of the 2020-21 fiscal year were \$13.122 million. This amount is \$1.404 million lower than expected at the prior quarterly analysis. We are currently not aware of any impacts of the COVID-19 pandemic on the timing or amount of benefit payments. Based on modeled severities and an expected 58.89 additional participants, expected benefit payments in the remaining three quarters of the 2020-21 fiscal year are \$45.910. Estimated total benefit payments for

the 2020-21 fiscal year (4/1/20 - 3/31/21) are therefore \$59.032 million. See Exhibit 3 for more detail regarding these numbers. It is important to recognize that these amounts can vary significantly each quarter. We are continuing to monitor our estimation methodology closely as it is quite sensitive to several key assumptions.

# **Amount of Benefits Paid**

Based on payment data provided by PCG, \$13.122 million was paid to Fund participants during the first quarter of the 2020-21 fiscal year (4/1/20 - 6/30/20). These payments are \$1.404 million lower than the expected benefit payments as of the March 31, 2020 analysis. While the expansion of Fund benefits due to COVID-19 might be expected to increase benefits payments, the waiver of the timely filing requirement means that the actual payment of these benefits may be delayed. See Exhibit 3 for more detail.

We have investigated to see if there are material differences in the types of injuries experienced by participants in the New York Fund versus those in Virginia and Florida that may explain some of the differences we are seeing between actual and expected payments. As noted previously, the Virginia program requires both a physical and developmental/cognitive disability and the participant must "need assistance with all daily living activities" to qualify for admittance. This standard for Virginia is therefore stricter than for the Fund, which requires either a physical or mental disability but not necessarily both. This difference appears to be contributing to the Fund's higher frequency of participants per live births as well as a higher frequency of participants with less than \$25,000 in payments per year. For example, the Center for Disease Control and Prevention considers cerebral palsy a motor disability<sup>6</sup>. While children with cerebral palsy often have a co-occurring physical or developmental disability, cerebral palsy can exist separately from intellectual disability. As participants with cerebral palsy account for 21% of the Fund's participants and 30% of the Fund's payments (see Exhibit 1, Page 2), this distinction could be impacting the Fund's divergence from Virginia's experience. In addition, we recognize that certain diagnoses tend to be "physical-only" (i.e. Brachial Plexus and Erb's Palsy). However, we do not have detailed diagnosis data nor the medical expertise that could inform further investigation.

### Patterns of Utilization

It is too early in the life of the Fund to provide any credible conclusions regarding patterns of utilization, particularly as the legislative change may have impacted Fund utilization. However, Pinnacle continues to work with PCG and the New York DOH to develop the data capabilities to provide this type of analysis in the future. Specifically, we have developed and continue to maintain detailed benefit payment information by participant, diagnosis, Fund fiscal year and benefit type. The benefit

<sup>&</sup>lt;sup>5</sup> From vabirthinjury.com/eligibility-benefits-claims

<sup>&</sup>lt;sup>6</sup> https://www.cdc.gov/ncbddd/cp/data.html#references

types being captured are intended to reflect the benefits provided by the Fund's legislation and follow form with existing databases in Florida and Virginia.

Exhibit 1 shows payment detail (provided through 6/30/20) grouped into the following categories:

- Medical Treatment
- Hospital Based Care
- Surgical Care
- Nursing Care
- Dental Care
- Rehabilitation Care
- Custodial Care
- Durable Medical Equipment
- Home Modifications
- Vehicle Modifications
- Prescription and Non-Prescriptive Drugs
- Other Health Care Costs
- Assistive Technology
- Other Payments

Our analysis suggests benefit payment patterns that differ from the Virginia data. To date, the Fund has a substantially higher percentage of overall costs in medical and hospital costs, medical equipment and prescription drug costs, and corresponding lower percentages in nursing costs. To improve our understanding of the prescription drug costs, PCG now provides vendor payment data that allow us to explore prescription drug costs on a by-member basis (although these summaries do not directly map to the quarterly payment summaries and prescription drugs must still be handled in bulk for our overall analysis). This data is summarized in Exhibit 1, Page 1 and shown graphically below. Exhibit 1, Page 1 also compares New York data to benefit payments in Virginia. Nursing costs are the majority of total payments in both states.




Chart 6: Benefit Payments by Category

In 2017, two significant changes occurred – the legislation signed in December 31, 2016 to increase reimbursement rates went into effect, and claims handling for the Fund's benefit payments was switched from Alicare to PCG. The Payments Per Participant Summary is provided to illustrate the impact of these changes, comparing the 2016-17 fiscal year (the year prior to these changes) to payments in the most recent four quarters of the Fund. While the overall increase in average payments of 53.2% is due primarily to the increased reimbursement rates, the distribution of payments between categories may have been affected by the change from Alicare to PCG. The Other Health Costs Category in particular now includes medical supplies, hearing screenings, and other assessments not separately identified in the Alicare data but provided in a more granular way in the PCG data. This category may be reflecting payments that would previously have been assigned to another category of payments. The Assistive Technology category has also seen significant increase. While this increase

may be due to the change to PCG, most of the new payments are related to speech generating devices, which may simply be a technology that was not often utilized by participants in the past.

Another key aspect of the database needed to evaluate patterns of utilization is differences in the medical and mental condition of the Fund's participants. To facilitate this dimension of our future analysis, Pinnacle worked with Alicare to track a number of characteristics for each Fund participant, including:

- Current Age
- Gender
- Injury Description
- Other Insurance (i.e. whether participant holds other insurance)
- Ambulatory Status
- Use of a gastric feeding tube (G-Tube)
- Ability to lift head from the prone position
- Use of a ventilator
- Use of a tracheostomy tube (trach tube).

Most of these characteristics are still available through the data PCG now provides, although we have not yet been provided with the participant limitations (such as the use of a gastric feeding tube) that have been found to be valuable in the Virginia analysis. In Virginia, several of these characteristics have been shown to influence life expectancies and average annual benefit payments. While we do not have the data yet to evaluate life expectancies by diagnosis, we are continuing to compile average annual benefit payment information for all members with over 1 year of participation in the Fund and are tracking current patterns to inform future analyses.

# Benefit Payments and Injury Type

For nearly all Fund participants, the nature of the injury and primary diagnosis permitting entrance into the Fund has been provided to Pinnacle as part of the quarterly enrollment data. Although strict standardization of participant injury types is not provided, sufficiently detailed descriptions of the nature of the injury have allowed us to judgmentally categorize participants into standardized injury type groups. As with the benefit type categorization, injury type categorization can aid in identifying differences in injury types that are relevant to the management of the Fund.

We have categorized the primary diagnosis for each Fund participant into one of the following injury types:

- Brachial Plexus
- Cerebral Palsy
- Developmental Delays

- Encephalopathy
- Erb's Palsy
- Hemiplegia
- Mental Retardation
- Neurological Disabilities
- Quadriplegia
- Spastic Diplegia
- Spastic Paraplegia
- Spastic Quadriplegia
- Other
- Not Available

The following is a graph of the distribution of participants by injury type group above. Spastic quadriplegia, cerebral palsy, and encephalopathy combine to make up about 74% of total benefit payments.




Chart 7: Benefit Payments by Injury Type

It is clear from the graph that the Fund's participant composition by injury type is varied, but also concentrated in a handful of categories. The following graph illustrates the number of participants and average payment by injury type through the current quarter.




Chart 8: Average To Date Payments per Participant

Participants with injury types of Cerebral Palsy, Encephalopathy or Spastic Quadriplegia comprise approximately 52% of the total participants, but account for approximately 74% of total payments, resulting in relatively large average payments. Conversely, participants with injury types of Brachial Plexus, Erb's Palsy, Spastic Diplegia, Hemiplegia, Mental Retardation, or Developmental Delays have relatively low average payments, accounting for only 9% of total payments while comprising approximately 31% of the total participants. The large number of participants in the Neurological Disabilities categories with relatively low benefit payments is also noteworthy.

# Inflationary Patterns of Types of Services

It is far too early in the life of the Fund to provide any credible conclusions regarding inflationary patterns based on Fund payments alone. However, data from the Bureau of Labor Statistics provides a helpful look at the impact of inflation on medical costs in the state of New York through the end of calendar year 2019:




Chart 9: Medical Care Inflation in the State of New York

Average inflation over the past five years is 3.2%. In the March 31, 2019 analysis, we reviewed these inflationary trends and adjusted our assumptions to contemplate a 3.0% inflation rate for the Fund's benefit payments, reduced from the 3.5% inflationary rate used in prior analyses. Sensitivity tests for the impact of the inflation rate on the current estimated unfunded liability are shown in the following table:

Inflation Rate Sensitivity Test												
(\$ in the	ousands, or	n a present value b	asis)									
		Surplus/	Difference									
	Inflation	(Unfunded	From									
	<u>Rate</u>	<u>Liability)</u>	<u>Baseline</u>									
		/ <b>.</b>										
	2.5%	(1,782,412.7)	295,033.3									
Baseline	3.0%	(2,077,446.0)	-									
	3.5%	(2,440,411.6)	(362,965.5)									
At 2.5% discount	3.5%	(2,045,926.7)	31,519.3									

Table 10: Sensitivity of Results to Inflation Rate

In addition, based on our experience in Virginia, we are confident that the detailed claims benefits payment database being constructed will prove invaluable once more benefits experience has been accumulated.

### **Administrative Expenses**

Pinnacle was provided information in early 2017 on administrative expenses charged by Alicare to the Fund for claims administration and enrollment services. As of September 1, 2017, the claims administration was taken over by PCG while Alicare continued to service enrollment to the Fund. One year later at September 1, 2018, PCG began providing enrollment services as well in place of Alicare.

Prior to these changes in claims administration, Alicare was charging the Fund \$809 per Fund participant per month. Under the current payment structure, the total administrative costs were initially estimated at approximately \$653 per Fund participant per month (see Exhibit 8 for current cost estimates). This cost is set to continue decreasing over the next few years as the addition of new participants will reduce the fixed cost per member. Estimated future administrative expenses (including expenses attributable to the Department) comprise approximately 11% of expected future benefit payments on a nominal basis; this is expected to decrease to approximately 10% of future payments over the next ten years. In Virginia, future expenses are closer to 5% of future benefit payments. As more participants join the Fund, we expect the per participant administrative costs to continue decreasing under the current contract.

At the beginning of the fiscal year (March 31, 2020), we estimated \$5.788 million in administrative expenses during the upcoming 2020-2021 fiscal year (see Exhibit 2, Page 1 of our report for 2020 Q1). This number was based on expected, not actual, participant counts and did not include administrative

expenses due to the Department. We annually compare expected administrative expenses to actual administrative expenses as a check on our estimates.

# Impact of Available Health Insurance

It is also far too early in the life of the Fund to provide any credible conclusions regarding the impact of available health insurance. However, the detailed benefit payment database described earlier and summarized in Exhibit 1 will prove invaluable once more payment experience has been accumulated. One early item of note is the number of participants with Medicaid has been consistently tracking at more than half of the Fund's participants. Currently about 60% of all Fund participants rely on Medicaid. As shown below, average annual payments relative to time in the Fund appears to differ somewhat between members with and without insurance.

<u>Pa</u>	rticipant Years	Paid Benefits	Total Severity		
With Insurance	1,174.75	52,248,373	44,476		
Without Insurance	1,995.00	118,136,342	59,216		
Not Available	3.50	136,579	39,023		

Table 11: Participant Years of Participation and Paid Benefits, with and without Insurance

### **Investment Earnings**

The Fund earned \$5,214,165 of investment income during the period from 4/1/19 through 3/31/20. Over that period, we estimate the Fund's average balance to be \$247,926,907, indicating a 2.1% investment return on the Fund balance. During the prior period (from 4/1/18 through 3/31/19), we estimated an average 1.9% investment return on the Fund's investments (see our report as of 3/31/2019). This is in comparison to the 2.0% discount rate used in our current analysis. We have tested the sensitivity of our analysis to changes in the discount rate. The results of this testing are shown in the following table.

Discount Rate Sensitivity Test (\$ in thousands, on a present value basis)											
·		Surplus/	Difference								
	Discount	(Unfunded	From								
	<u>Rate</u>	<u>Liability)</u>	<u>Baseline</u>								
Baseline	1.5% 2.0% 2.5%	(2,481,261.6) (2,077,446.0) (1,752,781.0)	(403,815.5) - 324,665.1								
At 3.5% inflation	2.5%	(2,045,926.7)	31,519.3								

Table 12: Sensitivity of Results to Discount Rate

We have not been provided further information regarding the Fund's investment returns on the Fund's invested assets at this time. It appears that the Fund's investment performance is not tracked separately from other assets of the state of New York. Building up investment income on the Fund's balance will be essential to the Fund's ongoing financial strength as participants continue to enter the Fund and calendar year benefit payments continue to grow.

### **Distribution & Use**

This Report has been prepared for the intended use of the NY DOH. Further distribution of this report is controlled by Pinnacle's contract with the NY DOH. Third parties reviewing the report should recognize that the furnishing of this report is not a substitute for their own due diligence and should place no reliance on this report or the data contained herein that would result in the creation of any duty or liability by Pinnacle to the third party.

Pinnacle consents to reference by the Department to Pinnacle's reports, opinions, advice and firm name in documents released by or at the direction of the Department concerning such financial examination findings. In any instances other than the Department's final examination report regarding the review of reserves and solvency analysis of the Fund in which Pinnacle is identified as the source of a paraphrase, quotation or partial quotation, the Department shall notify Pinnacle prior to such publication, so that Pinnacle may review said reference(s).

The exhibits attached in support of our findings are an integral part of this report. These sections have been prepared so that our actuarial assumptions and judgments are documented. Judgments about the conclusions drawn in this report should be made only after considering the report in its entirety.

We remain available to answer any questions that may arise regarding this report. We assume that the user of this report will seek such explanation on any matter in question.

Our conclusions are predicated on a number of assumptions as to future conditions and events. Those assumptions, which are documented in subsequent sections of this report, must be understood in order to place our conclusions in their appropriate context. In addition, our work is subject to inherent limitations, which are also discussed in this report.

"Any and all Department communications, records, documents, written, oral or electronic communication or other information of any kind are confidential. [Pinnacle] shall not copy, transmit, deliver or communicate in any way to any other person or entity any such communications and/or information without the prior written consent of the Department."

"All information and materials received hereunder by [Pinnacle] from Department are and shall remain the sole and exclusive property of Department, and [Pinnacle] shall have no right, title or interest in or to any such information or materials by virtue of their use or possession hereunder by [Pinnacle]."

### **Reliances & Limitations**

We have prepared this report in conformity with its intended use by persons technically competent in the areas addressed and for the stated purposes only. We are not accountants; our estimates in Exhibit 2 regarding balance sheet and income statement items are for illustrative purposes only and not intended as a strict interpretation of statutory or GAAP accounting.

Throughout our analysis we have, without audit or verification, relied on historical data and qualitative information provided by NYS DOH related agencies and MIF's services providers. The accuracy of our results is dependent upon the accuracy and completeness of this underlying data. Therefore, any material discrepancies discovered in this data or other information provided by NYS DOH, its related agencies or MIF's other service providers should be reported to us and this report amended accordingly.

This report includes graphs summarizing the Fund's raw data received for this and prior reports, information from the prior fiscal year-end report at March 31, 2020, and summary information from similar funds in other states. In addition, we also reference the Fund's analysis as of March 31, 2017 reflecting the a priori estimates of the legislation signed into law on December 31, 2016. Review of these prior reports may provide further clarification of our comments and conclusions.

There is a limitation upon the accuracy of these estimates in that there is inherent uncertainty in any estimate of unpaid claims obligations and benefits. This is due to the fact that the ultimate liability for claims is subject to the outcome of events yet to occur, e.g., future program participant life

expectancies, medical cost inflationary trends, etc. We have employed generally accepted actuarial techniques and assumptions that we believe are reasonable and appropriate. Further, the conclusions presented herein are reasonable and appropriate and supported by our analysis, given the information currently available. However, it should be recognized that future loss emergence will likely deviate, perhaps materially, from our estimates.

Additional uncertainty arises from lack of historical data and use of industry benchmarks. Our projections of future loss emergence and benefit payments are based primarily on aggregate insurance industry loss development patterns. It is possible that these patterns may not be indicative of future loss development for MIF.

A substantial source of uncertainty relates to the emergence of the COVID-19 pandemic in early 2020. This uncertainty could impact the estimation of future payments in several different ways including changes associated with ongoing medical care of current participants due to the virus and administrative changes in response to the virus. At this point, it is not possible to reliably forecast these impacts. The COVID-19 pandemic may have a material impact on our estimates of future payments as its effects emerge.

Estimates discounted for the time value of money can be more uncertain than those on an undiscounted basis. In addition to the usual uncertainty in projecting unpaid claims obligations and benefits, discounted estimates are also influenced by:

- Variations in the timing of actual benefit payments versus the rate of payment assumed in discounting estimates to present value
- Variation in the actual investment yield on the assets underlying the liabilities versus the assumed interest rate used in discounting.

While an explicit risk margin may be applied to account for this additional uncertainty, we have not incorporated an explicit risk margin in our analysis. Sudden unforeseen events such as the COVID-19 pandemic can have significant impact on investment yields, the timing of benefit payments and the Fund's financial results. The inherent risks of discounting are increased at this time.

The findings in this report are materially influenced by the discount rate of 2% provided to us by the Fund's administration. We have compared this to discount rates for other medical professional liability insurance programs in New York and the Fund's own investment experience and believe that it is reasonable.

# **INDEX OF EXHIBITS**

EXHIBIT	DESCRIPTION
1	Fund Payments by Benefit and Injury Categories
2	Projected Balance Sheets and Income Statements
3	Actual vs. Expected Participant Counts & Benefit Payments
4	Average Payments per Participant by Admittance Quarter
5	Projected Incremental Payments by Admittance Quarter – Nominal and Discounted
6	Estimated Fund Payments by Admittance Year and Admittance Quarter
7	Participant Profile
8	Administrative Expense Summary
	Payments Per Participant Summary

### **New York State Department of Health**

**Quarterly Analysis of New York Medical Indemnity Fund** 

As of June 30, 2020

**Fund Payments by Benefit Category** 

Exhibit 1 Page 1

Virginia Birth Fund

												•	Percent
Benefit Category	2020Q2	FY 19/20	FY 18/19	FY 17/18	FY 16/17	FY 15/16	FY 14/15	FY 13/14	FY 12/13	Total	Percent of Total	Benefit Category	of Total
Medical Treatment	456,717	2,713,732	2,080,094	1,723,663	1,111,413	868,110	573,589	263,209	35,184	9,825,712	5.34%		
Hospital Based Care	356,159	1,538,233	1,536,112	2,612,112	1,885,043	2,092,358	1,673,039	300,325	42,922	12,036,302	6.54%	Hospital/Physician	1.40%
Surgical Care	151,597	702,101	467,854	244,859	113,032	146,685	101,149	18,896	2,190	1,948,363	1.06%		
Nursing Care	7,292,069	26,034,310	20,018,097	15,456,991	10,627,012	8,153,130	6,438,280	2,345,151	552,120	96,917,161	52.63%	Nursing	66.07%
Dental Care	1,557	55,534	53,254	65,950	43,620	43,956	28,510	8,619	586	301,586	0.16%		
Rehabilitation Care	201,309	1,484,865	1,095,576	1,032,868	1,135,719	995,410	630,482	62,821	60,191	6,699,241	3.64%	Physical Therapy	2.59%
Custodial Care	1,472,453	4,515,716	2,980,583	2,143,798	1,131,480	485,434	69,581	9,248	-	12,808,292	6.96%		
Durable Med Equip	615,077	2,499,628	2,255,354	1,788,009	945,751	880,138	533,009	416,785	42,169	9,975,920	5.42%	Medical Equipment	1.75%
Home Modifications	665,043	2,238,494	2,090,972	1,743,688	1,208,614	674,666	700,673	292,218	6,110	9,620,477	5.22%	Housing	10.33%
Vehicle Modifications	157,541	109,925	111,415	334,887	249,284	153,585	180,606	37,247	-	1,334,489	0.72%	Vans	4.93%
Prescription and Non-Prescriptive Drugs	1,041,432	4,367,122	2,901,653	2,900,007	2,537,792	1,669,450	872,352	281,662	65,176	16,636,647	9.04%	Prescription Drugs	1.18%
Other Health Care Costs	615,828	1,985,409	1,662,641	693,265	46,590	38,122	43,311	12,976	360	5,098,503	2.77%	All Other	11.76%
Assistive Technology	-	44,567	76,132	616	500	1,244	-	-	-	123,060	0.07%		
Other Payments	94,985	372,140	173,062	83,211	64,014	14,022	7,404	(4)	8	808,842	0.44%		
Total	13 121 765	48 661 777	37 502 799	30 823 926	21 099 865	16 216 310	11 851 988	4 049 151	807 015	184 134 596	100 00%		

### Notes

Fiscal years begin on April 1st; quarters shown are labeled by calendar year

FY 12/13 includes only 4th quarter 2012 and 1st quarter 2013; FY 12/13 does not include payments when Sedgwick was TPA

### **New York State Department of Health**

**Quarterly Analysis of New York Medical Indemnity Fund** 

As of June 30, 2020

Fund Payments by Injury Category

													Percent	Total Injury	Number of	Injury Category
										Total	Percent of	Number of	of Total	Category	Participant	Annualized
Injury Category	2020Q2	FY 19/20	FY 18/19	FY 17/18	FY 16/17	FY 15/16	FY 14/15	FY 13/14	FY 12/13	<u>Payments</u>	Total Payments	<u>Participants</u>	<u>Participants</u>	Severity	Quarters	Severity
Brachial Plexus	11,346	88,797	50,167	43,110	10,549	11,927	8,466	2,687	=	227,048	0.13%	28	3.83%	8,109	486	1,869
Erbs Palsy	106,269	242,763	172,564	95,773	32,885	34,007	25,640	3,617	-	713,517	0.42%	61	8.34%	11,697	888	3,214
Spastic Diplegia	56,733	138,269	112,766	113,869	58,214	65,865	53,702	-	=	599,418	0.35%	12	1.64%	49,952	191	12,553
Hemiplegia	50,844	196,484	148,477	67,331	86,939	18,250	52,271	53,464	4,331	678,389	0.40%	23	3.15%	29,495	401	6,767
Mental Retardation	86,562	401,450	312,398	576,004	433,236	514,888	176,580	32,714	14,964	2,548,796	1.50%	16	2.19%	159,300	362	28,163
Developmental Delays	1,011,002	2,546,704	1,887,943	1,507,988	1,251,998	1,265,010	949,237	152,790	389	10,573,061	6.22%	84	11.49%	125,870	1,512	27,971
Neurological Disabilities	750,636	3,157,064	3,837,485	3,097,854	1,788,924	1,130,909	571,830	169,875	17,260	14,521,837	8.54%	66	9.03%	220,028	1,237	46,958
Spastic Paraplegia	26,127	107,519	125,554	71,800	21,081	39,287	57,729	-	=	449,096	0.26%	2	0.27%	224,548	39	46,061
Cerebral Palsy	3,399,488	14,161,037	10,472,684	8,018,968	5,909,418	4,116,581	3,052,208	1,227,845	212,024	50,570,253	29.74%	155	21.20%	326,260	2,894	69,897
Encephalopathy	2,512,240	10,069,671	8,174,506	6,400,545	4,109,928	3,785,684	3,244,944	1,055,853	209,787	39,563,159	23.27%	129	17.65%	306,691	2,319	68,242
Spastic Quadriplegia	3,188,911	10,235,886	7,496,311	5,917,532	3,839,667	2,999,106	2,096,547	675,214	45,764	36,494,939	21.46%	95	13.00%	384,157	1,397	104,495
Other	611,165	2,356,342	1,357,326	1,699,827	892,244	640,451	707,892	492,737	233,864	8,991,849	5.29%	50	6.84%	179,837	687	52,354
Quadriplegia	208,205	746,728	452,194	493,110	327,236	272,060	127,694	-	-	2,627,228	1.55%	2	0.27%	1,313,614	41	256,315
Not Available	87,893	150,218	214,621	277,318	351,832	128,354	149,457	46,031	68,632	1,474,355	0.87%	8	1.09%	184,294	239	24,675
Total	12,107,422	44,598,930	34,814,996	28,381,030	19,114,151	15,022,378	11,274,197	3,912,827	807,015	170,032,945		731	100.00%	232,603	12,693	53,583

Fiscal years begin on April 1st; quarters shown are labeled by calendar year

FY 12/13 includes only 4th quarter 2012 and 1st quarter 2013; FY 12/13 does not include payments when Sedgwick was TPA  $Vendor\ invoices\ for\ prescriptions\ are\ excluded\ on\ this\ summary;\ hence\ Total\ on\ this\ page\ does\ not\ match\ Page\ 1$ 

Total Injury Category Severity = Total Payments / Number of Participants

Total Injury Category Annualized Severity = Total Payments / Number of Participant Quarters x 4

Exhibit 1

Page 2

### BALANCE SHEET

With 2.00% Discount

	Projections as of Fiscal Year-End												
	At 6/30/20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28	2028-29	2029-30		
<u>Assets</u>													
Fund Balance	230,998.5	184,170.2	164,491.7	136,583.6	100,096.6	59,912.9	18,484.3	(24,227.8)	(68,244.3)	(113,584.5)	(160,134.0)		
<u>Liabilities</u>													
Future Benefits for Current Participants	2,078,220.6	2,227,431.1	2,455,889.2	2,690,883.1	2,932,852.2	2,906,611.8	2,879,416.2	2,851,226.6	2,822,018.4	2,791,772.5	2,760,599.3		
Future Administrative Expenses - PCG	191,853.3	211,009.0	230,253.1	249,208.1	267,697.2	260,859.8	254,137.1	247,527.6	241,030.0	234,642.5	228,363.5		
Future Administrative Expenses - DOH/Treasury	38,370.7	42,201.8	46,050.6	49,841.6	53,539.4	52,172.0	50,827.4	49,505.5	48,206.0	46,928.5	45,672.7		
Surplus/(Unfunded Liability)	(2,077,446.0)	(2,296,471.7)	(2,567,701.2)	(2,853,349.3)	(3,153,992.2)	(3,159,730.6)	(3,165,896.5)	(3,172,487.6)	(3,179,498.6)	(3,186,928.0)	(3,194,769.6)		

### **INCOME STATEMENT**

	At 6/30/20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28	2028-29	2029-30
Initial Fund Balance		230,998.5	184,170.2	164,491.7	136,583.6	100,096.6	59,912.9	18,484.3	(24,227.8)	(68,244.3)	(113,584.5)
Annual Funding			52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0
Investment Income @ 2.00%		4,110.6	2,937.2	2,466.1	1,828.5	1,069.4	261.4	(571.7)	(1,430.4)	(2,315.1)	(3,224.9)
Benefit Payments		45,910.1	67,143.2	74,424.8	81,683.4	84,268.9	84,695.7	85,143.2	85,593.5	86,044.6	86,363.4
Administrative Expenses - PCG		4,388.5	6,044.6	6,507.1	7,175.4	7,512.9	7,508.4	7,496.3	7,476.7	7,449.5	7,414.9
Administrative Expenses - DOH/Treasury		640.3	1,428.0	1,442.3	1,456.7	1,471.2	1,486.0	1,500.8	1,515.8	1,531.0	1,546.3
Final Fund Balance	230,998.5	184,170.2	164,491.7	136,583.6	100,096.6	59,912.9	18,484.3	(24,227.8)	(68,244.3)	(113,584.5)	(160,134.0)
Change in Fund Balance		(46,828.3)	(19,678.5)	(27,908.1)	(36,487.0)	(40,183.7)	(41,428.7)	(42,712.1)	(44,016.4)	(45,340.3)	(46,549.5)
Coming Year Liabilities as % of Fund Assets		32.3%	50.1%	66.1%	93.2%	156.4%	509.3%	-390.4%	-139.2%	-83.9%	
Number of Participants											
Initial		719	774	857	939	1,022	1,011	1,000	988	975	962
Expected New		59	89	90	91	-	-	-	-	-	-
Expected Deceased		4	5	7	8	10	11	12	13	14	14
Final	719	774	857	939	1,022	1,011	1,000	988	975	962	947

Notes

Balance Sheet - Assets Calculated in Income Statement

Balance Sheet - Liabilities Future Benefits from Exhibit 5, Pages 4-6 discounted to current evaluation

Future Expenses based on current administrative costs

Balance Sheet - Surplus = Assets - Liabilities

Income Statement - Initial Fund Balance

= Final Fund Balance of prior period Income Statement - Annual Funding Provided by MIF

Income Statement - Investment Income

Calculated based on 2.0% assumed investment return and assuming average date of benefit and expense payments is the middle of the fiscal period

Income Statement - Benefit Payments

Income Statement - Admin Expenses Calculated based on current and projected participant counts and administrative expense contracts provided by MIF

Income Statement - Final Fund Balance = Initial Fund Balance + Annual Funding + Investment Income - Benefit Payments - Administrative Expenses

Income Statement - Change in Fund Balance = Final Fund Balance - Initial Fund Balance

Income Statement - Coming Year Liabilities % = (Benefit Payments + Administrative Expenses) / Initial Fund Balance

of Initial Fund Balance Income Statement - Number of Participants Initial from Exhibit 7

Expected New from Exhibit 3

Expected Deceased based on assumed increasing rate of deaths for current participants, up to 1.5%

Final = Initial + Expected New - Expected Deceased

Exhibit 2

Page 1

Exhibit 2 Page 2

### **Quarterly Analysis of New York Medical Indemnity Fund** Future Fund Balances by Fiscal Year (000s) as of June 30, 2020

Undiscounted

### BALANCE SHEET

	Projections as of Fiscal Year-End												
	At 6/30/20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28	2028-29	2029-30		
<u>Assets</u>													
Fund Balance	230,998.5	180,059.7	157,443.9	127,069.7	88,754.2	47,501.1	5,811.1	(36,329.3)	(78,915.3)	(121,940.4)	(165,265.0)		
<u>Liabilities</u>													
Future Benefits for Current Participants	4,211,703.7	4,571,471.9	5,128,134.3	5,717,712.9	6,342,214.7	6,376,478.8	6,409,098.3	6,439,960.5	6,468,968.5	6,496,024.4	6,521,188.3		
Future Administrative Expenses - PCG	359,922.8	403,024.5	447,375.2	492,349.3	537,757.5	530,208.5	522,637.7	515,045.4	507,432.4	499,798.7	492,144.7		
Future Administrative Expenses - DOH/Treasury	71,984.6	80,604.9	89,475.0	98,469.9	107,551.5	106,041.7	104,527.5	103,009.1	101,486.5	99,959.7	98,428.9		
Surplus/(Unfunded Liability)	(4,412,612.5)	(4,875,041.7)	(5,507,540.7)	(6,181,462.4)	(6,898,769.5)	(6,965,227.9)	(7,030,452.5)	(7,094,344.3)	(7,156,802.6)	(7,217,723.3)	(7,277,027.0)		

### **INCOME STATEMENT**

	At 6/30/20	2020-21	<u>2021-22</u>	<u>2022-23</u>	2023-24	2024-25	<u>2025-26</u>	<u>2026-27</u>	<u>2027-28</u>	<u>2028-29</u>	2029-30
Initial Fund Balance		230,998.5	180,059.7	157,443.9	127,069.7	88,754.2	47,501.1	5,811.1	(36,329.3)	(78,915.3)	(121,940.4)
Annual Funding			52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0
Benefit Payments		45,910.1	67,143.2	74,424.8	81,683.4	84,268.9	84,695.7	85,143.2	85,593.5	86,044.6	86,363.4
Administrative Expenses - PCG		4,388.5	6,044.6	6,507.1	7,175.4	7,512.9	7,508.4	7,496.3	7,476.7	7,449.5	7,414.9
Administrative Expenses - DOH/Treasury		640.3	1,428.0	1,442.3	1,456.7	1,471.2	1,486.0	1,500.8	1,515.8	1,531.0	1,546.3
Final Fund Balance	230,998.5	180,059.7	157,443.9	127,069.7	88,754.2	47,501.1	5,811.1	(36,329.3)	(78,915.3)	(121,940.4)	(165,265.0)
Change in Fund Balance		(50,938.9)	(22,615.7)	(30,374.2)	(38,315.5)	(41,253.1)	(41,690.0)	(42,140.4)	(42,586.0)	(43,025.1)	(43,324.6)
Coming Year Liabilities as % of Fund Assets		32.3%	52.3%	71.1%	105.1%	197.2%	1620.0%	-260.4%	-120.4%	-78.2%	
Number of Participants											
Initial		719	774	857	939	1,022	1,011	1,000	988	975	962
Expected New		59	89	90	91	-	-	-	-	-	-
Expected Deceased		4	5	7	8	10	11	12	13	14	14
Final	719	774	857	939	1,022	1,011	1,000	988	975	962	947

Notes

Balance Sheet - Assets Calculated in Income Statement

Balance Sheet - Liabilities Future Benefits from Exhibit 5, Pages 1-3 discounted to current evaluation

Future Expenses based on current administrative costs

Balance Sheet - Surplus = Assets - Liabilities

Income Statement - Initial Fund Balance = Final Fund Balance of prior period

Income Statement - Annual Funding Provided by MIF

From Exhibit 5, Pages 1-3 Income Statement - Benefit Payments

Income Statement - Admin Expenses Calculated based on current and projected participant counts and administrative expense contracts provided by MIF

Income Statement - Final Fund Balance = Initial Fund Balance + Annual Funding - Benefit Payments - Administrative Expenses

Income Statement - Change in Fund Balance = Final Fund Balance - Initial Fund Balance

Income Statement - Coming Year Liabilities % = (Benefit Payments + Administrative Expenses) / Initial Fund Balance

of Initial Fund Balance Income Statement - Number of Participants

Initial from Exhibit 7 Expected New from Exhibit 3

Expected Deceased based on assumed increasing rate of deaths for current participants, up to 1.5%

Final = Initial + Expected New - Expected Deceased

### Exhibit 3

### **New York State Department of Health Quarterly Analysis of New York Medical Indemnity Fund Actual vs. Expected Participant Counts & Benefit Payments** As of June 30, 2020

Fiscal	N	lew Participants	<b>;</b>	T	otal Participants	<b>;</b>	Incremental Benefit Payments					
Period	Actual	Expected	Difference	Actual	Expected	Difference	Actual	Revised Expected	Prior Expected	Difference		
(1)	(2a)	(2b)	(2c)	(3a)	(3b)	(3c)	(4a)	(4b)	(4c)	(4d)		
Fiscal 2011-12 Total	22.00	22.00	-	22.00	22.00	-	3,146	3,146	3,146	0		
Fiscal 2012-13 Total	86.00	86.00	-	108.00	108.00	-	1,317,450	1,317,450	1,317,450	0		
Fiscal 2013-14 Total	84.00	84.00	-	192.00	192.00	-	4,049,151	4,049,151	4,049,151	0		
Fiscal 2014-15 Total	91.00	91.00	-	283.00	283.00	-	11,851,988	11,851,988	11,851,988	0		
Fiscal 2015-16 Total	85.00	85.00	-	368.00	368.00	-	16,216,310	16,216,310	16,216,310	0		
Fiscal 2016-17 Total	91.00	91.00	-	459.00	459.00	-	21,099,865	21,099,865	21,099,865	0		
Fiscal 2017-18 Total	72.00	72.00	-	531.00	531.00	-	30,823,926	30,823,926	30,823,926	0		
Fiscal 2018-19 Total	73.00	73.00	-	604.00	604.00	-	37,502,799	37,502,799	37,502,799	0		
Fiscal 2019-20 Total to Date	104.00	104.00	-	708.00	708.00	-	48,661,777	48,661,777	48,661,777	0		
2nd Qtr 2020	23.00	27.71	4.71	731.00	735.71	4.71	13,121,765	13,121,765	14,525,920	1,404,155		
3rd Qtr 2020		22.52	-	-	758.23	-	0	14,900,411	14,987,931	87,520		
4th Qtr 2020		19.05	-	-	777.28	-	0	15,336,960	15,422,939	85,979		
1st Qtr 2021		17.32	-	-	794.60		0	15,672,739	7,879,093	-7,793,646		
Fiscal 2020-21 Total	23.00	27.71	4.71	731.00	735.71	4.71	13,121,765	13,121,765	14,525,920	-6,215,992		
Fiscal 2021-22 Total		88.53	-	-	824.24	-						
Fiscal 2022-23 Total		89.56	-	-	913.81	-						
Fiscal 2023-24 Total*		90.59	-	-	1,004.40	-						
Fiscal 2024-25 Total			-	-	1,004.40	-						
Fiscal 2025-26 Total			-	-	1,004.40	-						
Fiscal 2026-27 Total			-	-	1,004.40	-						
Fiscal 2027-28 Total			-	-	1,004.40	-						
Fiscal 2028-29 Total			-	-	1,004.40	-						
Fiscal 2029-30 Total			-	-	1,004.40	-						

### **Notes**

(2a), (3a), (4a)	Provided by Fund
(2b), (3b)	Based on Pinnacle estimates of future Fund participation rates
(2c), (3c)	Part (b) - Part (a) for both sections respectively
(4b)	Expected future benefit payments as of the current analysis
(4c)	Expected future benefit payments as of the prior analysis
(4d)	(4c) - (4b)

Asset to liability ratio over 80% expected at fiscal year-end 2023-24 results in no future participants added

### **New York State Department of Health** Quarterly Analysis of New York Medical Indemnity Fund Average Payments per Participant by Admittance Quarter As of June 30, 2020

Admittance	ance Living Incremental Severity per Participant by Participation Quarter																	
Quarter	<u>Participants</u>	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	Q5	<u>Q6</u>	<u>Q7</u>	<u>Q8</u>	<u>Q9</u>	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
2011Q4	11	-	286	8,569	13,107	2,539	3,833	2,065	9,226	6,332	2,670	2,621	4,983	4,330	2,506	4,435	9,878	4,680
2012Q1	11	-	1,083	2,565	1,404	346	843	2,267	2,670	4,095	5,922	3,055	3,532	2,065	1,604	1,728	4,323	732
2012Q2	15	48	14,263	14,845	14,404	14,717	14,627	18,964	19,142	24,056	22,503	20,705	18,966	21,919	24,649	23,694	21,532	25,875
2012Q3	25	689	2,356	4,779	4,710	6,430	5,920	8,449	12,018	17,357	11,480	13,978	10,705	12,099	9,180	9,068	10,248	12,872
2012Q4	38	10	1,989	3,851	11,363	16,419	13,708	27,508	31,066	30,676	30,232	32,077	23,539	25,744	24,417	35,645	30,901	23,856
2013Q1	5	-	156	2,171	7,343	7,418	17,277	35,542	32,511	26,405	27,378	23,864	23,499	17,529	24,984	29,815	22,185	26,411
2013Q2	30	-	1,380	2,257	2,615	3,646	5,367	7,258	6,056	3,874	4,505	6,573	8,547	5,567	9,125	7,187	6,376	9,517
2013Q3	26	-	361	3,449	6,787	13,399	14,088	15,667	16,587	13,919	14,093	11,991	10,411	13,096	11,666	10,831	12,529	5,000
2013Q4	8	8	1,973	2,805	6,501	6,885	4,744	19,051	5,278	5,161	8,548	15,033	13,236	5,734	9,212	12,455	9,399	11,548
2014Q1	17	35	2,325	5,898	9,823	8,440	15,862	16,623	21,908	13,381	23,766	19,518	21,438	21,409	32,354	25,694	24,963	27,121
2014Q2	24	1,289	5,529	8,560	9,595	13,992	9,266	14,599	11,681	11,348	13,626	10,611	11,056	19,409	10,035	8,583	15,331	9,324
2014Q3	20	1,223	5,283	32,222	19,624	14,143	15,262	14,838	12,484	18,900	13,228	17,583	21,358	23,018	18,518	39,158	8,734	19,460
2014Q4	19	85	3,861	5,473	9,093	10,454	8,379	10,208	13,406	13,903	17,699	18,721	17,596	19,088	17,776	12,856	18,281	24,343
2015Q1	26	150	4,576	5,271	7,082	7,514	8,872	11,081	8,182	13,644	13,039	8,441	24,330	14,022	9,568	14,247	15,669	11,417
2015Q2	31	4,421	12,991	14,039	11,387	13,234	16,886	12,313	21,351	19,941	14,838	14,716	26,627	17,721	25,509	34,983	26,270	22,506
2015Q3	16	-	1,885	6,469	5,035	4,362	5,735	4,299	13,939	10,981	18,601	16,212	15,286	23,839	12,059	15,086	27,850	20,086
2015Q4	19	202	5,373	4,799	9,054	16,912	11,111	13,282	9,511	7,676	14,857	16,684	16,148	25,200	17,934	10,439	16,174	21,567
2016Q1	18	12	931	10,298	9,142	9,815	12,341	14,723	8,422	13,953	7,506	13,385	17,310	9,288	12,519	14,781	15,745	21,455
2016Q2	35	290	2,039	4,599	7,550	5,772	11,891	7,051	15,321	23,381	19,189	22,872	23,165	15,596	11,413	23,218	33,883	13,514
2016Q3	22	-	4,303	9,321	8,150	9,762	7,706	8,976	7,065	9,392	7,546	4,865	9,971	9,386	9,252	9,098	8,331	
2016Q4	14	-	11,232	11,240	18,161	12,826	23,382	11,326	27,431	12,930	25,701	16,436	14,768	17,266	20,672	19,503		
2017Q1	19	-	6,444	9,167	24,862	12,653	17,038	10,317	12,334	7,910	12,886	12,185	13,175	19,722	25,905			
2017Q2	28	340	5,987	6,603	13,511	11,404	15,585	10,178	12,831	12,465	13,189	13,957	12,754	12,859				
2017Q3	17	44	1,820	5,189	10,466	10,661	14,347	15,226	35,539	18,346	27,656	28,191	13,047					
2017Q4	11	83	1,217	24,666	21,320	3,655	72,019	22,907	6,483	15,885	18,603	44,915						
2018Q1 2018Q2	15 15	-	114 1,768	5,951 5,748	11,837 7,862	12,153 12,327	7,283 24,376	27,057 17,287	27,999 24,406	20,090 11,241	9,729							
2018Q2 2018Q3	18	-	3,104	2,291	12,816	7,065	17,273	8,868	8,473	11,241								
2018Q3 2018Q4	20	-	358	12,740	18,775	21,730	42,739	15,231	0,473									
2018Q4 2019Q1	19	2	651	7,727	19,151	31,562	20,779	13,231										
2019Q1 2019Q2	25	-	1,228	8,634	8,176	29,107	20,773											
2019Q2 2019Q3	10	-	3,903	9,446	5,747	23,107												
2019Q4	41	171	8,362	12,315	3,, .,													
2020Q1	28	149	1,689	12,013														
2020Q2	23	-	_,															
<del></del>																		
Total	719																	

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

### **New York State Department of Health Quarterly Analysis of New York Medical Indemnity Fund** Average Payments per Participant by Admittance Quarter As of June 30, 2020

Admittance	Living						Incre	mental Seve	rity per Parti	cipant by Pa	ticipation Qu	arter
Quarter	<u>Participants</u>	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28
2011Q4	11	2,614	4,516	4,553	5,070	5,433	6,349	5,433	5,168	13,122	9,719	8,93
2012Q1	11	753	1,306	3,692	5,932	9,553	12,852	2,766	14,592	55,240	3,844	3,27
2012Q2	15	23,286	22,464	25,066	29,353	28,463	23,256	47,581	34,446	29,018	42,196	27,12
2012Q3	25	12,306	9,536	12,574	15,561	10,479	20,311	16,598	13,262	12,371	8,958	16,05
2012Q4	38	27,316	46,825	40,156	20,090	40,543	20,434	45,752	50,732	35,330	51,431	36,75
2013Q1	5	31,833	35,052	26,082	32,230	44,378	20,788	36,876	43,227	56,146	37,003	43,93
2013Q2	30	8,214	4,678	12,809	8,178	9,627	6,925	17,208	16,538	21,244	29,727	31,85
2013Q3	26	8,989	5,455	4,491	6,246	12,642	5,386	8,352	6,414	6,450	7,937	6,02
2013Q4	8	11,407	13,560	6,748	15,107	7,601	10,755	12,051	14,876	22,398	65,497	
2014Q1	17	16,497	25,539	44,600	19,930	14,739	29,049	22,389	25,496	16,386		
2014Q2	24	13,047	17,769	17,639	16,652	14,556	19,026	9,208	8,353			
2014Q3	20	23,341	24,812	22,963	24,914	26,748	30,849	24,177				
2014Q4	19	13,139	15,768	24,100	23,237	24,247	18,724					
2015Q1	26	14,305	17,001	21,162	16,697	19,957						
2015Q2	31	25,897	21,107	22,098	29,785							
2015Q3	16	16,124	17,035	14,880								
2015Q4	19	27,916	40,502									
2016Q1	18	14,937										
2016Q2	35											
2016Q3	22											
2016Q4	14											
2017Q1	19											
2017Q2	28											
2017Q3	17											
2017Q4	11											
2018Q1	15											
2018Q2	15											
2018Q3	18											
2018Q4	20											
2019Q1	19											
2019Q2	25											
2019Q3	10											
2019Q4	41											
2020Q1	28											
2020Q2	23											
Total	719											

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

8,937

3,278

27,129

16,050

36,757

43,935

31,855

6,023

Q29

11,009

10,385

27,768

15,423

50,842

33,745

19,302

Q30

16,633

2,014

31,817

18,300

40,847

38,591

Q31

13,186

3,162

42,774

12,993

45,773

Q32

15,755

3,392

36,619

10,302

Q33

11,691

4,164

32,550

Q34

10,597

3,893

Q34

9,346

Admittance	Living						Cumula	tive Severity	by Fund Part	icipation Qu	arter							
Quarter	<u>Participants</u>	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Q5</u>	<u>Q6</u>	<u>Q7</u>	<u>Q8</u>	<u>Q9</u>	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
2011Q4	11	-	286	8,855	21,962	24,500	28,334	30,399	39,625	45,957	48,628	51,248	56,231	60,561	63,067	67,501	77,380	82,060
2012Q1	11	-	1,083	3,648	5,052	5,397	6,240	8,508	11,177	15,273	21,195	24,251	27,783	29,848	31,451	33,179	37,502	38,234
2012Q2	15	48	14,310	29,155	43,560	58,277	72,904	91,867	111,009	135,065	157,568	178,273	197,239	219,159	243,808	267,502	289,033	314,908
2012Q3	25	689	3,045	7,823	12,534	18,964	24,884	33,333	45,351	62,708	74,188	88,166	98,871	110,970	120,150	129,218	139,466	152,339
2012Q4	38	10	1,999	5,850	17,213	33,633	47,340	74,848	105,914	136,589	166,821	198,898	222,437	248,181	272,599	308,244	339,144	363,000
2013Q1	5	-	156	2,327	9,670	17,088	34,365	69,907	102,417	128,822	156,200	180,064	203,563	221,092	246,076	275,891	298,075	324,486
2013Q2	30	-	1,380	3,637	6,252	9,897	15,265	22,523	28,579	32,452	36,957	43,531	52,078	57,645	66,770	73,957	80,334	89,851
2013Q3	26	-	361	3,810	10,597	23,996	38,084	53,751	70,338	84,257	98,350	110,341	120,752	133,848	145,514	156,345	168,874	173,874
2013Q4	8	8	1,981	4,786	11,287	18,173	22,917	41,967	47,246	52,406	60,955	75,988	89,224	94,958	104,169	116,624	126,024	137,572
2014Q1	17	35	2,361	8,258	18,081	26,521	42,383	59,006	80,914	94,295	118,062	137,580	159,018	180,427	212,781	238,475	263,437	290,558
2014Q2	24	1,289	6,819	15,379	24,974	38,966	48,232	62,831	74,512	85,860	99,486	110,097	121,153	140,562	150,597	159,180	174,511	183,835
2014Q3	20	1,223	6,506	38,728	58,353	72,496	87,758	102,596	115,080	133,980	147,207	164,791	186,149	209,167	227,684	266,843	275,576	295,036
2014Q4	19	85	3,945	9,418	18,511	28,965	37,344	47,552	60,958	74,861	92,560	111,281	128,877	147,965	165,741	178,597	196,878	221,221
2015Q1	26	150	4,726	9,997	17,079	24,593	33,465	44,546	52,728	66,372	79,412	87,853	112,183	126,205	135,772	150,019	165,688	177,105
2015Q2	31	4,421	17,412	31,452	42,839	56,073	72,958	85,272	106,623	126,564	141,401	156,117	182,744	200,466	225,975	260,958	287,228	309,734
2015Q3	16	-	1,885	8,354	13,389	17,751	23,486	27,785	41,724	52,705	71,305	87,517	102,803	126,643	138,702	153,788	181,638	201,724
2015Q4	19	202	5,575	10,374	19,427	36,340	47,451	60,732	70,243	77,919	92,776	109,460	125,608	150,808	168,743	179,182	195,356	216,923
2016Q1	18	12	942	11,240	20,382	30,198	42,538	57,262	65,684	79,637	87,143	100,527	117,837	127,125	139,645	154,425	170,171	191,626
2016Q2	35	290	2,329	6,928	14,477	20,249	32,140	39,191	54,512	77,893	97,081	119,953	143,118	158,714	170,128	193,346	227,229	240,743
2016Q3	22	-	4,303	13,624	21,774	31,536	39,242	48,218	55,283	64,676	72,221	77,086	87,058	96,443	105,695	114,793	123,124	
2016Q4	14	-	11,232	22,473	40,633	53,460	76,841	88,167	115,599	128,528	154,229	170,666	185,434	202,700	223,371	242,874		
2017Q1	19	-	6,444	15,611	40,473	53,126	70,164	80,481	92,815	100,724	113,610	125,796	138,970	158,692	184,598			
2017Q2	28	340	6,326	12,929	26,440	37,843	53,429	63,607	76,438	88,903	102,093	116,050	128,803	141,662				
2017Q3	17	44	1,864	7,053	17,520	28,181	42,527	57,754	93,292	111,639	139,295	167,486	180,533					
2017Q4	11	83	1,299	25,965	47,285	50,941	122,960	145,867	152,349	168,235	186,838	231,753						
2018Q1	15	-	114	6,065	17,902	30,055	37,338	64,395	92,393	112,484	122,213							
2018Q2	15	-	1,768	7,516	15,377	27,704	52,080	69,368	93,774	105,015								
2018Q3	18	-	3,104	5,395	18,211	25,276	42,549	51,416	59,890									
2018Q4	20	-	358	13,097	31,872	53,602	96,341	111,572										
2019Q1	19	2	653	8,380	27,531	59,094	79,873											
2019Q2	25	-	1,228	9,862	18,037	47,144												
2019Q3	10	-	3,903	13,349	19,096													
2019Q4	41	171	8,532	20,848														
2020Q1	28	149	1,838															
2020Q2	23	-																
Total	719																	

Admittance	Living							Cumulative	Severity by F	und Particip	ation Quarte		
Quarter	<u>Participants</u>	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	Q29
2011Q4	11	84,674	89,190	93,743	98,814	104,246	110,595	116,028	121,196	134,317	144,037	152,974	163,983
2011Q4 2012Q1	11	38,987	40,293	43,985	49,917	59,470	72,322	75,087	89,679	144,919	148,763	152,042	162,426
2012Q2	15	338,195	360,658	385,724	415,077	443,540	466,797	514,378	548,823	577,841	620,036	647,166	674,934
2012Q3	25	164,644	174,180	186,754	202,315	212,794	233,104	249,702	262,964	275,335	284,293	300,343	315,765
2012Q4	38	390,316	437,141	477,297	497,387	537,930	558,364	604,116	654,848	690,178	741,608	778,365	829,207
2013Q1	5	356,319	391,371	417,453	449,684	494,062	514,849	551,726	594,953	651,099	688,102	732,036	765,781
2013Q2	30	98,064	102,742	115,552	123,729	133,356	140,280	157,488	174,026	195,269	224,996	256,851	276,153
2013Q3	26	182,862	188,317	192,809	199,054	211,696	217,082	225,434	231,847	238,297	246,234	252,257	
2013Q4	8	148,979	162,539	169,287	184,394	191,995	202,749	214,800	229,676	252,075	317,572		
2014Q1	17	307,055	332,594	377,194	397,124	411,863	440,912	463,301	488,797	505,183			
2014Q2	24	196,881	214,651	232,290	248,942	263,498	282,524	291,732	300,085				
2014Q3	20	318,377	343,189	366,152	391,066	417,815	448,663	472,841					
2014Q4	19	234,360	250,128	274,228	297,465	321,712	340,437						
2015Q1	26	191,410	208,411	229,573	246,270	266,227							
2015Q2	31	335,630	356,737	378,835	408,620								
2015Q3	16	217,848	234,883	249,763									
2015Q4	19	244,840	285,342										
2016Q1	18	206,563											
2016Q2	35												
2016Q3	22												
2016Q4	14												
2017Q1	19												
2017Q2	28												
2017Q3	17												
2017Q4	11												
2018Q1	15												
2018Q2	15												
2018Q3	18												
2018Q4	20												
2019Q1	19												
2019Q2	25												
2019Q3	10												
2019Q4	41												
2020Q1 2020Q2	28 23												
2020Q2	23												
Total	719												

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

Q30

Q31

180,616 193,802

164,440 167,601

706,751 749,525

334,065 347,058 870,054 915,827 804,372

Q32

209,557

170,994

786,144

357,361

Q33

175,158

818,695

Q34

179,051

221,249 231,846

Q34

241,191

Admittance	Living						Ir	ncremental Be	nefits Paid by	Fund Particip	ation Quarter							
Quarter	<u>Participants</u>	<u>Q1</u>	<u>Q2</u>	Q3	Q4	<u>Q5</u>	Q6	Q7	Q8	<u>Q9</u>	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
2011Q4	11	-	3,146	94,260	144,173	27,926	42,167	22,720	101,483	69,656	29,373	28,827	54,812	47,626	27,564	48,782	108,661	51,481
2012Q1	11	-	11,909	28,215	15,444	3,802	9,275	24,942	29,365	45,050	65,147	33,607	38,857	22,710	17,639	19,004	47,555	8,050
2012Q2	15	717	213,939	222,675	216,063	220,760	219,402	284,456	287,128	360,835	337,540	310,577	284,497	328,790	369,738	355,414	322,973	388,125
2012Q3	25	17,222	58,895	119,468	117,755	160,748	148,012	211,218	300,445	433,929	286,997	349,458	267,625	302,467	229,506	226,706	256,203	321,808
2012Q4	38	371	75,588	146,333	431,812	623,934	520,889	1,045,294	1,180,508	1,165,671	1,148,800	1,218,933	894,490	978,263	927,857	1,354,514	1,174,223	906,524
2013Q1	5	-	780	10,857	36,713	37,090	86,384	177,708	162,554	132,023	136,890	119,318	117,497	87,645	124,918	149,075	110,923	132,056
2013Q2	30	-	41,406	67,708	78,441	109,369	161,013	217,746	181,675	116,207	135,157	197,202	256,410	167,023	273,743	215,624	191,285	285,507
2013Q3	26	-	9,394	89,664	176,462	348,379	366,278	407,351	431,269	361,886	366,426	311,761	270,692	340,485	303,320	281,603	325,761	129,991
2013Q4	8	60	15,787	22,442	52,010	55,080	37,953	152,406	42,227	41,285	68,386	120,264	105,891	45,872	73,694	99,640	75,194	92,384
2014Q1	17	602	39,529	100,258	166,996	143,474	269,659	282,592	372,432	227,482	404,028	331,801	364,447	363,952	550,020	436,798	424,367	461,052
2014Q2	24	30,945	132,707	205,442	230,289	335,796	222,383	350,374	280,346	272,353	327,022	254,665	265,346	465,824	240,840	205,985	367,940	223,774
2014Q3	20	24,460	105,657	644,449	392,488	282,863	305,247	296,763	249,677	377,991	264,554	351,669	427,155	460,362	370,354	783,163	174,676	389,194
2014Q4	19	1,609	73,351	103,984	172,768	198,623	159,203	193,955	254,713	264,161	336,275	355,696	334,321	362,678	337,740	244,266	347,343	462,515
2015Q1	26	3,902	118,971	137,048	184,125	195,370	230,680	288,099	212,728	354,753	339,026	219,468	632,582	364,574	248,757	370,420	407,394	296,841
2015Q2	31	137,049	402,726	435,224	352,996	410,257	523,451	381,714	661,892	618,164	459,971	456,194	825,441	549,361	790,790	1,084,462	814,368	697,691
2015Q3	16	-	30,164	103,507	80,558	69,794	91,758	68,778	223,018	175,695	297,615	259,387	244,576	381,432	192,952	241,371	445,606	321,371
2015Q4	19	3,829	102,088	91,181	172,019	321,337	211,106	252,349	180,709	145,837	282,289	316,999	306,819	478,795	340,754	198,342	307,314	409,781
2016Q1	18	210	16,754	185,361	164,559	176,678	222,131	265,022	151,593	251,157	135,105	240,923	311,580	167,178	225,351	266,054	283,418	386,185
2016Q2	35	10,141	71,367	160,956	264,242	202,010	416,172	246,795	536,249	818,321	671,599	800,518	810,776	545,852	399,465	812,641	1,185,904	473,004
2016Q3	22	-	94,668	205,067	179,295	214,771	169,535	197,464	155,428	206,635	166,004	107,035	219,367	206,483	203,549	200,151	183,271	
2016Q4	14	-	157,250	157,366	254,248	179,571	327,343	158,566	384,037	181,017	359,813	230,110	206,758	241,719	289,402	273,035		
2017Q1	19	-	122,431	174,172	472,382	240,410	323,718	196,024	234,344	150,282	244,833	231,521	250,321	374,717	492,203			
2017Q2	28	9,506	167,627	184,879	378,303	319,302	436,388	284,986	359,278	349,027	369,305	390,795	357,099	360,054				
2017Q3	17	750	30,939	88,216	177,929	181,238	243,892	258,850	604,157	311,889	470,160	479,241	221,805					
2017Q4	11	910	13,384	271,321	234,524	40,209	792,209	251,977	71,311	174,740	204,636	494,067						
2018Q1	15	-	1,706	89,268	177,560	182,290	109,247	405,850	419,980	301,351	145,941							
2018Q2	15	-	26,518	86,218	117,923	184,907	365,639	259,310	366,091	168,617								
2018Q3	18	-	55,875	41,230	230,697	127,167	310,909	159,618	152,516									
2018Q4	20	-	7,151	254,792	375,503	434,592	854,774	304,617										
2019Q1	19	43	12,364	146,822	363,869	599,678	394,806											
2019Q2	25	-	30,693	215,848	204,388	727,671												
2019Q3	10		39,033	94,459	57,469													
2019Q4	41	7,002	342,828	504,930														
2020Q1	28	4,181	47,286															
2020Q2	23	-																
Total	719																	

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

Admittance	Living							Increm	ental Benefit	s Paid by Fund	l Participation	Quarter								
Quarter	<u>Participants</u>	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	Q29	Q30	Q31	Q32	Q33	Q34	Q35	Total
2011Q4	11	28,752	49,678	50,087	55,775	59,762	69,834	59,758	56,849	144,337	106,913	98,308	121,098	182,965	145,051	173,303	128,606	116,570	102,802	2,653,106
2012Q1	11	8,287	14,368	40,610	65,249	105,081	141,372	30,423	160,512	607,638	42,285	36,061	114,231	22,149	34,779	37,316	45,809	42,822		1,969,564
2012Q2	15	349,296	336,954	375,984	440,301	426,941	348,845	713,715	516,684	435,265	632,934	406,936	416,523	477,262	641,614	549,281	488,256			12,280,419
2012Q3	25	307,643	238,399	314,347	389,016	261,971	507,772	414,951	331,539	309,276	223,944	401,243	385,568	457,496	324,832	257,553				8,934,013
2012Q4	38	1,038,009	1,779,355	1,525,926	763,402	1,540,636	776,503	1,738,563	1,927,812	1,342,537	1,954,365	1,396,773	1,931,997	1,552,175	1,739,388					34,801,444
2013Q1	5	159,165	175,258	130,412	161,152	221,890	103,938	184,382	216,135	280,731	185,013	219,674	168,724	192,955						4,021,861
2013Q2	30	246,411	140,344	384,275	245,332	288,796	207,737	516,227	496,133	637,311	891,812	955,645	579,065							8,284,603
2013Q3	26	233,702	141,831	116,773	162,384	328,688	140,031	217,140	166,754	167,698	206,360	156,590								6,558,675
2013Q4	8	91,257	108,478	53,984	120,859	60,805	86,037	96,409	119,008	179,187	523,978									2,540,576
2014Q1	17	280,450	434,155	758,208	338,804	250,559	493,832	380,612	433,439	278,562										8,588,110
2014Q2	24	313,120	426,463	423,346	399,652	349,347	456,615	220,993	200,477											7,202,045
2014Q3	20	466,826	496,231	459,264	498,283	534,967	616,974	483,546												9,456,814
2014Q4	19	249,641	299,587	457,909	441,494	460,699	355,764													6,468,296
2015Q1	26	371,925	442,027	550,201	434,119	518,889														6,921,900
2015Q2	31	802,793	654,317	685,037	923,324															12,667,222
2015Q3	16	257,980	272,563	238,079																3,996,203
2015Q4	19	530,408	769,545																	5,421,500
2016Q1	18	268,874																		3,718,134
2016Q2	35																			8,426,013
2016Q3	22																			2,708,721
2016Q4	14																			3,400,234
2017Q1	19																			3,507,358
2017Q2	28																			3,966,550
2017Q3 2017Q4	17 11																			3,069,066
2017Q4 2018Q1	15																			2,549,286 1,833,194
2018Q1 2018Q2	15																			1,575,224
2018Q2 2018Q3	18																			1,078,012
2018Q3 2018Q4	20																			2,231,430
2019Q1	19																			1,517,583
2019Q2	25																			1,178,600
2019Q3	10																			190,961
2019Q4	41																			854,760
2020Q1	28																			51,468
2020Q2	23																			-
Total	719																			184,622,945

Admittance	Living	· · · · · · · · · · · · · · · · · · ·																
Quarter	<u>Participants</u>	<u>Q1</u>	Q2	<u>Q3</u>	Q4	Q5	<u>Q6</u>	<u>Q7</u>	<u>Q8</u>	<b>Q9</b>	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
2011Q4	11	-	3,146	97,406	241,579	269,505	311,672	334,391	435,875	505,531	534,904	563,731	618,543	666,169	693,733	742,515	851,176	902,658
2012Q1	11	-	11,909	40,124	55,568	59,370	68,645	93,587	122,952	168,002	233,149	266,756	305,613	328,323	345,962	364,966	412,521	420,571
2012Q2	15	717	214,656	437,331	653,394	874,153	1,093,555	1,378,011	1,665,139	2,025,974	2,363,513	2,674,090	2,958,587	3,287,378	3,657,115	4,012,529	4,335,502	4,723,627
2012Q3	25	17,222	76,117	195,585	313,341	474,089	622,100	833,319	1,133,763	1,567,693	1,854,690	2,204,148	2,471,773	2,774,240	3,003,745	3,230,451	3,486,654	3,808,463
2012Q4	38	371	75,958	222,292	654,104	1,278,038	1,798,927	2,844,220	4,024,728	5,190,399	6,339,199	7,558,133	8,452,623	9,430,886				13,794,005
2013Q1	5	-	780	11,637	48,351	85,440	171,825	349,533	512,087	644,110	781,000	900,318	1,017,815	1,105,460	1,230,378	1,379,453	1,490,376	1,622,432
2013Q2	30	-	41,406	109,114	187,555	296,924	457,936	675,682	857,357	973,565	1,108,721	1,305,923	1,562,333	1,729,356	2,003,100	2,218,724	2,410,008	2,695,515
2013Q3	26	-	9,394	99,058	275,521	623,900	990,178	1,397,528	1,828,797	2,190,683	2,557,109	2,868,870	3,139,562	3,480,047	3,783,367	4,064,970	4,390,731	4,520,722
2013Q4	8	60	15,848	38,290	90,300	145,380	183,334	335,739	377,966	419,251	487,637	607,900	713,791	759,662	833,356	932,996	1,008,190	1,100,574
2014Q1	17	602	40,131	140,389	307,385	450,858	720,517	1,003,109	1,375,541	1,603,023	2,007,051	2,338,852	2,703,299	3,067,251	3,617,271	4,054,069	4,478,436	4,939,488
2014Q2	24	30,945	163,652	369,094	599,383	935,179	1,157,563	1,507,937	1,788,283	2,060,636	2,387,658	2,642,323	2,907,669	3,373,493	3,614,333	3,820,318	4,188,258	4,412,032
2014Q3	20	24,460	130,117	774,566	1,167,055	1,449,918	1,755,165	2,051,928	2,301,605	2,679,596	2,944,150	3,295,818	3,722,974	4,183,336	4,553,690	5,336,853	5,511,529	5,900,724
2014Q4	19	1,609	74,960	178,944	351,712	550,336	709,539	903,494	1,158,207	1,422,368	1,758,643	2,114,339	2,448,660	2,811,338	3,149,078	3,393,344	3,740,687	4,203,202
2015Q1	26	3,902	122,872	259,920	444,045	639,416	870,096	1,158,195	1,370,923	1,725,676	2,064,703	2,284,171	2,916,752	3,281,327	3,530,084	3,900,504	4,307,898	4,604,738
2015Q2	31	137,049	539,776	974,999	1,327,995	1,738,252	2,261,703	2,643,417	3,305,309	3,923,472	4,383,444	4,839,638	5,665,079	6,214,440	7,005,230	8,089,692	8,904,060	9,601,751
2015Q3	16	-	30,164	133,672	214,230	284,024	375,782	444,559	667,577	843,272	1,140,887	1,400,274	1,644,850	2,026,282	2,219,234	2,460,605	2,906,211	3,227,582
2015Q4	19	3,829	105,918	197,098	369,117	690,453	901,560	1,153,908	1,334,617	1,480,454	1,762,744	2,079,742	2,386,561	2,865,356	3,206,110	3,404,452	3,711,766	4,121,546
2016Q1	18	210	16,964	202,325	366,884	543,562	765,693	1,030,715	1,182,308	1,433,465	1,568,570	1,809,493	2,121,073	2,288,252	2,513,603	2,779,657	3,063,075	3,449,260
2016Q2	35	10,141	81,508	242,464	506,706	708,716	1,124,888	1,371,684	1,907,933	2,726,253	3,397,852	4,198,370	5,009,147	5,554,999	5,954,464	6,767,105	7,953,009	8,426,013
2016Q3	22	-	94,668	299,734	479,029	693,799	863,335	1,060,799	1,216,227	1,422,862	1,588,866	1,695,901	1,915,267	2,121,750	2,325,299	2,525,450	2,708,721	
2016Q4	14	-	157,250	314,616	568,864	748,435	1,075,778	1,234,343	1,618,380	1,799,397	2,159,210	2,389,320	2,596,078	2,837,797	3,127,198	3,400,234		
2017Q1	19	-	122,431	296,602	768,985	1,009,395	1,333,113	1,529,136	1,763,480	1,913,762	2,158,595	2,390,116	2,640,438	3,015,154	3,507,358			
2017Q2	28	9,506	177,133	362,013	740,316	1,059,618	1,496,005	1,780,991	2,140,269	2,489,296	2,858,602	3,249,397	3,606,496	3,966,550				
2017Q3	17	750	31,689	119,904	297,834	479,072	722,964	981,814	1,585,971	1,897,860	2,368,020	2,847,261	3,069,066					
2017Q4	11	910	14,294	285,615	520,139	560,348	1,352,557	1,604,533	1,675,844	1,850,584	2,055,219	2,549,286						
2018Q1	15	-	1,706	90,975	268,535	450,825	560,073	965,923	1,385,902	1,687,253	1,833,194							
2018Q2	15	-	26,518	112,736	230,660	415,567	781,205	1,040,516	1,406,607	1,575,224								
2018Q3	18	-	55,875	97,105	327,802	454,969	765,878	925,496	1,078,012									
2018Q4	20	-	7,151	261,944	637,447	1,072,039	1,926,813	2,231,430										
2019Q1	19	43	12,408	159,229	523,098	1,122,777	1,517,583											
2019Q2	25	-	30,693	246,541	450,929	1,178,600												
2019Q3	10	-	39,033	133,492	190,961													
2019Q4	41	7,002	349,830	854,760														
2020Q1	28	4,181	51,468															
2020Q2	23	-																
Total	719																	

Admittance	Living							Cumulativ	e Benefits by	Fund Participa	ation Quarter									
Quarter	<u>Participants</u>	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	Q29	Q30	Q31	Q32	Q33	Q34	Q35	Total
2011Q4	11	931,410	981,088	1,031,175	1,086,949	1,146,711	1,216,546	1,276,304	1,333,154	1,477,490	1,584,403	1,682,712	1,803,809	1,986,774	2,131,825	2,305,128	2,433,734	2,550,304	2,653,106	2,653,106
2012Q1	11	428,858	443,225	483,835	549,084	654,165	795,538	825,961	986,473	1,594,111	1,636,396	1,672,457	1,786,689	1,808,837	1,843,616	1,880,932	1,926,741	1,969,564		1,969,564
2012Q2	15	5,072,924	5,409,877	5,785,861	6,226,162	6,653,103	7,001,948	7,715,663	8,232,347	8,667,612	9,300,547	9,707,483	10,124,006	10,601,268	11,242,882	11,792,163	12,280,419			12,280,419
2012Q3	25	4,116,105	4,354,505	4,668,852	5,057,868	5,319,839	5,827,611	6,242,562	6,574,100	6,883,377	7,107,321	7,508,564	7,894,132	8,351,628	8,676,460	8,934,013				8,934,013
2012Q4	38	14,832,013		18,137,294	18,900,696		21,217,834	22,956,397		26,226,747	28,181,111		31,509,881	33,062,056	34,801,444					34,801,444
2013Q1	5	1,781,597	1,956,855	2,087,267	2,248,419	2,470,309	2,574,247	2,758,629	2,974,764	3,255,495	3,440,508	3,660,182	3,828,906	4,021,861						4,021,861
2013Q2	30	2,941,926	3,082,271	3,466,545	3,711,877	4,000,673	4,208,410	4,724,637	5,220,770	5,858,081	6,749,893	7,705,538	8,284,603							8,284,603
2013Q3	26	4,754,424	4,896,255	5,013,028	5,175,413	5,504,101	5,644,132	5,861,273	6,028,027	6,195,725	6,402,085	6,558,675								6,558,675
2013Q4	8	1,191,831	1,300,310	1,354,293	1,475,152	1,535,957	1,621,994	1,718,403	1,837,411	2,016,598	2,540,576									2,540,576
2014Q1	17	5,219,939	5,654,094	6,412,303	6,751,107	7,001,666	7,495,497	7,876,109	8,309,548	8,588,110										8,588,110
2014Q2	24	4,725,152	5,151,615	5,574,962	5,974,614	6,323,960	6,780,575	7,001,568	7,202,045											7,202,045
2014Q3	20	6,367,549	6,863,780	7,323,044	7,821,327	8,356,294	8,973,268	9,456,814												9,456,814
2014Q4	19	4,452,843	4,752,430	5,210,338	5,651,832	6,112,531	6,468,296													6,468,296
2015Q1	26	4,976,664	5,418,691	5,968,892	6,403,010	6,921,900														6,921,900
2015Q2	31	10,404,544		11,743,898	12,667,222															12,667,222
2015Q3	16	3,485,562	3,758,125	3,996,203																3,996,203
2015Q4	19	4,651,954	5,421,500																	5,421,500
2016Q1	18	3,718,134																		3,718,134
2016Q2	35																			8,426,013
2016Q3	22																			2,708,721
2016Q4 2017Q1	14																			3,400,234
2017Q1 2017Q2	19 28																			3,507,358 3,966,550
2017Q2 2017Q3	17																			3,966,550
2017Q3 2017Q4	11																			2,549,286
2017Q4 2018Q1	15																			1,833,194
2018Q1 2018Q2	15																			1,575,224
2018Q2 2018Q3	18																			1,078,012
2018Q4	20																			2,231,430
2019Q1	19																			1,517,583
2019Q2	25																			1,178,600
2019Q3	10																			190,961
2019Q4	41																			854,760
2020Q1	28																			51,468
2020Q2	23																			- ,
Total	719																			184,622,945

#### Exhibit 5 Page 1

**New York State Department of Health** 

## Quarterly Analysis of New York Medical Indemnity Fund

Projected Incremental Nominal Payments per Participant by Admittance Quarter

#### As of June 30, 2020

Admittance											Inc	remental Bene	fits Paid by F	und Participati	on Quarter												
Quarter	<b>Participants</b>	<u>Q1</u>	<u>Q2</u>	Q3	Q4	Q5	Q6	<u>Q7</u>	Q8	<u>Q9</u>	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26
2011Q4	11	-	3,146	94,260	144,173	27,926	42,167	22,720	101,483	69,656	29,373	28,827	54,812	47,626	27,564	48,782	108,661	51,481	28,752	49,678	50,087	55,775	59,762	69,834	59,758	56,849	144,337
2012Q1	11	-	11,909	28,215	15,444	3,802	9,275	24,942	29,365	45,050	65,147	33,607	38,857	22,710	17,639	19,004	47,555	8,050	8,287	14,368	40,610	65,249	105,081	141,372	30,423	160,512	607,638
2012Q2	15	717	213,939	222,675	216,063	220,760	219,402	284,456	287,128	360,835	337,540	310,577	284,497	328,790	369,738	355,414	322,973	388,125	349,296	336,954	375,984	440,301	426,941	348,845	713,715	516,684	435,265
2012Q3	25	17,222	58,895	119,468	117,755	160,748	148,012	211,218	300,445	433,929	286,997	349,458	267,625	302,467	229,506	226,706	256,203	321,808	307,643	238,399	314,347	389,016	261,971	507,772	414,951	331,539	309,276
2012Q4	38	371	75,588	146,333	431,812	623,934	520,889	1,045,294	1,180,508	1,165,671	1,148,800	1,218,933	894,490	978,263	927,857	1,354,514	1,174,223	906,524	1,038,009	1,779,355	1,525,926	763,402	1,540,636	776,503	1,738,563	1,927,812	1,342,537
2013Q1	5	-	780	10,857	36,713	37,090	86,384	177,708	162,554	132,023	136,890	119,318	117,497	87,645	124,918	149,075	110,923	132,056	159,165	175,258	130,412	161,152	221,890	103,938	184,382	216,135	280,731
2013Q2	30	-	41,406	67,708	78,441	109,369	161,013	217,746	181,675	116,207	135,157	197,202	256,410	167,023	273,743	215,624	191,285	285,507	246,411	140,344	384,275	245,332	288,796	207,737	516,227	496,133	637,311
2013Q3	26	-	9,394	89,664	176,462	348,379	366,278	407,351	431,269	361,886	366,426	311,761	270,692	340,485	303,320	281,603	325,761	129,991	233,702	141,831	116,773	162,384	328,688	140,031	217,140	166,754	167,698
2013Q4	8	60	15,787	22,442	52,010	55,080	37,953	152,406	42,227	41,285	68,386	120,264	105,891	45,872	73,694	99,640	75,194	92,384	91,257	108,478	53,984	120,859	60,805	86,037	96,409	119,008	179,187
2014Q1	17	602	39,529	100,258	166,996	143,474	269,659	282,592	372,432	227,482	404,028	331,801	364,447	363,952	550,020	436,798	424,367	461,052	280,450	434,155	758,208	338,804	250,559	493,832	380,612	433,439	278,562
2014Q2	24	30,945	132,707	205,442	230,289	335,796	222,383	350,374	280,346	272,353	327,022	254,665	265,346	465,824	240,840	205,985	367,940	223,774	313,120	426,463	423,346	399,652	349,347	456,615	220,993	200,477	462,635
2014Q3	20	24,460	105,657	644,449	392,488	282,863	305,247	296,763	249,677	377,991	264,554	351,669	427,155	460,362	370,354	783,163	174,676	389,194	466,826	496,231	459,264	498,283	534,967	616,974	483,546	604,791	604,059
2014Q4	19	1,609	73,351	103,984	172,768	198,623	159,203	193,955	254,713	264,161	336,275	355,696	334,321	362,678	337,740	244,266	347,343	462,515	249,641	299,587	457,909	441,494	460,699	355,764	379,622	388,752	388,282
2015Q1	26	3,902	118,971	137,048	184,125	195,370	230,680	288,099	212,728	354,753	339,026	219,468	632,582	364,574	248,757	370,420	407,394	296,841	371,925	442,027	550,201	434,119	518,889	393,739	393,262	402,721	402,234
2015Q2	31	137,049	402,726	435,224	352,996	410,257	523,451	381,714	661,892	618,164	459,971	456,194	825,441	549,361	,	1,084,462	814,368	697,691	802,793	654,317	685,037	923,324	828,827	827,824	826,822	846,709	845,684
2015Q3	16		30,164	103,507	80,558	69,794	91,758	68,778	223,018	175,695	297,615	259,387	244,576	381,432	192,952	241,371	445,606	321,371	257,980	272,563	238,079	192,276	192,044	191,811	191,579	196,187	195,950
2015Q4	19	3,829	102,088	91,181	172,019	321,337	211,106	252,349	180,709	145,837	282,289	316,999	306,819	478,795	340,754	198,342	307,314	409,781	530,408	769,545	338,062	320,826	320,438	320,051	319,663	327,352	326,956
2016Q1	18	210	16,754	185,361	164,559	176,678	222,131	265,022	151,593	251,157	135,105	240,923	311,580	167,178	225,351	266,054	283,418	386,185	268,874	312,731	312,353	296,428	296,069	295,711	295,353	302,457	302,091
2016Q2	35	10,141	71,367	160,956	264,242	202,010	416,172	246,795	536,249	818,321	671,599	800,518	810,776	545,852	399,465	812,641	1,185,904	473,004	567,985	567,298	566,611	537,723	537,072	536,422	535,773	548,660	547,996
2016Q3	22	-	94,668	205,067	179,295	214,771	169,535	197,464	155,428	206,635	166,004	107,035	219,367	206,483	203,549	200,151	183,271	379,108	378,649	378,191	377,734	358,475	358,041	357,608	357,175	365,766	365,324
2016Q4	14	-	157,250	157,366	254,248	179,571	327,343	158,566	384,037	181,017	359,813	230,110	206,758	241,719	289,402	273,035	276,299	292,569	292,215	291,861	291,508	276,645	276,311	275,976	275,642	282,272	281,931
2017Q1	19	0.500	122,431	174,172	472,382	240,410	323,718	196,024	234,344	150,282	244,833	231,521	250,321	374,717	492,203	340,801	340,389	360,433	359,997	359,561	359,126	340,816	340,404	339,992	339,581	347,748	347,327
2017Q2 2017Q3	28 17	9,506 750	167,627 30.939	184,879	378,303 177,929	319,302	436,388 243.892	284,986 258,850	359,278	349,027	369,305 470,160	390,795 479,241	357,099 221,805	360,054 296,937	479,656 296,578	479,076 296,219	478,496 295,861	506,673 313,283	506,060 312.904	505,448 312,525	504,836	479,097 296,232	478,517 295.874	477,938 295,516	477,360	488,842 302,257	488,250 301.892
2017Q3 2017Q4		910	13,384	88,216 271,321	234,524	181,238 40,209	792,209	258,850	604,157	311,889 174,740	204,636	479,241	256,455	243,564	243,269	242,975	242,681	256,971	256.660	256,350	312,147	242,985	295,874	242,398	295,158 242,105	247.928	247.628
2017Q4 2018Q1	11 15	910	1.706	89,268	177,560	182,290	109,247	405,850	71,311 419,980	301,351	145,941	261,017	250,455	243,564	243,269	242,975	242,681	261,226	260,910	260,594	256,040 260.279	242,985	242,691	242,398	242,105	252,032	251.727
201802	15		26.518	86.218	117,923	184,907	365,639	259,310	366,091	168,617	290,658	290,306	289,955	275,380	275,046	274.714	274.381	290,538	290,310	289.836	289,485	274,726	274,393	274,061	273,730	280.313	279,974
201803	18		55.875	41,230	230,697	127,167	310,909	159,618	152,516	338,281	337,872	337,463	337,055	320,112	319,725	319,338	318,952	337,733	337.325	336.917	336,509	319,352	318,966	318,580	318,194	325.847	325.453
2018Q3	20		7.151	254,792	375,503	434,592	854,774	304.617	382,806	406,579	406,087	405,595	405,105	384.741	384,276	383,811	383,347	405,920	405,429	404.939	404,449	383.828	383,363	382,900	382.436	391.635	391.161
2019Q1	19	43	12.364	146,822	363,869	599,678	394.806	352,487	352,060	373,923	373,471	373,019	372,568	353,840	353,412	352,984	352,557	373,318	372.866	372.415	371.964	353,000	352,573	352,146	351.720	360,179	359,744
201902	25		30.693	215.848	204,388	727,671	459,922	459,365	458.810	487.302	486,712	486.124	485,535	461.129	460,571	460.014	459,457	486.513	485,924	485.336	484,749	460.034	459,478	458,922	458.366	469.391	468.823
201903	10		39.033	94,459	57,469	184,406	184.183	183,960	183,737	195,147	194,911	194,675	194,440	184.666	184,443	184.219	183,997	194.831	194,596	194.360	194,125	184.227	184.005	183,782	183,560	187.975	187.747
2019Q4	41	7.002	342.828	504,930	775,215	763,005	762.082	761,160	760,239	807.450	806,473	805,497	804.523	764.082	763,158	762,234	761,312	806.142	805.167	804.193	803.220	762.268	761.345	760,424	759,504	777.772	776.831
202001	28	4.181	47.286	525,807	525.171	516,899	516,274	515,649	515.025	547.009	546,347	545,686	545,026	517.629	517.003	516.377	515,753	546.123	545,462	544.802	544,143	516,400	515,775	515.151	514,528	526,903	526.266
202002	23	-,101	428,970	428,451	427.932	421.192	420,683	420.174	419.665	445.727	445.187	444,649	444.111	421.787	421,277	420.767	420,258	445.005	444.466	443,929	443.392	420,785	420,276	419,768	419.260	429.344	428.824
222002			,,,,,	,-51	,552	,	,003	,_,	,003	, , ,	,107	,043	,	,,,,,,	,_,	,,,,,,	,	, 0 0 3	,400	, 52.5	,	,,,	,_,	,, 00	,_	.22,544	0,024

Sources:

719

Total

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

#### Quarterly Analysis of New York Medical Indemnity Fund

## Projected Incremental Nominal Payments per Participant by Admittance Quarter

#### As of June 30, 2020

Admittance									Inci	emental Be	nefits Paid by	Fund Partic	pation Quart	er													
Quarter	<b>Participants</b>	Q27	Q28	Q29	Q30	Q31	Q32	Q33	Q34	Q35	Q36	Q37	Q38	Q39	Q40	Q41	Q42	Q43	Q44	Q45	Q46	Q47	Q48	Q49	Q50	<u>051</u>	Q52
2011Q4	11	106,913	98,308	121,098	182,965	145,051	173,303	128,606	116,570	102,802	116,674	111,830	111,694	111,559	111,424	117,601	117,459	117,316	117,175	111,689	111,554	111,419	111,284	115,341	115,201	115,062	114,923
2012Q1	11	42,285	36,061	114,231	22,149	34,779	37,316	45,809	42,822	76,796	76,703	73,519	73,430	73,341	73,252	77,313	77,219	77,126	77,033	73,427	73,338	73,249	73,160	75,827	75,735	75,644	75,552
2012Q2	15	632,934	406,936	416,523	477,262	641,614	549,281	488,256	591,561	590,846	590,131	565,629	564,945	564,261	563,578	594,820	594,100	593,382	592,664	564,920	564,236	563,554	562,872	583,390	582,684	581,979	581,275
2012Q3	25	223,944	401,243	385,568	457,496	324,832	257,553	481,436	480,854	480,272	479,691	459,775	459,218	458,663	458,108	483,503	482,918	482,333	481,750	459,198	458,643	458,088	457,533	474,211	473,638	473,065	472,492
2012Q4	38	1,954,365	1,396,773	1,931,997	1,552,175	1,739,388	1,616,862	1,712,037	1,709,966	1,707,897	1,705,830	1,635,005	1,633,027	1,631,051	1,629,078	1,719,385	1,717,305	1,715,227	1,713,151	1,632,956	1,630,980	1,629,007	1,627,036	1,686,344	1,684,304	1,682,266	1,680,231
2013Q1	5																204,396	204,148									
2013Q2	30	891,812 955,645 79,065 332,226 331,824 331,423 350,931 350,507 350,083 349,659 335,142 334,736 334,736 334,31 333,927 352,438 352,011 351,585 351,160 334,721 334,316 333,912 333,508 345,665 345,247 344,64															344,829	344,412									
2013Q3	26	206,360 156,590 388,057 387,87 387,119 386,650 409,410 408,914 408,420 407,926 390,989 390,516 390,043 389,571 411,167 410,670 410,173 409,676 390,499 390,026 389,554 389,083 403,266 402,778 402,21															402,291	401,804									
2013Q4	8	523,978	120,496	122,664	122,515	122,367	122,219	129,413	129,257	129,100	128,944	123,590	123,441	123,291	123,142	129,969	129,811	129,654	129,497	123,435	123,286	123,137	122,988	127,471	127,317	127,163	127,009
2014Q1	17	453,041	452,493	460,632	460,075	459,518	458,962	485,978	485,390	484,803	484,217	464,112	463,551	462,990	462,430	488,064	487,474	486,884	486,295	463,530	462,970	462,409	461,850	478,685	478,106	477,528	476,950
2014Q2	24	462,076	461,517	469,818	469,250	468,682	468,115	495,670	495,070	494,471	493,873	473,368	472,795	472,223	471,652	497,798	497,195	496,594	495,993	472,775	472,202	471,631	471,061	488,232	487,641	487,051	486,462
2014Q3	20	603,329	602,599	613,438	612,696	611,955	611,214	647,193	646,410	645,628	644,846	618,073	617,325	616,578	615,832	649,970	649,184	648,399	647,614	617,298	616,551	615,805	615,060	637,480	636,709	635,939	635,169
2014Q4	19	387,812	387,343	394,310	393,833	393,357	392,881	416,007	415,504	415,001	414,499	397,289	396,809	396,329	395,849	417,793	417,287	416,782	416,278	396,791	396,311	395,832	395,353	409,764	409,268	408,773	408,279
2015Q1	26	401,747	401,261	408,479	407,984	407,491	406,998	430,955	430,434	429,913	429,393	411,565	411,067	410,570	410,073	432,805	432,281	431,758	431,236	411,049	410,552	410,055	409,559	424,488	423,974	423,461	422,949
2015Q2 2015Q3	31 16	844,661 195.713	843,639 195,476	858,815 198.992	857,776 198.751	856,738 198.511	855,701 198,271	906,071 209.942	904,975 209.688	903,880 209.434	902,786 209.180	865,303 200.495	864,256 200.253	863,211 200.011	862,166 199.769	909,960 210.843	908,859 210.587	907,759 210.333	906,661 210.078	864,218 200,244	863,173 200.002	862,128 199.760	861,085 199.518	892,474 206.791	891,394 206.541	890,315 206.291	889,238 206.041
2015Q3 2015Q4	19	326,560	326,165	332,032	331,630	331,229	330,828	350,302	349,878	349,455	349,032	334,541	334,136	333,732	333,328	351,806	351,380	350,955	350,530	334,121	333,717	333,313	332,910	345,045	344,628	344,211	343,794
2016Q1	18	301.725	301.360	306,781	306.410	306.039	305,669	323.662	323,270	322.879	322,488	309.099	308,725	308,351	307.978	325.051	324.658	324.265	323.873	308,712	308.338	307,965	307,592	318.805	318,419	318.034	317.649
2016Q1	35	547,333	546,671	556,504	555,831	555.158	554,487	587,126	586,415	585.706	584,997	560,709	560,030	559,353	558.676	589,646	588.932	588.220	587,508	560,006	559,328	558,651	557,975	578,315	577.615	576,916	576.218
2016Q3	22	364,882	364,440	370,996	370,547	370.098	369,651	391,410	390,936	390,463	389,991	373,799	373,346	372,895	372,443	393,090	392,614	392,139	391,664	373,330	372,878	372,427	371,976	385,536	385,069	384,603	384,138
2016Q4	14	281,589	281.249	286.308	285,961	285,616	285,270	302.062	301.697	301.332	300.967	288,471	288.122	287,773	287,425	303.358	302,991	302.625	302,259	288.109	287.761	287,413	287.065	297,529	297.169	296,809	296.450
201701	19	346,907	346,487	352,720	352,293	351.867	351,441	372,128	371,678	371,229	370,779	355.385	354,955	354,525	354,096	373,726	373,273	372.822	372,371	354,939	354,510	354.081	353,653	366,544	366,100	365,657	365,215
2017Q2	28	487,659	487,069	495,831	495,231	494,632	494,033	523,114	522,481	521,849	521,217	499,577	498,972	498,369	497,766	525,359	524,723	524,088	523,454	498,951	498,347	497,744	497,142	515,263	514,640	514,017	513,395
2017Q3	17	301,526	301,162	306,579	306,208	305,837	305,467	323,448	323,057	322,666	322,276	308,895	308,521	308,148	307,775	324,837	324,444	324,051	323,659	308,508	308,135	307,762	307,389	318,594	318,209	317,824	317,439
2017Q4	11	247,328	247,029	251,472	251,168	250,864	250,561	265,310	264,989	264,668	264,348	253,372	253,066	252,759	252,454	266,448	266,126	265,804	265,482	253,055	252,748	252,443	252,137	261,328	261,012	260,696	260,381
2018Q1	15	251,423	251,119	255,636	255,326	255,017	254,709	269,702	269,376	269,050	268,724	257,567	257,255	256,944	256,633	270,860	270,532	270,205	269,878	257,244	256,933	256,622	256,312	265,655	265,333	265,012	264,692
2018Q2	15	279,636	279,297	284,321	283,977	283,634	283,290	299,966	299,603	299,241	298,879	286,469	286,123	285,777	285,431	301,253	300,889	300,525	300,161	286,110	285,764	285,418	285,073	295,464	295,107	294,750	294,393
2018Q3	18	325,059	324,666	330,506	330,106	329,707	329,308	348,692	348,270	347,849	347,428	333,003	332,600	332,198	331,796	350,189	349,765	349,342	348,919	332,586	332,183	331,782	331,380	343,460	343,044	342,629	342,214
2018Q4	20	390,688	390,215	397,234	396,753	396,273	395,794	419,092	418,585	418,078	417,572	400,235	399,751	399,267	398,784	420,891	420,381	419,873	419,365	399,733	399,250	398,767	398,284	412,803	412,303	411,804	411,306
2019Q1	19	359,308	358,874	365,329	364,887	364,446	364,005	385,431	384,965	384,499	384,034	368,089	367,644	367,199	366,755	387,086	386,617	386,149	385,682	367,628	367,183	366,739	366,295	379,647	379,188	378,729	378,271
2019Q2	25	468,256	467,689	476,102	475,526	474,951	474,376	502,300	501,692	501,085	500,479	479,699	479,119	478,539	477,960	504,455	503,845	503,235	502,627	479,098	478,518	477,939	477,361	494,762	494,163	493,565	492,968
2019Q3	10	187,520	187,293	190,662	190,431	190,201	189,971	201,153	200,910	200,667	200,424	192,103	191,870	191,638	191,406	202,017	201,772	201,528	201,284	191,862	191,630	191,398	191,166	198,135	197,895	197,655	197,416
2019Q4	41	775,891	774,952	788,892	787,937	786,984	786,032	832,301	831,294	830,288	829,283	794,852	793,890	792,930	791,970	835,873	834,861	833,851	832,842	793,856	792,895	791,936	790,978	819,810	818,818	817,828	816,838
2020Q1	28	525,629	524,993	534,437	533,790	533,144	532,499	563,844	563,162	562,480	561,800	538,474	537,823	537,172	536,522	566,264	565,579	564,894	564,211	537,799	537,149	536,499	535,850	555,382	554,710	554,039	553,369
2020Q2	23	428,305	427,787	435,482	434,955	434,429	433,903	459,445	458,889	458,334	457,779	438,772	438,242	437,711	437,182	461,417	460,858	460,301	459,744	438,222	437,692	437,163	436,634	452,550	452,002	451,455	450,909

Sources:

719

Total

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

## Quarterly Analysis of New York Medical Indemnity Fund

## Projected Incremental Nominal Payments per Participant by Admittance Quarter

#### As of June 30, 2020

Admittance											Incremer	ital Benefits	Paid by Fund	l Participatio	n Quarter												
Quarter	<u>Participants</u>	Q53	Q54	Q55	Q56	Q57	Q58	Q59	Q60	Q61	Q62	Q63	Q64	Q65	Q66	Q67	Q68	Q69	Q70	<u>Q71</u>	<u>Q72</u>	Q73	<u>Q74</u>	Q75	Q76	After Q76	Total
2011Q4	11	115,229	115,090	114,950	114,811	120,488	120,342	120,196	120,051	114,869	114,730	114,591	114,453	119,822	119,677	119,532	119,387	113,470	113,333	113,196	113,059	116,842	116,700	116,559	116,418	25,456,106	32,846,212
2012Q1	11	75,754	75,662	75,570	75,479	79,211	79,115	79,019	78,924	75,517	75,425	75,334	75,243	78,773	78,677	78,582	78,487	74,597	74,507	74,417	74,327	76,814	76,721	76,628	76,535	16,735,284	21,895,830
2012Q2	15	582,824	582,119	581,414	580,711	609,422	608,685	607,948	607,213	581,002	580,299	579,597	578,896	606,052	605,319	604,587	603,855	573,927	573,233	572,539	571,847	590,979	590,264	589,550	588,837	128,755,866	166,178,232
2012Q3	25	473,751	473,178	472,606	472,034	495,372	494,773	494,174	493,576	472,271	471,699	471,129	470,559	492,633	492,037	491,441	490,847	466,520	465,955	465,392	464,829	480,381	479,799	479,219	478,639	104,659,886	134,512,100
2012Q4	38	1,684,709	1,682,670	1,680,635	1,678,601	1,761,594	1,759,462	1,757,333	1,755,207	1,679,444	1,677,412	1,675,382	1,673,355	1,751,853	1,749,733	1,747,616	1,745,502	1,658,992	1,656,985	1,654,980	1,652,978	1,708,283	1,706,216	1,704,152	1,702,090	372,181,286	482,986,858
2013Q1	5	204,692	204,445	204,197	203,950	214,034	213,775	213,516	213,258	204,053	203,806	203,559	203,313	212,850	212,593	212,336	212,079	201,568	201,324	201,080	200,837	207,557	207,305	207,055	206,804	45,220,063	58,673,120
2013Q2	30	345,330	344,912	344,495	344,078	361,089	360,653	360,216	359,780	344,250	343,834	343,418	343,002	359,093	358,658	358,224	357,791	340,058	339,647	339,236	338,826	350,162	349,738	349,315	348,892	76,289,300	100,817,194
2013Q3	26	402,875	402,387	401,900	401,414	421,261	420,751	420,242	419,733	401,616	401,130	400,644	400,160	418,931	418,424	417,918	417,413	396,725	396,245	395,766	395,287	408,512	408,018	407,524	407,031	89,001,983	114,898,752
2013Q4	8	127,347	127,193	127,039	126,886	133,159	132,998	132,837	132,676	126,949	126,796	126,642	126,489	132,423	132,263	132,103	131,943	125,404	125,252	125,100	124,949	129,129	128,973	128,817	128,661	28,133,248	36,907,031
2014Q1	17	478,221	477,642	477,065	476,487	500,046	499,441	498,836	498,233	476,726	476,150	475,574	474,998	497,281	496,679	496,078	495,478	470,921	470,351	469,782	469,214	484,913	484,326	483,740	483,155	105,647,293	138,095,676
2014Q2	24	487,758	487,168	486,579	485,990	510,018	509,401	508,784	508,169	486,234	485,645	485,058	484,471	507,198	506,584	505,971	505,359	480,313	479,732	479,151	478,571	494,583	493,985	493,387	492,790	107,754,192	139,754,984
2014Q3	20	636,862	636,091	635,322	634,553	665,926	665,121	664,316	663,512	634,872	634,103	633,336	632,570	662,244	661,443	660,643	659,843	627,141	626,382	625,624	624,867	645,774	644,992	644,212	643,432	140,693,816	183,134,954
2014Q4 2015Q1	19 26	409,367 424,076	408,872 423,563	408,377 423.051	407,883 422.539	428,049 443,430	427,531 442.893	427,014 442,357	426,497 441.822	408,087 422,751	407,594 422,239	407,101 421.728	406,608 421.218	425,682 440,978	425,167 440,444	424,653 439.911	424,139 439,379	403,118 417.603	402,630 417.098	402,143 416,593	401,657 416,089	415,095 430.010	414,593 429,490	414,091 428,970	413,590 428.451	90,436,210 93,685,765	118,486,034 123.358.400
2015Q1 2015Q2	31	891,608	890.529	889.452	888.376	932,298	931.170	930.043	928,918	888,821	887.746	886.672	885,599	927,143	926,021	924,901	923,782	877.998	876,936	875.875	874.815	904.084	902,990	901,898	900,806	196,971,603	258,300,412
2015Q2	16	206.590	206.340	206.091	205.841	216.019	215.757	215.496	215.235	205.945	205.696	205.447	205.198	214.824	214,564	214,305	214.045	203.437	203,191	202.945	202,699	209,481	209,228	208,975	208,722	45,639,384	61.103.017
2015Q3 2015Q4	19	344,711	344.293	343.877	343,461	360,442	360,006	359,570	359,135	343,633	343,217	342,802	342,387	358.449	358,015	357,582	357.149	339,449	339,038	338,628	338,218	349,534	349,111	348,689	348,267	76,152,511	101,046,282
2016Q1	18	318,495	318,110	317.725	317.341	333.031	332.628	332,225	331.823	317.500	317.116	316.732	316,349	331.189	330,788	330,388	329,988	313,634	313,254	312.875	312,497	322,952	322,561	322.171	321.781	70,361,155	92,383,436
2016Q2	35	577,754	577.055	576.357	575,659	604.121	603,390	602,660	601,931	575,948	575,251	574,555	573,860	600.780	600,053	599,327	598,602	568,935	568.246	567,559	566,872	585,838	585,130	584,422	583,714	127,635,824	169,833,725
2016Q3	22	385,162	384,696	384,230	383,765	402,739	402,252	401,765	401,279	383,958	383,494	383.030	382,566	400.513	400.028	399,544	399,060	379,283	378.824	378,365	377.907	390,551	390.079	389,607	389,135	85,088,908	110,690,894
2016Q4	14	297,240	296,881	296,522	296,163	310,805	310,429	310,054	309,679	296,311	295,953	295,595	295,237	309,087	308,713	308,339	307,966	292,703	292,349	291,995	291,642	301,400	301,035	300,671	300,307	65,665,539	87,009,458
2017Q1	19	366,188	365,745	365,303	364,861	382,900	382,437	381,974	381,512	365,044	364,602	364,161	363,721	380,783	380,322	379,862	379,402	360,599	360,162	359,727	359,291	371,312	370,863	370,414	369,966	80,897,346	106,851,414
2017Q2	28	514,764	514,141	513,519	512,897	538,256	537,605	536,954	536,304	513,155	512,534	511,914	511,295	535,280	534,632	533,985	533,339	506,906	506,293	505,680	505,068	521,967	521,335	520,704	520,074	113,720,198	149,720,522
2017Q3	17	318,285	317,900	317,516	317,131	332,811	332,408	332,006	331,604	317,291	316,907	316,523	316,140	330,971	330,570	330,170	329,771	313,427	313,048	312,669	312,291	322,739	322,349	321,959	321,569	70,314,743	93,487,664
2017Q4	11	261,075	260,759	260,443	260,128	272,989	272,659	272,329	272,000	260,259	259,944	259,629	259,315	271,480	271,151	270,823	270,496	257,089	256,778	256,468	256,157	264,728	264,408	264,088	263,768	57,675,899	76,971,893
2018Q1	15	265,397	265,076	264,755	264,435	277,509	277,173	276,838	276,503	264,568	264,247	263,928	263,608	275,974	275,640	275,307	274,974	261,346	261,030	260,714	260,398	269,111	268,785	268,460	268,135	58,630,778	77,748,955
2018Q2	15	295,178	294,821	294,464	294,108	308,649	308,275	307,902	307,530	294,255	293,899	293,544	293,189	306,942	306,571	306,200	305,829	290,672	290,320	289,969	289,618	299,308	298,946	298,584	298,223	65,209,890	86,300,347
2018Q3	18	343,126	342,711	342,297	341,882	358,786	358,352	357,918	357,485	342,054	341,640	341,227	340,814	356,802	356,370	355,939	355,508	337,889	337,480	337,072	336,664	347,928	347,507	347,086	346,666	75,802,557	99,904,129
2018Q4	20	412,402	411,903	411,405	410,907	431,223	430,701	430,180	429,660	411,113	410,616	410,119	409,623	428,838	428,320	427,801	427,284	406,107	405,616	405,125	404,635	418,173	417,667	417,162	416,657	91,106,764	121,392,918
2019Q1	19	379,279	378,820	378,362	377,904	396,588	396,108	395,629	395,150	378,094	377,636	377,179	376,723	394,395	393,918	393,441	392,965	373,489	373,038	372,586	372,135	384,586	384,121	383,656	383,192	83,789,270	111,460,769
2019Q2	25	494,282	493,684	493,086	492,490	516,839	516,214	515,589	514,965	492,737	492,141	491,545	490,951	513,981	513,359	512,738	512,118	486,737	486,148	485,560	484,972	501,198	500,592	499,986	499,381	109,195,361	144,918,036
2019Q3	10	197,942	197,703	197,464	197,225	206,976	206,725	206,475	206,225	197,324	197,085	196,847	196,608	205,831	205,582	205,334	205,085	194,921	194,685	194,450	194,214	200,712	200,469	200,227	199,985	43,728,897	57,937,949
2019Q4	41	819,015	818,024	817,034	816,046	856,392	855,356	854,321	853,288	816,455	815,468	814,481	813,496	851,657	850,627	849,597	848,569	806,513	805,537	804,563	803,589	830,476	829,471	828,467	827,465	180,934,596	240,566,440
2020Q1	28	554,844	554,172	553,502	552,832	580,165	579,463	578,762	578,062	553,110	552,440	551,772	551,104	576,957	576,259	575,562	574,865	546,374	545,713	545,053	544,393	562,608	561,927	561,247	560,568	122,574,555	162,970,499
2020Q2	23	452,111	451,564	451,018	450,472	472,744	472,172	471,601	471,030	450,698	450,153	449,608	449,064	470,130	469,561	468,993	468,425	445,210	444,671	444,133	443,596	458,437	457,883	457,329	456,775	99,879,110	133,182,524
Total	719																								т	otal thru 2020Q2	4,396,326,663

Sources:

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

#### **New York State Department of Health** Quarterly Analysis of New York Medical Indemnity Fund

## Projected Incremental Discounted Payments per Participant by Admittance Quarter

#### As of June 30, 2020

Admittance											Inc	remental Ben	efits Paid by	Fund Partici	pation Quart	er											
Quarter	<b>Participants</b>	<u>Q1</u>	<u>Q2</u>	Q3	Q4	Q5	<u>Q6</u>	<u>Q7</u>	<u>Q8</u>	<u>Q9</u>	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26
2011Q4	11		3,146	94,260	144,173	27,926	42,167	22,720	101,483	69,656	29,373	28,827	54,812	47,626	27,564	48,782	108,661	51,481	28,752	49,678	50,087	55,775	59,762	69,834	59,758	56,849	144,337
2012Q1	11	-	11,909	28,215	15,444	3,802	9,275	24,942	29,365	45,050	65,147	33,607	38,857	22,710	17,639	19,004	47,555	8,050	8,287	14,368	40,610	65,249	105,081	141,372	30,423	160,512	607,638
2012Q2	15	717	213,939	222,675	216,063	220,760	219,402	284,456	287,128	360,835	337,540	310,577	284,497	328,790	369,738	355,414	322,973	388,125	349,296	336,954	375,984	440,301	426,941	348,845	713,715	516,684	435,265
2012Q3	25	17,222	58,895	119,468	117,755	160,748	148,012	211,218	300,445	433,929	286,997	349,458	267,625	302,467	229,506	226,706	256,203	321,808	307,643	238,399	314,347	389,016	261,971	507,772	414,951	331,539	309,276
2012Q4	38	371	75,588	146,333	431,812	623,934	520,889	1,045,294	1,180,508	1,165,671	1,148,800	1,218,933	894,490	978,263	927,857	1,354,514	1,174,223	906,524	1,038,009	1,779,355	1,525,926	763,402	1,540,636	776,503	1,738,563	1,927,812	1,342,537
2013Q1	5	-	780	10,857	36,713	37,090	86,384	177,708	162,554	132,023	136,890	119,318	117,497	87,645	124,918	149,075	110,923	132,056	159,165	175,258	130,412	161,152	221,890	103,938	184,382	216,135	280,731
2013Q2	30	-	41,406	67,708	78,441	109,369	161,013	217,746	181,675	116,207	135,157	197,202	256,410	167,023	273,743	215,624	191,285	285,507	246,411	140,344	384,275	245,332	288,796	207,737	516,227	496,133	637,311
2013Q3	26	-	9,394	89,664	176,462	348,379	366,278	407,351	431,269	361,886	366,426	311,761	270,692	340,485	303,320	281,603	325,761	129,991	233,702	141,831	116,773	162,384	328,688	140,031	217,140	166,754	167,698
2013Q4	8	60	15,787	22,442	52,010	55,080	37,953	152,406	42,227	41,285	68,386	120,264	105,891	45,872	73,694	99,640	75,194	92,384	91,257	108,478	53,984	120,859	60,805	86,037	96,409	119,008	179,187
2014Q1	17	602	39,529	100,258	166,996	143,474	269,659	282,592	372,432	227,482	404,028	331,801	364,447	363,952	550,020	436,798	424,367	461,052	280,450	434,155	758,208	338,804	250,559	493,832	380,612	433,439	278,562
2014Q2	24	30,945	132,707	205,442	230,289	335,796	222,383	350,374	280,346	272,353	327,022	254,665	265,346	465,824	240,840	205,985	367,940	223,774	313,120	426,463	423,346	399,652	349,347	456,615	220,993	200,477	460,351
2014Q3	20	24,460	105,657	644,449	392,488	282,863	305,247	296,763	249,677	377,991	264,554	351,669	427,155	460,362	370,354	783,163	174,676	389,194	466,826	496,231	459,264	498,283	534,967	616,974	483,546	601,805	598,108
2014Q4	19	1,609	73,351	103,984	172,768	198,623	159,203	193,955	254,713	264,161	336,275	355,696	334,321	362,678	337,740	244,266	347,343	462,515	249,641	299,587	457,909	441,494	460,699	355,764	377,747	384,922	382,558
2015Q1	26	3,902	118,971	137,048	184,125	195,370	230,680	288,099	212,728	354,753	339,026	219,468	632,582	364,574	248,757	370,420	407,394	296,841	371,925	442,027	550,201	434,119	518,889	391,794	389,388	396,784	394,347
2015Q2	31	137,049	402,726	435,224	352,996	410,257	523,451	381,714	661,892	618,164	459,971	456,194	825,441	549,361	790,790	1,084,462	814,368	697,691	802,793	654,317	685,037	923,324	824,734	819,668	814,633	830,107	825,008
2015Q3	16	-	30,164	103,507	80,558	69,794	91,758	68,778	223,018	175,695	297,615	259,387	244,576	381,432	192,952	241,371	445,606	321,371	257,980	272,563	238,079	191,327	190,152	188,984	187,823	191,390	190,215
2015Q4	19	3,829	102,088	91,181	172,019	321,337	211,106	252,349	180,709	145,837	282,289	316,999	306,819	478,795	340,754	198,342	307,314	409,781	530,408	769,545	336,393	317,666	315,714	313,775	311,848	317,771	315,819
2016Q1	18	210	16,754	185,361	164,559	176,678	222,131	265,022	151,593	251,157	135,105	240,923	311,580	167,178	225,351	266,054	283,418	386,185	268,874	311,187	309,276	292,058	290,264	288,481	286,709	292,155	290,360
2016Q2	35	10,141	71,367	160,956	264,242	202,010	416,172	246,795	536,249	818,321	671,599	800,518	810,776	545,852	399,465		1,185,904	473,004	565,180	561,709	558,258	527,179	523,941	520,723	517,524	527,355	524,115
2016Q3	22	-	94,668	205,067	179,295	214,771	169,535	197,464	155,428	206,635	166,004	107,035	219,367	206,483	203,549	200,151	183,271	377,236	374,919	372,616	370,327	349,710	347,562	345,428	343,306	349,827	347,678
2016Q4	14	-	157,250	157,366	254,248	179,571	327,343	158,566	384,037	181,017	359,813	230,110	206,758	241,719	289,402	273,035	274,934	289,686	287,907	286,138	284,381	268,549	266,899	265,260	263,631	268,638	266,988
2017Q1	19	-	122,431	174,172	472,382	240,410	323,718	196,024	234,344	150,282	244,833	231,521	250,321	374,717	492,203	339,118	337,035	355,119	352,938	350,770	348,616	329,208	327,186	325,176	323,178	329,317	327,294
2017Q2	28	9,506	167,627	184,879	378,303	319,302	436,388	284,986	359,278	349,027	369,305	390,795	357,099	360,054	477,288	474,356	471,442	496,738	493,687	490,655	487,641	460,493	457,665	454,853	452,060	460,646	457,817
2017Q3	17	750	30,939	88,216	177,929	181,238	243,892	258,850	604,157	311,889	470,160	479,241	221,805	295,471	293,656	291,852	290,060	305,623	303,746	301,880	300,026	283,323	281,583	279,853	278,134	283,417	281,676
2017Q4	11	910	13,384	271,321	234,524	40,209	792,209	251,977	71,311	174,740	204,636	494,067	255,188	241,164	239,683	238,211	236,747	249,450	247,918	246,395	244,882	231,249	229,829	228,417	227,014	231,326	229,905
2018Q1	15	-	1,706	89,268	177,560	182,290	109,247	405,850	419,980	301,351	145,941	259,728	258,132	243,946	242,448	240,959	239,478	252,328	250,778	249,238	247,707	233,917	232,480	231,052	229,633	233,994	232,557
2018Q2	15	-	26,518	86,218	117,923	184,907	365,639	259,310	366,091	168,617	289,222	287,446	285,680	269,980	268,322	266,674	265,036	279,256	277,541	275,836	274,142	258,880	257,290	255,710	254,139	258,966	257,376
2018Q3	18	-	55,875	41,230	230,697	127,167	310,909	159,618	152,516	336,611	334,543	332,488	330,446	312,286	310,367	308,461	306,566	323,016	321,032	319,060	317,100	299,446	297,607	295,779	293,962	299,546	297,706
2018Q4	20	43	7,151 12.364	254,792	375,503 363,869	434,592 599.678	854,774	304,617 350,746	380,916	402,573	400,100 366.148	397,643 363.899	395,200	373,481 341.788	371,187	368,907	366,641 335.528	386,314	383,941	381,583	379,239 347.057	358,126	355,926	353,740	351,567	358,245	356,045
2019Q1	19	43	,	146,822	,		394,806	,	348,591	368,411	,	,	361,664	. ,	339,688	337,602	,-	353,531	351,360	349,202	. ,	327,736	325,723	323,722	321,733	327,845	325,831
2019Q2	25	-	30,693	215,848	204,388	727,671	457,651	454,840	452,046	477,747	474,813	471,896	468,998	443,223	440,501	437,795	435,106	458,452	455,636	452,837	450,056	425,000	422,390	419,795	417,217	425,142	422,530
2019Q3 2019Q4	10 41	7.002	39,033 342,828	94,459	57,469 771,386	183,495	182,368	181,248	180,134	190,376	189,207	188,045	186,889	176,619	175,534 722,709	174,456	173,384	182,687	181,565	180,450	179,341	169,357	168,317	167,283	166,256 684,509	169,414	168,373
2019Q4	41 28	4.181	47,286	504,930 523,211	519,997	755,487 509.279	750,847	746,235 503.042	741,651 499,952	783,818 528,377	779,004 525.132	774,219	769,463 518.700	727,176 490.194	487,183	718,270 484.191	713,858 481,217	752,162 507.037	747,541 503.923	742,950 500.827	738,386 497.751	697,279 470.041	692,996 467.153	688,740 464,284	461.432	697,511	693,227 467.309
	28	4,181	426,851	424,229		412.934	506,151	407.876	499,952		425,787	521,906	,	397,459		. , .		,	408,590	406.081	- , -	381.118	378,777	376.451	374.138	470,197	378.903
2020Q2	23		420,851	424,229	421,624	412,934	410,397	407,876	405,371	428,419	425,/8/	423,172	420,573	397,459	395,018	392,591	390,180	411,116	408,590	406,081	403,586	381,118	3/8,///	5/0,451	3/4,138	381,245	5/8,903

Sources:

719

Total

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity and a discount factor of 2.0% Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

Quarterly Analysis of New York Medical Indemnity Fund

Projected Incremental Discounted Payments per Participant by Admittance Quarter

As of June 30, 2020

Admittance									Incr	emental Ber	efits Paid by	Fund Partic	ipation Quar	ter													
Quarter	<b>Participants</b>	Q27	Q28	Q29	Q30	Q31	Q32	Q33	Q34	Q35	Q36	Q37	Q38	Q39	Q40	Q41	Q42	Q43	Q44	Q45	Q46	Q47	Q48	Q49	Q50	Q51	Q52
2011Q4	11	106,913	98,308	121,098	182,965	145,051	173,303	128,606	116,570	102,802	116,098	110,728	110,048	109,372	108,700	114,159	113,458	112,761	112,068	106,295	105,642	104,993	104,348	107,618	106,957	106,300	105,647
2012Q1	11	42,285	36,061	114,231	22,149	34,779	37,316	45,809	42,822	76,417	75,948	72,435	71,990	71,548	71,108	74,679	74,221	73,765	73,312	69,535	69,108	68,683	68,261	70,400	69,968	69,538	69,111
2012Q2	15	632,934	406,936	416,523	477,262	641,614	549,281	488,256	588,640	585,024	581,431	554,538	551,132	547,747	544,382	571,722	568,211	564,721	561,252	532,337	529,067	525,817	522,587	538,962	535,651	532,361	529,091
2012Q3	25	223,944	401,243	385,568	457,496	324,832	257,553	479,059	476,116	473,192	470,285	448,533	445,778	443,040	440,319	462,433	459,592	456,769	453,964	430,576	427,931	425,303	422,690	435,935	433,257	430,596	427,951
2012Q4	38																1,523,680	1,514,321									
2013Q1	5	185,013 219,674 168,724 192,955 195,716 194,513 204,946 203,687 202,436 201,193 191,887 190,708 189,537 188,373 196,618 195,410 194,210 184,205 183,073 181,949 180,831 186,497 185,352 18															184,213	183,082									
2013Q2	30	891,812 955,645 579,065 330,585 326,555 326,537 344,050 341,937 339,837 337,749 322,128 320,149 318,183 316,228 332,110 330,070 328,042 326,027 309,231 307,331 305,444 303,568 313,079 311,156 30															309,245	307,346									
2013Q3	26	206,360	156,590	386,141	383,769	381,412	379,069	399,400	396,947	394,509	392,085	373,950	371,653	369,371	367,102	385,538	383,170	380,817	378,478	358,979	356,774	354,582	352,404	363,447	361,214	358,995	356,790
2013Q4	8	523,978	119,901	121,455	120,709	119,968	119,231	125,626	124,854	124,087	123,325	117,621	116,898	116,180	115,467	121,266	120,521	119,781	119,045	112,912	112,218	111,529	110,844	114,317	113,615	112,917	112,223
2014Q1	17	450,803	448,034	453,841	451,054	448,283	445,530	469,426	466,542	463,676	460,828	439,514	436,814	434,131	431,465	453,134	450,350	447,584	444,835	421,917	419,326	416,750	414,190	427,168	424,545	421,937	419,345
2014Q2	24	457,523	454,713	460,606	457,777	454,965	452,171	476,423	473,496	470,588	467,697	446,065	443,325	440,602	437,896	459,888	457,063	454,256	451,466	428,206	425,576	422,962	420,364	433,536	430,873	428,226	425,596
2014Q3	20	594,434	590,783	598,440	594,764	591,111	587,480	618,989	615,187	611,409	607,653	579,548	575,988	572,450	568,934	597,507	593,837	590,189	586,564	556,345	552,927	549,531	546,156	563,269	559,809	556,370	552,953
2014Q4	19	380,208	377,872	382,770	380,419	378,082	375,760	395,914	393,482	391,065	388,663	370,686	368,409	366,146	363,897	382,173	379,826	377,493	375,174	355,845	353,660	351,487	349,328	360,274	358,061	355,862	353,676
2015Q1	26	391,924	389,517	394,566	392,142	389,733	387,339	408,114	405,607	403,116	400,640	382,109	379,762	377,430	375,111	393,950	391,530	389,126	386,735	366,811	364,558	362,319	360,093	371,376	369,095	366,828	364,575
2015Q2	31	819,940	814,904	825,466	820,396	815,356	810,348	853,811	848,567	843,354	838,174	799,406	794,496	789,616	784,766	824,179	819,116	814,085	809,084	767,401	762,688	758,003	753,347	776,952	772,180	767,437	762,723
2015Q3	16	189,046	187,885	190,320	189,151	187,989	186,835	196,856	195,646	194,445	193,250	184,312	183,180	182,055	180,937	190,024	188,856	187,696	186,543	176,933	175,846	174,766	173,693	179,135	178,035	176,941	175,854
2015Q4	19	313,879	311,951	315,995	314,054	312,125	310,207	326,845	324,838	322,842	320,859	306,019	304,139	302,271	300,414	315,502	313,564	311,638	309,724	293,767	291,963	290,169	288,387	297,423	295,596	293,781	291,976
2016Q1	18	288,577	286,804	290,522	288,737	286,964	285,201	300,498	298,652	296,817	294,994	281,350	279,622	277,904	276,197	290,068	288,287	286,516	284,756	270,086	268,427	266,778	265,139	273,447	271,768	270,098	268,439
2016Q2	35	520,896	517,697	524,406	521,185	517,984	514,802	542,414	539,082	535,771	532,480	507,851	504,732	501,631	498,550	523,589	520,372	517,176	513,999	487,519	484,524	481,548	478,590	493,586	490,554	487,541	484,547
2016Q3	22	345,542	343,420	347,871	345,734	343,611	341,500	359,816	357,606	355,410	353,227	336,889	334,820	332,763	330,719	347,329	345,195	343,075	340,967	323,401	321,415	319,440	317,478	327,426	325,415	323,416	321,430
2016Q4	14	265,348	263,718	267,136	265,495	263,865	262,244	276,309	274,612	272,925	271,249	258,703	257,114	255,535	253,965	266,720	265,081	263,453	261,835	248,345	246,820	245,304	243,797	251,436	249,892	248,357	246,831
2017Q1	19	325,284	323,286	327,476	325,465	323,465	321,479	338,721	336,640	334,573	332,518	317,138	315,190	313,254	311,330	326,965	324,957	322,961	320,977	304,441	302,571	300,712	298,865	308,230	306,336	304,455	302,585
2017Q2	28	455,005	452,210	458,071	455,257	452,461	449,682	473,800	470,890	467,998	465,123	443,610	440,885	438,177	435,486	457,357	454,547	451,755	448,981	425,849	423,234	420,634	418,050	431,149	428,501	425,869	423,253
2017Q3	17	279,946	278,227	281,833	280,102	278,381	276,671	291,510	289,720	287,940	286,172	272,935	271,259	269,593	267,937	281,393	279,665	277,947	276,240	262,008	260,399	258,799	257,210	265,269	263,640	262,020	260,411
2017Q4	11	228,493	227,089	230,033	228,620	227,215	225,820	237,932	236,470	235,018	233,574	222,771	221,402	220,042	218,691	229,674	228,263	226,861	225,468	213,852	212,538	211,233	209,935	216,513	215,183	213,862	212,548
2018Q1	15	231,129	229,709	232,686	231,257	229,837	228,425	240,676	239,198	237,729	236,268	225,340	223,956	222,581	221,214	232,323	230,896	229,478	228,069	216,319	214,990	213,669	212,357	219,011	217,666	216,329	215,000
2018Q2	15	255,795	254,224	257,519	255,937	254,365	252,802	266,361	264,725	263,099	261,483	249,389	247,857	246,335	244,821	257,117	255,538	253,968	252,408	239,404	237,934	236,472	235,020	242,384	240,895	239,415	237,945
2018Q3	18	295,878	294,060	297,871	296,042	294,223	292,416	308,100	306,207	304,326	302,457	288,468	286,696	284,935	283,185	297,407	295,580	293,765	291,960	276,919	275,218	273,527	271,847	280,365	278,643	276,931	275,230
2018Q4	20	353,858	351,684	356,242	354,054	351,879	349,718	368,475	366,212	363,962	361,727	344,996	342,877	340,771	338,678	355,687	353,502	351,331	349,173	331,184	329,149	327,128	325,118	335,305	333,246	331,199	329,165
2019Q1	19	323,830	321,840	326,012	324,009	322,019	320,041	337,206	335,135	333,077	331,031	315,720	313,780	311,853	309,938	325,503	323,504	321,517	319,542	303,080	301,218	299,368	297,529	306,852	304,967	303,094	301,232
2019Q2	25	419,935	417,356	422,765	420,168	417,587	415,022	437,282	434,596	431,927	429,274	409,419	406,904	404,404	401,920	422,106	419,513	416,936	414,375	393,027	390,613	388,214	385,829	397,918	395,474	393,045	390,631
2019Q3	10	167,339	166,311	168,466	167,432	166,403	165,381	174,251	173,181	172,117	171,060	163,148	162,146	161,150	160,160	168,204	167,171	166,144	165,123	156,616	155,654	154,698	153,748	158,565	157,591	156,623	155,661
2019Q4	41	688,969	684,737	693,612	689,351	685,117	680,909	717,429	713,022	708,643	704,290	671,715	667,589	663,488	659,413	692,530	688,276	684,049	679,847	644,822	640,861	636,925	633,012	652,847	648,837	644,852	640,891
2020Q1	28	464,438	461,586	467,568	464,696	461,842	459,005	483,624	480,653	477,701	474,767	452,807	450,026	447,262	444,515	466,839	463,972	461,122	458,289	434,679	432,009	429,355	426,718	440,089	437,385	434,699	432,029
2020Q2	23	376,576	374,263	379,114	376,785	374,471	372,170	392,132	389,723	387,329	384,950	367,145	364,890	362,649	360,421	378,522	376,197	373,887	371,590	352,446	350,281	348,130	345,991	356,832	354,641	352,462	350,297

Sources:

719

Total

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity and a discount factor of 2.0% Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

#### Quarterly Analysis of New York Medical Indemnity Fund

Projected Incremental Discounted Payments per Participant by Admittance Quarter

As of June 30, 2020

Admittance											Incremen	tal Benefits I	Paid by Fund	Participation	Quarter												
Quarter	<u>Participants</u>	Q53	Q54	Q55	Q56	Q57	Q58	Q59	Q60	Q61	Q62	Q63	Q64	Q65	Q66	Q67	Q68	Q69	Q70	<u>Q71</u>	<u>Q72</u>	<u>Q73</u>	Q74	<u>Q75</u>	Q76	After Q76	Total
2011Q4	11	105,405	104,758	104,114	103,475	108,054	107,391	106,731	106,075	100,995	100,375	99,759	99,146	103,284	102,650	102,019	101,393	95,892	95,303	94,717	94,135	96,805	96,210	95,619	95,032	10,982,793	17,910,422
2012Q1	11	68,953	68,529	68,108	67,690	70,686	70,252	69,820	69,391	66,068	65,662	65,259	64,858	67,565	67,150	66,738	66,328	62,729	62,344	61,961	61,581	63,327	62,938	62,551	62,167	7,184,621	12,026,869
2012Q2	15	527,882	524,639	521,417	518,214	541,149	537,825	534,522	531,239	505,798	502,691	499,603	496,534	517,260	514,083	510,925	507,787	480,237	477,287	474,355	471,442	484,809	481,831	478,871	475,930	55,003,174	89,864,596
2012Q3	25	426,972	424,350	421,743	419,153	437,704	435,015	432,343	429,688	409,110	406,597	404,099	401,617	418,381	415,811	413,257	410,719	388,435	386,049	383,678	381,321	392,133	389,725	387,331	384,952	44,488,825	72,166,339
2012Q4	38	, ,	1,501,579	1,492,355	1,483,189	1,548,833	1,539,319	1,529,864	1,520,467	1,447,652	1,438,760	1,429,922	1,421,139	,,	1,471,365	1,462,327	1,453,345	1,374,494	1,366,051	1,357,660	1,349,321	1,387,580	1,379,057	1,370,586	1,362,167	157,425,533	260,160,500
2013Q1	5	182,663	181,541	180,426	179,318	187,254	186,104	184,961	183,825	175,021	173,946	172,878	171,816	178,988	177,888	176,795	175,710	166,176	165,156	164,141	163,133	167,759	166,728	165,704	164,686	19,032,759	31,463,505
2013Q2	30	306,643	304,759	302,887	301,027	314,350	312,419	310,500	308,593	293,814	292,010	290,216	288,433	300,473	298,627	296,793	294,970	278,966	277,253	275,550	273,857	281,622	279,892	278,173	276,465	31,950,980	54,682,465
2013Q3	26	355,975	353,788	351,615	349,455	364,922	362,680	360,452	358,238	341,082	338,987	336,905	334,836	348,812	346,669	344,540	342,424	323,845	321,856	319,879	317,914	326,929	324,921	322,925	320,941	37,091,141	60,807,002
2013Q4	8	111,967	111,279	110,595	109,916	114,781	114,076	113,375	112,679	107,283	106,624	105,969	105,318	109,714	109,040	108,370	107,705	101,861	101,235	100,614	99,996	102,831	102,199	101,571	100,948	11,666,493	19,723,520
2014Q1	17	418,386	415,816	413,262	410,724	428,902	426,268	423,649	421,047	400,883	398,421	395,973	393,541	409,968	407,450	404,947	402,460	380,624	378,286	375,963	373,653	384,248	381,888	379,542	377,211	43,594,209	73,246,456
2014Q2	24	424,623	422,015	419,422	416,846	435,295	432,622	429,964	427,323	406,859	404,360	401,876	399,407	416,079	413,523	410,983	408,459	386,298	383,925	381,567	379,223	389,976	387,580	385,199	382,833	44,244,017	73,284,529
2014Q3	20	551,689	548,300	544,932	541,585	565,555	562,081	558,629	555,197	528,609	525,362	522,135	518,928	540,588	537,267	533,967	530,688	501,895	498,812	495,748	492,703	506,673	503,561	500,468	497,394	57,483,784	95,915,904
2014Q4	19	352,867	350,700	348,546	346,405	361,736	359,514	357,306	355,111	338,105	336,028	333,964	331,913	345,767	343,643	341,532	339,435	321,019	319,047	317,087	315,139	324,075	322,084	320,106	318,140	36,767,377	62,146,403
2015Q1	26	363,741	361,507	359,287	357,080	372,884	370,593	368,317	366,055	348,524	346,383	344,256	342,141	356,422	354,233	352,057	349,895	330,911	328,879	326,859	324,851	334,062	332,010	329,970	327,944	37,900,406	64,707,586
2015Q2	31	760,979	756,305	751,659	747,042	780,105	775,314	770,551	765,818	729,143	724,664	720,213	715,789	745,667	741,087	736,535	732,011	692,295	688,043	683,817	679,617	698,886	694,594	690,327	686,087	79,290,988	134,384,701
2015Q3	16	175,452	174,374	173,303	172,239	179,862	178,757	177,659	176,568	168,112	167,079	166,053	165,033	171,922	170,866	169,816	168,773	159,616	158,636	157,662	156,693	161,136	160,146	159,163	158,185	18,281,421	32,250,851
2015Q4	19	291,308	289,519	287,741	285,973	298,630	296,796	294,973	293,161	279,122	277,407	275,703	274,010	285,447	283,694	281,951	280,219	265,016	263,388	261,770	260,162	267,539	265,896	264,262	262,639	30,353,191	52,669,931
2016Q1	18	267,825	266,180	264,545	262,920	274,557	272,871	271,194	269,529	256,621	255,045	253,478	251,921	262,436	260,824	259,222	257,630	243,652	242,156	240,668	239,190	245,972	244,461	242,960	241,467	27,906,350	47,468,948
2016Q2	35	483,439	480,469	477,518	474,585	495,589	492,545	489,520	486,513	463,214	460,369	457,541	454,731	473,711	470,801	467,910	465,036	439,805	437,104	434,419	431,750	443,992	441,265	438,555	435,861	50,372,398	87,963,663
2016Q3	22	320,695	318,725	316,767	314,821	328,755	326,736	324,729	322,734	307,278	305,391	303,515	301,651	314,242	312,312	310,393	308,487	291,750	289,958	288,177	286,407	294,527	292,718	290,920	289,133	33,415,114	55,848,179
2016Q4	14	246,267	244,754	243,251	241,757	252,457	250,906	249,365	247,833	235,964	234,515	233,075	231,643	241,312	239,830	238,356	236,892	224,040	222,664	221,296	219,937	226,173	224,784	223,403	222,031	25,660,048	44,481,883
2017Q1	19	301,893	300,039	298,196	296,364	309,481	307,580	305,691	303,813	289,263	287,486	285,721	283,966	295,818	294,001	292,196	290,401	274,645	272,958	271,281	269,615	277,260	275,557	273,864	272,182	31,456,050	54,207,504
2017Q2	28	422,286	419,692	417,114	414,552	432,899	430,240	427,598	424,971	404,619	402,134	399,664	397,209	413,789	411,247	408,721	406,210	384,171	381,812	379,466	377,136	387,829	385,447	383,079	380,726	44,000,486	75,362,821
2017Q3	17	259,815	258,220	256,633	255,057	266,346	264,710	263,084	261,468	248,946	247,417	245,897	244,387	254,588	253,024	251,470	249,925	236,365	234,914	233,471	232,037	238,616	237,150	235,693	234,246	27,071,743	47,291,813
2017Q4	11	212,062	210,759	209,465	208,178	217,392	216,057	214,730	213,411	203,190	201,942	200,702	199,469	207,795	206,519	205,250	203,989	192,922	191,737	190,559	189,389	194,759	193,562	192,374	191,192	22,096,025	38,899,193
2018Q1	15	214,508	213,191	211,881	210,580	219,900	218,549	217,207	215,873	205,534	204,272	203,017	201,770	210,192	208,901	207,618	206,343	195,148	193,949	192,758	191,574	197,005	195,795	194,593	193,397	22,350,919	38,862,152
2018Q2	15	237,401	235,942	234,493	233,053	243,367	241,873	240,387	238,910	227,469	226,072	224,683	223,303	232,624	231,195	229,775	228,364	215,974	214,647	213,329	212,018	218,030	216,691	215,360	214,037	24,736,210	42,845,136
2018Q3	18	274,601	272,914	271,238	269,572	281,503	279,774	278,055	276,347	263,113	261,497	259,891	258,294	269,076	267,423	265,780	264,148	249,816	248,282	246,757	245,241	252,195	250,646	249,106	247,576	28,612,348	49,151,486
2018Q4	20	328,412	326,395	324,390	322,397	336,666	334,598	332,543	330,501	314,673	312,740	310,819	308,910	321,804	319,827	317,863	315,910	298,771	296,935	295,112	293,299	301,615	299,762	297,921	296,091	34,219,230	60,106,308
2019Q1	19	300,543	298,697	296,862	295,039	308,097	306,204	304,324	302,454	287,970	286,201	284,443	282,696	294,496	292,687	290,889	289,102	273,417	271,738	270,068	268,410	276,020	274,325	272,640	270,965	31,315,401	54,831,969
2019Q2	25	389,738	387,344	384,965	382,600	399,533	397,079	394,640	392,216	373,433	371,139	368,860	366,594	381,896	379,550	377,219	374,902	354,561	352,383	350,219	348,068	357,937	355,738	353,553	351,382	40,609,132	70,773,189
2019Q3	10	155,305	154,352	153,403	152,461	159,209	158,231	157,259	156,293	148,808	147,894	146,986	146,083	152,181	151,246	150,317	149,393	141,288	140,420	139,558	138,701	142,633	141,757	140,886	140,021	16,182,216	28,107,003
2019Q4	41	639,425	635,498	631,594	627,715	655,497	651,470	647,469	643,492	612,675	608,912	605,171	601,454	626,559	622,711	618,886	615,084	581,713	578,140	574,589	571,059	587,251	583,644	580,059	576,496	66,625,587	116,562,366
2020Q1	28	431,041	428,393	425,762	423,147	441,875	439,161	436,463	433,782	413,008	410,471	407,950	405,444	422,368	419,773	417,195	414,632	392,137	389,728	387,334	384,955	395,870	393,438	391,022	388,620	44,912,757	78,573,954
2020Q2	23	349,496	347,350	345,216	343,096	358,281	356,080	353,893	351,719	334,875	332,818	330,774	328,742	342,464	340,361	338,270	336,192	317,952	315,999	314,058	312,129	320,979	319,008	317,048	315,101	36,416,149	64,094,431
Total	719																								Tota	al thru 2020Q2	2,262,843,577

Sources:

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity and a discount factor of 2.0% Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

Exhibit 6

Page 1

**Quarterly Analysis of New York Medical Indemnity Fund Expected Fund Payments by Admittance Year - All Participants** As of June 30, 2020

Fiscal		Admitted	Cumulative Benefit	Adjusted Benefit	Expected Benefit	Expected % of Benefits	Development of Current	B-F Indicated Benefit	Selected Ultimate	Indicated Ultimate
Year	Live Births	Participants	Payments	Payments	Payments	Paid	Payments	Payments	Payments	Severity
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
2011	239,608	22	4,834,032	3,909,199	36,170,443	10.05%	39,815,381	37,368,696	38,592,038	1,754,184
2012	238,237	86	60,409,044	52,065,578	499,728,104	8.89%	593,824,935	515,697,427	554,761,181	6,450,711
2013	235,956	84	25,956,749	22,255,366	211,816,970	7.77%	290,063,012	221,311,792	255,687,402	3,043,898
2014	237,491	91	30,004,040	25,181,839	310,846,036	6.68%	381,627,374	320,076,278	350,851,826	3,855,515
2015	235,139	85	25,733,008	20,801,323	262,921,558	5.62%	375,097,695	273,879,800	324,488,748	3,817,515
2016	231,623	91	17,983,026	13,785,928	246,569,907	4.52%	309,125,413	253,405,412	281,265,413	3,090,829
2017	232,920	72	11,392,425	8,460,314	166,663,018	3.46%	247,725,327	172,295,392	210,010,359	2,916,811
2018	231,603	73	6,362,357	4,742,407	147,638,421	2.37%	202,033,419	150,507,193	176,270,306	2,414,662
2019	230,287	104	2,268,483	1,685,769	304,726,899	1.31%	129,042,292	302,996,465	302,996,465	2,913,428
2020	228,971	23	-	-	80,147,722	0.26%	-	79,936,753	79,936,753	3,475,511
Total		731	184,943,164	152,887,723	2,267,229,080		2,568,354,848	2,327,475,208	2,574,860,491	3,522,381

#### Sources:

- (2) Vital Statistics of New York State; adjusted to MIF fiscal year
- (3) Provided by MIF; includes all living and deceased participants admitted through 06/30/20
- (4) Provided by MIF; includes 8.3% load for prescription drugs
- Adjusted to reflect pre-legislation payment levels (5)
- Pinnacle estimate of expected payments and payment distributions based on admittance year and 3.0% inflation rate (6), (7)
- Col (5) / Col (7) + [Col (4) Col (5)] (8)
- Col (4) + {Col (6) x [1-Col (7)]} (9)
- (10)Selected based on Cols (8) and (9)
- (11)Col (10) / Col (3)

					Estimated	Estimated	Indicated	Indicated	Prior Quarter		Selected
Admittance	Living	Deceased	Paid For		Ultimate	Ultimate	Ultimate	Ultimate	Selected	Selected	Ultimate
Quarter	Participants	Participants	Deceased	% Paid	Severity	Benefits	Severity	Payments	Severity	Severity	Benefits
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
										•	
2011Q4	11	0	-	9.5%	2,544,698	27,991,679	1,986,598	21,852,576	1,632,624	2,986,019	32,846,212
2012Q1	11	0	-	9.2%	1,949,284	21,442,124	1,521,769	16,739,462	1,099,698	1,990,530	21,895,830
2012Q2	15	1	276,786	8.9%	8,998,786	135,258,577	7,210,759	108,438,172	6,003,763	11,060,096	166,178,232
2012Q3	25	0	-	8.6%	4,155,320	103,883,000	3,331,362	83,284,053	2,909,330	5,380,484	134,512,100
2012Q4	38	2	1,382,899	8.3%	10,565,094	402,856,465	8,462,927	322,974,110	6,848,279	12,673,788	482,986,858
2013Q1	5	0	-	8.0%	9,994,846	49,974,230	8,012,969	40,064,846	6,338,244	11,734,624	58,673,120
2013Q2	30	0	-	7.8%	3,553,289	106,598,667	2,896,455	86,893,644	1,829,262	3,360,573	100,817,194
2013Q3	26	1	2,127,253	7.5%	2,273,838	61,247,030	1,838,389	49,925,368	2,288,279	4,337,365	114,898,752
2013Q4	8	0	-	7.2%	4,395,597	35,164,778	3,583,060	28,664,484	2,441,364	4,613,379	36,907,031
2014Q1	17	2	959,711	7.0%	6,452,935	110,659,604	5,249,659	90,203,907	4,314,319	8,066,821	138,095,676
2014Q2	24	1	1,553,019	6.7%	3,522,020	86,081,488	2,708,648	66,560,576	3,041,266	5,758,415	139,754,984
2014Q3	20	0	-	6.4%	7,374,203	147,484,053	5,701,936	114,038,730	4,872,535	9,156,748	183,134,954
2014Q4	19	0	-	6.1%	5,537,463	105,211,790	4,281,719	81,352,652	3,324,759	6,236,107	118,486,034
2015Q1	26	1	167,134	5.9%	4,415,589	114,972,457	3,412,797	88,899,868	2,520,638	4,738,126	123,358,400
2015Q2	31	0	-	5.6%	7,271,521	225,417,149	5,082,015	157,542,457	4,414,124	8,332,271	258,300,412
2015Q3	16	0	-	5.4%	4,663,888	74,622,213	3,259,559	52,152,939	2,053,103	3,818,939	61,103,017
2015Q4	19	1	1,070,124	5.1%	4,510,770	86,774,749	3,135,586	60,646,260	2,796,770	5,261,903	101,046,282
2016Q1	18	0	-	4.8%	4,304,195	77,475,515	3,008,172	54,147,092	2,701,564	5,132,413	92,383,436
2016Q2	35	0	-	4.5%	5,324,954	186,373,383	3,495,538	122,343,840	2,576,943	4,852,392	169,833,725
2016Q3	22	0	-	4.2%	2,901,828	63,840,219	1,904,890	41,907,580	2,614,535	5,031,404	110,690,894
2016Q4	14	1	61,720	4.0%	5,990,563	83,929,602	3,930,959	55,095,152	3,259,752	6,210,553	87,009,458
2017Q1	19	0	-	3.7%	4,964,448	94,324,520	3,258,886	61,918,841	2,927,464	5,623,759	106,851,414
2017Q2	28	1	4,649	3.5%	4,094,100	114,639,438	2,339,652	65,514,904	2,778,341	5,346,995	149,720,522
2017Q3	17	0	-	3.2%	5,652,585	96,093,943	3,230,377	54,916,402	2,875,608	5,499,274	93,487,664
2017Q4	11	0	-	2.9%	7,942,243	87,364,674	4,538,886	49,927,742	3,632,098	6,997,445	76,971,893
2018Q1	15	0	-	2.6%	4,625,516	69,382,747	2,643,421	39,651,311	2,689,994	5,183,264	77,748,955
2018Q2	15	0	-	2.4%	4,437,918	66,568,764	2,324,334	34,865,004	2,970,237	5,753,356	86,300,347
2018Q3	18	1	-	2.1%	2,864,877	51,567,781	1,500,463	27,008,326	2,846,156	5,550,229	99,904,129
2018Q4	20	0	-	1.8%	6,093,200	121,863,994	3,191,278	63,825,560	3,128,428	6,069,646	121,392,918
2019Q1	19	0	-	1.6%	5,081,972	96,557,471	2,661,653	50,571,415	3,003,140	5,866,356	111,460,769
2019Q2	25	0	-	1.3%	3,592,482	89,812,051	2,594,426	64,860,661	2,943,178	5,796,721	144,918,036
2019Q3	10	0	-	1.1%	4,328,175	43,281,745	3,125,730	31,257,304	2,951,416	5,793,795	57,937,949
2019Q4	41	0	-	0.8%	4,245,399	174,061,355	3,065,951	125,704,004	2,983,200	5,867,474	240,566,440
2020Q1	28	0	-	0.5%	4,014,346	112,401,692	2,899,089	81,174,496	2,960,530	5,820,375	162,970,499
2020Q2	23	0	-	0.3%	3,976,148	91,451,404	3,475,511	79,936,753		5,790,545	133,182,524
Total	719	12	7,603,295			3,616,630,350		2,574,860,491			4,396,326,663

#### Sources:

(2) - (4) Provided by MIF

- (5) Based on Virginia Birth Fund patterns
- (6) [Exhibit 4, Page 2 Total - Col (4)] / Col (5) / Col (2)
- [Col (6) x Col (2)] + Col (4) (7)
- [Col (9) Col (4)]/ Col (2)
- (9) From Exhibit 6, Page 1, Col (10); allocated based on Col (7)
- (10) From Pinnacle analysis as of 3/31/2020
- (11) Selected severity for currently living participants (based on Col (6), Col (8) and prior selected severity)
- (12) [Col (11) x Col (2)] + Col (4)

_	Paid Benefits			ı		Estimate of
	Current	Cumulative		Incurred	Current	Cumulative Incurred
Row	Quarter	To Date	Medicaid	to Date	Annual Paid	in 12 Months
1 2	11,849 389	209,433 112,420	- 35,221	209,433 147,641	26,179 16,873	235,612 164,514
3	24,493	582,082	- 35,221	582,082	70,555	652,637
4		276,786	1,631	278,416	123,741	278,416
5	17,701	1,166,365	-	1,166,365	137,219	1,303,584
6 7	3,501	311,614 280	-	311,614 280	37,771 35	349,385 315
8	148,143	3,763,182	-	3,763,182	456,143	4,219,325
9	- 1,722	3,520	8,946	12,466 16,291	1,425 1,975	13,891 18,266
10 11	11,015	16,291 206,333	7,885	214,218	24,482	238,701
12	-	1,417	-	1,417	172	1,589
13	-	41,693	11,723	53,416	6,475	59,890
14 15	3,923 154	176,576 20,073	1,853	176,576 21,926	21,403 2,580	197,980 24,506
16	4,255	124,056	10,875	134,930	15,421	150,351
17	160	104,458	-	104,458	12,289	116,747
18 19	6,406 36,580	148,749 1,964,500	-	148,749 1,964,500	17,000 245,562	165,749 2,210,062
20	150	291,515	-	291,515	36,439	327,954
21	6,800	420,751	25,289	446,039	54,065	500,105
22	-	1,400	8,025	9,425	1,109	10,534
23 24	1,695	- 29,742	10,565	40,307	4,886	45,193
25	2,051	174,538		174,538	21,817	196,356
26	- 2.620	202 700	6,530	6,530	768	7,299
27 28	2,630	282,780 9,660	-	282,780 9,660	35,348 1,171	318,128 10,831
29	94,068	3,043,356	3,057	3,046,413	369,262	3,415,676
30	1,905	51,849	-	51,849	6,481	58,331
31 32	- 3,475	12,297 53,167	-	12,297 53,167	1,537 6,646	13,834 59,813
33	-	-	147	147	18	165
34	11,283	105,014	9,231	114,245	13,057	127,302
35 36	57,611 5,485	653,781 75,882		653,781 75,882	81,723 8,927	735,504 84,809
37	-	8,831	-	8,831	1,104	9,935
38	78,652	1,266,882	65,793	1,332,675	161,536	1,494,212
39 40	5,600 11,659	144,675 235,500	-	144,675 235,500	18,084 29,437	162,760 264,937
41	5,158	131,153	-	131,153	14,989	146,142
42	-	27,516	-	27,516	3,439	30,955
43 44	357	37,715 114,854	-	37,715 114,854	4,714 13,512	42,429 128,366
45	3,164	3,961	-	3,961	466	4,427
46	-	106,748	4,130	110,878	12,672	123,550
47 48	50 12,748	6,693 313,420	-	6,693 313,420	787 36,873	7,481 350,293
49	1,635	91,659	_	91,659	11,457	103,116
50	1,684	178,951	-	178,951	22,369	201,320
51 52	8,179 29,145	665,632 653,000	- 50,146	665,632 703,146	83,204	748,836 783,506
53	29,145 50	653,000 11,131	30,140	11,131	80,360 1,310	783,506 12,441
54	290	104,072	-	104,072	13,009	117,081
55 56	25,716 1,487	854,247 36,477	22,702	876,949 36,477	100,223 4,169	977,172 40,646
57	1,487 87,517	1,488,128	- 38,552	1,526,680	4,169 185,052	1,711,732
58		309	-	309	37	347
59 60	- 79,928	291 2,633,782		291 2,633,782	36 329,223	328 2,963,004
61		1,702,879		1,702,879	219,726	1,922,606
62	254,389	1,965,439	-	1,965,439	253,605	2,219,044
63	-	47 502	-	- 17,583	3 400	10 704
64 65	350 14,460	17,583 198,426		17,583	2,198 25,603	19,781 224,029
66	30,931	278,858	-	278,858	35,982	314,840
67	-	43,085	-	43,085	5,559	48,644
68 69	139,148	322,022 1,455,773		322,022 1,455,773	107,341 187,842	322,022 1,643,615
70	38,457	1,681,100	-	1,681,100	216,916	1,898,016
71 72	58,923 48,068	1,422,438	-	1,422,438	183,540	1,605,978
72 73	48,068 3,129	1,675,955 56,135		1,675,955 56,135	216,252 7,017	1,892,208 63,151
74	8,581	394,570	-	394,570	49,321	443,891
75	-	1,060,878	-	1,060,878	212,176	1,060,878

	Paid Benefits					Estimate of
Row	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
76	Quarte.	15,729	-	15,729	2,030	17,759
77	4,159	220,725	_	220,725	28,481	249,206
78	27,776	34,444	_	34,444	4,444	38,889
79	406	99,485	_	99,485	12,837	112,322
80	50,280	1,799,994	-	1,799,994	232,257	2,032,251
81	17,716	376,986	-	376,986	48,643	425,629
82	151,855	2,461,547	_	2,461,547	317,619	2,779,166
83	29,480	554,116	-	554,116	71,499	625,615
84	35,328	616,272		616,272	79,519	695,790
85	228,143	5,994,793	-	5,994,793	773,522	6,768,314
86	8,607	611,459	-	611,459	78,898	690,357
87	183,422	3,206,596	-	3,206,596	413,754	3,620,350
88	-	6,165	-	6,165	795	6,960
89	4,754	65,708	-	65,708	8,478	74,186
90	-	24,754	-	24,754	3,194	27,948
91	8,402	212,870	-	212,870	27,467	240,337
92	680	6,635	-	6,635	856	7,491
93	1,525	18,364	-	18,364	2,370	20,733
94	- 00.754	99,188	-	99,188	12,799	111,987
95	89,754	2,286,061	-	2,286,061	294,976	2,581,037
96	430	67,485	-	67,485	8,708	76,193
97	16,849	117,089	-	117,089	15,108	132,197
98	17,857	103,586	-	103,586	13,366	116,952
99 100	52,249	276,965 9,497	-	276,965 9.497	35,737 1,225	312,703 10,722
	1 211			-, -		
101 102	1,311	10,562	-	10,562	1,363	11,925
102	48,473	665,489	-	665,489	85,870	751,358
103	41,098 71,822	445,464 1,640,555	-	445,464 1,640,555	57,479 218,741	502,943 1,859,295
105	71,022	1,835	-	1,835	210,741	2,079
106	72,408	1,278,790	-	1,278,790	170,505	1,449,296
107	28,158	593,170		593,170	79,089	672,259
108	5,651	198,110		198,110	26,415	224,525
109	5,051	37,475		37,475	5,169	42,644
110	1,080	41,697	_	41,697	5,751	47,449
111	77,785	1,529,403		1,529,403	210,952	1,740,355
112	332	17,127	_	17,127	2,362	19,490
113	3,913	33,380	_	33,380	4,604	37,984
114	11,700	37,977	_	37,977	5,238	43,215
115	5,858	113,033	-	113,033	15,591	128,624
116	3,012	61,797	-	61,797	8,524	70,320
117	1,389	5,687	-	5,687	784	6,471
118		2,976	-	2,976	410	3,386
119	-	-	-	-	-	
120	7,885	663,694	-	663,694	91,544	755,238
121		-	-	-	-	
122	400	8,978	-	8,978	1,238	10,216
123	4,574	18,483	-	18,483	2,549	21,033
124	-	653	-	653	90	744
125	-	200	-	200	28	228
126	1,640	25,978	-	25,978	3,583	29,561
127	70,768	540,683	-	540,683	74,577	615,260
128	12,142	396,898	-	396,898	54,745	451,643
129	174,469	2,301,803	-	2,301,803	317,490	2,619,293
130		10.00		-		40.000
131	-	16,699	-	16,699	2,303	19,002
132	- 045	1,679	-	1,679	232	1,910
133	845	14,080	-	14,080 50,974	1,942	16,022
134 135	9,584 504	50,974 1,938	-	1,938	7,031 267	58,004 2,206
136	146,064	1,494,409		1,494,409	206,125	1,700,535
136	358	226,434		226,434	31,232	257,666
138	-	220,434	-	220,434	- 31,232	237,000
139	100	95,207	-	95,207	13,601	108,808
140	6,742	260,285	-	260,285	37,184	297,469
141		8,609	-	8,609	1,230	9,839
142	1,630	142,416	_	142,416	20,345	162,761
143	-	10,043	_	10,043	1,435	11,478
144	-	239	-	239	34	273
145	30,188	117,291	-	117,291	16,756	134,047
146	2,031	339,036	-	339,036	48,434	387,469
147	15,275	138,250	-	138,250	19,750	158,000
148	-	762	-	762	109	871
149	641	17,651	-	17,651	2,522	20,173
150				-		
-						

	Paid Benefits					Estimate of
Row	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
151	7,043	324,943	Miculculu	324,943	46,420	371,364
152	7,043	6,779		6,779	968	7,748
153	_	1,510	_	1,510	216	1,725
154	10,531	740,359	_	740,359	105,766	846,125
155	376	187,069	-	187,069	26,724	213,794
156	1,269	20,028	-	20,028	2,861	22,889
157	1,213	343,780	-	343,780	49,111	392,892
158	1,559	103,597	-	103,597	14,800	118,396
159	-	2,127,253	-	2,127,253	567,267	2,127,253
160	57,560	975,698	-	975,698	139,385	1,115,083
161	601	2,983	-	2,983	426	3,409
162	4,514	38,588	-	38,588	5,513	44,101
163	1,771	13,312	-	13,312	1,902	15,214
164	-	42,943	-	42,943	6,135	49,078
165	1,440	4,510	-	4,510	644	5,154
166	26,057	656,837	-	656,837	97,309	754,146
167	2,993	23,736	-	23,736	3,516	27,252
168	225	7,123	-	7,123	1,055	8,178
169	- 454,197	18,938		18,938	2,806	21,744
170	434,137	1,580,953		1,580,953	234,215	1,815,168
171 172	-	8,659 1,104	-	8,659 1,104	1,283 164	9,942 1,268
172	-	45,690	-	45,690	6,769	52,458
174	-	904,976	-	904,976	190,521	904,976
175		54,735	-	54,735	27,367	54,735
176	34,130	1,644,328	-	1,644,328	252,973	1,897,301
177		5,346	_	5,346	823	6,169
178	_	2,297	_	2,297	353	2,651
179	29,759	774,278	-	774,278	119,120	893,398
180	· -	373	-	373	57	430
181	12,587	323,469	-	323,469	49,764	373,233
182	183	12,990	-	12,990	1,998	14,988
183	7,480	106,956	-	106,956	16,455	123,410
184	-	-	-	-	-	
185	-	-	-	-	-	
186	146,782	2,671,576	-	2,671,576	411,012	3,082,588
187	3,910	530,376	-	530,376	81,596	611,973
188	-	62,042	-	62,042	9,545	71,587
189	14,374	384,677	-	384,677	59,181	443,858
190	220	49,172		49,172	7,565	56,737
191	7,604	396,372	-	396,372	60,980	457,353
192	-	3,597	-	3,597	553	4,150
193 194	- 7,229	127 432,339	-	127 432,339	20 69,174	147 501,514
195	7,229	432,333	-	432,339	09,174	301,314
196		13,187		13,187	2,110	15,297
197		1,553,019		1,553,019	310,604	1,553,019
198	_	1,555,615	_	105	17	1,555,015
199		-	-	-	-	122
200	302	19,738	-	19,738	3,158	22,896
201	-	15,509	-	15,509	2,481	17,991
202	12,272	226,885	-	226,885	36,302	263,186
203	· -	30,603	-	30,603	4,897	35,500
204	7,468	474,981	-	474,981	75,997	550,979
205	229	22,267	-	22,267	3,563	25,830
206	1,905	217,581	-	217,581	34,813	252,394
207	-	-	-	-	-	
208	42,840	255,394	-	255,394	40,863	296,257
209	-	37,295	-	37,295	5,967	43,262
210	596	122,467	-	122,467	19,595	142,061
211	28,404	813,927	-	813,927	130,228	944,155
212	3,931	303,165	-	303,165	48,506	351,671
213	26,127	449,096	-	449,096	71,855	520,951
214 215	3,742	152,609 1,663		152,609 1,663	24,417 266	177,026 1,929
216	38,721	900,191	_	900,191	144,030	1,044,221
217	11,214	611,014	-	611,014	97,762	708,776
217	11,214	8,351	-	8,351	1,392	9,743
219	21,461	709,074	_	709,074	118,179	827,253
220	-	13,793	-	13,793	2,299	16,091
221	154,841	2,107,381	-	2,107,381	351,230	2,458,611
222	15,652	298,510	-	298,510	49,752	348,261
223	-,	9,942	-	9,942	1,657	11,598
224	-	1,040	-	1,040	173	1,213
225	910	8,924	-	8,924	1,487	10,412

	Paid Benefits					Estimate of
	Current	Cumulative		Incurred	Current	Cumulative Incurred
Row	Quarter	To Date	Medicaid	to Date	Annual Paid	in 12 Months
226	10,512	164,896	-	164,896	27,483	192,378
227	201	8,307	-	8,307	1,384	9,691
228	3,815	44,584	-	44,584	7,431	52,015
229 230	6,465	190,028 7,400		190,028 7,400	31,671 1,233	221,699 8,633
231	-	14,116		14,116	2,353	16,469
232	235	47,484	-	47,484	7,914	55,398
233	-	-	-	-	-	
234	1,759	80,697	-	80,697	13,449	94,146
235	5,316	263,617	-	263,617	43,936	307,553
236 237	225,000	221 4,757,851	-	221 4,757,851	37 792,975	258
238	223,000	4,737,631	-	4,737,631	792,973	5,550,827
239	258	5,203	-	5,203	905	6,108
240	-	10,444	-	10,444	1,816	12,261
241	10,711	119,246	-	119,246	20,738	139,984
242	88,169	1,534,572	-	1,534,572	266,882	1,801,454
243 244	18,537 4,553	442,170 416,607	-	442,170 416,607	76,899 72,453	519,069 489,060
245	51,748	602,218	-	602,218	104,734	706,951
246	-	3,386	-	3,386	589	3,975
247	8,160	124,676	-	124,676	21,683	146,359
248	-	295	-	295	51	346
249 250	23 71,459	17,763 1,375,935	-	17,763 1,375,935	3,089 239,293	20,853 1,615,228
251	46,480	463,014		463,014	80,524	543,539
252	14,091	504,363	-	504,363	87,715	592,078
253	1,326	14,881		14,881	2,588	17,469
254	-	9,542	-	9,542	1,659	11,201
255	12,747	311,461	-	311,461	54,167	365,628
256	-	-	-	-	-	457.404
257	- 8,872	167,134 65,799	-	167,134 65,799	51,426 11,963	167,134 77,762
258 259	8,991	464,578	-	464,578	84,469	549,047
260	-	-	-	-	-	3 13,0 17
261	30,046	375,252	-	375,252	68,228	443,480
262	-	6,000	-	6,000	1,091	7,091
263	379	45,286	-	45,286	8,234	53,519
264 265	-	2,708 964	-	2,708 964	492 175	3,201 1,139
266	-	3,324	-	3,324	604	3,928
267	-	4,044	-	4,044	735	4,779
268	641	115,076	-	115,076	20,923	135,999
269	712	8,512	-	8,512	1,548	10,059
270 271	879 98,189	20,387 1,103,883	-	20,387 1,103,883	3,707 200,706	24,094 1,304,589
271	39,166	1,309,805	-	1,309,805	238,146	1,547,952
273	12,816	227,387	_	227,387	41,343	268,731
274	9,363	187,250	-	187,250	34,045	221,295
275	14,886	275,870	-	275,870	50,158	326,029
276	25,847	765,155	-	765,155	139,119	904,275
277 278	25,318 8,747	405,235 66,479	-	405,235 66,479	73,679 12,087	478,915 78,567
278	0,747	175	-	175	32	78,507 207
280	-	2,862	-	2,862	520	3,383
281	173,176	447,672	-	447,672	81,395	529,067
282	19,272	231,133	-	231,133	42,024	273,157
283	1,478	69,489	-	69,489	12,634	82,123
284 285	42,330 4,400	830,611 54,143		830,611 54,143	158,212 10,313	988,823 64,456
286	-	-		-	-	
287	-	1,259	-	1,259	240	1,499
288	-	10,532	-	10,532	2,006	12,539
289 290	550	54,960 2,270	-	54,960 2,270	10,469 432	65,428 2,702
291	82,791	2,356,525		2,356,525	448,862	2,805,386
292	-	6,555	-	6,555	1,248	7,803
293	6,125	325,194	-	325,194	61,942	387,136
294	340	20,572	-	20,572	3,918	24,490
295	513,876	5,276,620	-	5,276,620	1,005,071	6,281,691
296	73,174	852,859 116 631	-	852,859	162,449	1,015,308
297 298	11,258 7,302	116,621 85,965		116,621 85,965	22,214 16,374	138,835 102,339
299	9,698	367,167	_	367,167	69,937	437,103
300	-	-	-	- / -		- ,===
-						

	Paid Benefits			1		Estimate of
	Current	Cumulative		Incurred	Current	Cumulative Incurred
Row	Quarter	To Date	Medicaid	to Date	Annual Paid	in 12 Months
301	24,173	511,884	-	511,884 247	97,502	609,386
302 303	385	247 2,455		2,455	47 468	294 2,923
304	-	122	-	122	23	145
305	-	-	-	-	-	2.5
306	-	6,945	-	6,945	1,323	8,268
307	-	579	-	579	110	689
308	-	5,597	-	5,597	1,066	6,663
309	43,733	212,145	-	212,145	40,409	252,554
310 311	6,233	41,691 2,623		41,691 2,623	7,941 500	49,632 3,123
312		900	-	900	171	1,071
313	20,168	505,062	-	505,062	96,202	601,264
314	5,414	20,654	-	20,654	3,934	24,589
315	3,950	42,729	-	42,729	8,546	51,275
316	11,290	166,607	-	166,607	33,321	199,928
317	5,651	240,312	-	240,312	48,062	288,374
318 319	354 2,150	4,136 46,378	-	4,136 46,378	827 9,276	4,963 55,654
320	8,225	178,752	-	178,752	35,750	214,502
321	121,834	1,881,474	-	1,881,474	376,295	2,257,768
322	22,545	294,084	-	294,084	58,817	352,900
323	8,103	30,390	-	30,390	6,078	36,468
324	-	1,923	-	1,923	385	2,307
325	-	18,006		18,006	3,601	21,607
326 327	35,572	278,653 178	-	278,653 178	55,731 36	334,384 213
328		448,696	-	448,696	89,739	538,435
329	_		_	-	-	330,433
330	-	50,377	-	50,377	10,075	60,453
331	-	38,207	-	38,207	8,044	46,251
332	345	8,159	-	8,159	1,718	9,876
333	4,495	95,666	-	95,666	20,140	115,806
334 335	18,008	543,934 14,895		543,934 14,895	114,512 3,136	658,447 18,031
336	111,047	433,893		433,893	91,346	525,239
337	6,638	159,606	-	159,606	33,601	193,208
338	-	562	-	562	118	680
339	1,020	17,344	-	17,344	3,651	20,995
340	229	1,381	-	1,381	291	1,672
341 342	- 68	30 68	-	30 68	6 14	36 83
343	616	2,123		2,123	447	2,569
344	424,960	1,070,124	-	1,070,124	225,289	1,070,124
345	-	1,907	-	1,907	402	2,309
346	-	9,411	-	9,411	1,981	11,392
347	35,122	735,335	-	735,335	154,807	890,143
348	143	39,224 231,316	-	39,224	8,258	47,482
349 350	470 106,896	1,591,013	-	231,316 1,591,013	48,698 334,950	280,014 1,925,963
351	31,246	301,504	-	301,504	67,001	368,505
352	935	37,862	-	37,862	8,414	46,276
353	-	-	-	-	-	
354	-	1,366	-	1,366	304	1,670
355	-	16,996		16,996	3,777	20,773
356 357	-	73,754	-	73,754 2,580	16,390 573	90,144 3,153
358	36,984	2,580 613,830		613,830	136,407	750,237
359	53,533	656,461		656,461	145,880	802,342
360	-	903		903	201	1,103
361	33,078	383,246	-	383,246	85,166	468,411
362	19,029	384,578	-	384,578	85,462	470,040
363	4,513	167,507	-	167,507	37,224	204,731
364 365	3,307 630	57,027 8,276		57,027 8,276	12,673 1,839	69,700 10,115
366	22,106	420,837	-	420,837	93,519	514,356
367	37,081	174,416		174,416	38,759	213,175
368	5,644	120,401	-	120,401	26,756	147,157
	-		-			
369	-	34,474	-	34,474	8,111	42,585
370			_	614	145	759
370 371	-	614	_	014		
370 371 372	-	-	-	-	-	
370 371			-	7,391 64,029		9,130 79,095

	Paid Benefits					Estimate of
	Current	Cumulative		Incurred	Current	Cumulative Incurred
Row	Quarter	To Date	Medicaid	to Date	Annual Paid	in 12 Months
376	1,496	25,131	-	25,131	5,913	31,044
377 378	47,736 1,041	99,350	-	99,350 8,512	23,377	122,727
378 379	1,041	8,512 359	-	8,512 359	2,003 84	10,515 443
380	2,821	44,065		44,065	10,368	54,433
381	392	1,578	-	1,578	371	1,949
382	2,100	20,156	-	20,156	4,743	24,899
383	1,215	1,153,742	-	1,153,742	271,469	1,425,211
384	7,238	179,986	-	179,986	42,350	222,336
385	7,489	136,755		136,755	32,178	168,933
386 387	53,364	519,847 49,239	-	519,847 49,239	122,317 11,586	642,164 60,825
388	-	4,664	-	4,664	1,097	5,761
389	24,256	303,522	-	303,522	71,417	374,939
390	3,473	31,864	-	31,864	7,498	39,362
391	-	-	-	-	-	
392	1,633	5,706	-	5,706	1,342	7,048
393	41,111	1,176,190	-	1,176,190	276,751	1,452,940
394	61,552	1,375,767	-	1,375,767	323,710	1,699,477
395 396	88,611 2,429	697,678 52,383		697,678 52,383	164,160 12,325	861,837 64,709
396	2,429 5,538	52,383 17,527	-	52,383 17,527	4,124	21,651
398	254	8,561	-	8,561	2,014	10,575
399	6,120	224,054	-	224,054	52,719	276,772
400	-	-	-	-	-	
401	72,385	1,414,005	-	1,414,005	332,707	1,746,712
402	-	8,555	-	8,555	2,013	10,568
403	4,007	90,610	-	90,610	21,320	111,930
404 405	-	4,842 20	-	4,842 20	1,210 5	6,052 25
406		20,622		20,622	5,155	25,777
407	7,882	180,840	-	180,840	45,210	226,050
408	-	-	-	-	-	,,,,,
409	2,490	17,963	-	17,963	4,491	22,453
410	3,962	130,300	-	130,300	32,575	162,875
411	-		-			
412 413	2 100	8,253	-	8,253	2,063	10,316
413	2,100 1,608	3,020 54,053		3,020 54,053	755 13,513	3,775 67,566
415	-	12,018	-	12,018	3,005	15,023
416	-	89	-	89	22	112
417	-	118	-	118	29	147
418	148,143	2,009,946	-	2,009,946	502,486	2,512,432
419	482	482	-	482	121	603
420	-			2.067	742	2 700
421 422	486	2,967 3,462	-	2,967 3,462	742 865	3,709 4,327
423	871	43,447	-	43,447	10,862	54,309
424	-	1,074		1,074	269	1,343
425	1,080	2,080	-	2,080	520	2,600
426	73,482	1,475,865	-	1,475,865	393,564	1,869,430
427	14,521	91,949	-	91,949	24,520	116,468
428	18,614	395,405	-	395,405	105,441	500,847
429 430	95,141 220	337,981 8,562	-	337,981 8,562	90,128 2,283	428,109 10,846
431	-	61,720		61,720	61,720	61,720
432	-	-	-		-	01,720
433	411	25,729	-	25,729	6,861	32,590
434	-	54,518	-	54,518	14,538	69,056
435	15,621	259,432	-	259,432	69,182	328,614
436	28,845	222,972	-	222,972	59,459	282,431
437 438	-	72,264	-	72,264	19,271	91,535
439	- 2,537	- 58,651	-	58,651	15,640	74,291
440	2,537	67,011	-	67,011	17,870	84,881
441	22,123	136,579	-	136,579	39,023	175,601
442	100,335	413,472	-	413,472	118,135	531,607
443	9,100	52,601	-	52,601	15,029	67,630
444		4,692	-	4,692	1,341	6,032
445	233,504	1,079,512	-	1,079,512	308,432	1,387,944
446 447	12,190	105,768	-	105,768	30,219	135,987
447	-	-	-	-	-	
449		25,722	-	25,722	7,349	33,071
450	63,967	912,165	-	912,165	260,618	1,172,783
		•				

	Paid Benefi	İS					Estimate of
Ro	Current w Quarter		Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
45		.60	17,813	-	17,813	5,089	22,902
45		32	150,341	_	150,341	42,955	193,296
45	,	-	11,375	_	11,375	3,250	14,625
45		-	5,696	_	5,696	1,628	7,324
45		99	224,976	-	224,976	64,279	289,255
45	56 1,5	66	18,265	-	18,265	5,219	23,484
45	,	-	1,075	-	1,075	307	1,382
45		-		-		-	,
45	9 2,8	80	64,968	-	64,968	18,562	83,530
46		-	3,468	-	3,468	1,067	4,535
46	51	-	2,568	-	2,568	790	3,358
46	6,4	62	37,550	-	37,550	11,554	49,104
46		-	2,569	-	2,569	790	3,359
46	54 150,4	87	1,446,919	-	1,446,919	445,206	1,892,124
46		86	12,191	-	12,191	3,751	15,942
46	66	-	4,649	-	4,649	3,720	4,649
46	57 2,6	24	12,904	-	12,904	3,970	16,874
46			111,736	-	111,736	34,380	146,116
46		-	2,394		2,394	737	3,130
47		.60	13,618	-	13,618	4,190	17,808
47	1 63,5	58	831,744	-	831,744	255,921	1,087,665
47	,	98	35,270	-	35,270	10,852	46,122
47			353,483	-	353,483	108,764	462,247
47		-	25,744	_	25,744	7,921	33,665
47		83	382,180	-	382,180	117,594	499,774
47	· /-	-	-	-	- , , , ,		,
47		73	7,613		7,613	2,342	9,955
47		-	2,801		2,801	862	3,662
47		96	38,561		38,561	11,865	50,426
48		-	21,310		21,310	6,557	27,867
48		'54	286,436		286,436	88,134	374,570
48	,	34	200,430	-	200,430	00,134	374,370
48		-	-	-	-	-	
		-	-	-	- 1	-	
48 48			1,186		1,186	365	1,551
		_	6,135				
48				-	6,135	1,888	8,023
48	,	133	9,146	-	9,146	2,814	11,960
48		-	5,232	-	5,232	1,610	6,841
48 49		.85	32,899	-	32,899	10,966	43,865
49	,	85	637,574	-	637,574	212,525	850,099
49		-	407.500	-	407.500	-	252.255
49		-	187,699	-	187,699	62,566	250,265
49		-	-	-	-	-	
49		-					
49		43	4,672	-	4,672	1,557	6,229
49		.97	79,952	-	79,952	26,651	106,603
49	,		1,309,037	-	1,309,037	436,346	1,745,382
49			230,877	-	230,877	76,959	307,837
50		84	14,748		14,748	4,916	19,664
50		-	-	-	-		
50	,	64	224,690	-	224,690	74,897	299,587
50		-		-		-	
50		- 4F	893	-	893	298	1,191
50			102,557	-	102,557	34,186	136,742
50		79	1,318	-	1,318	479	1,798
50		25	554,214	-	554,214	201,532	755,746
50		-	70	-	70	25	95
50		.50	6,008	-	6,008	2,185	8,193
51			132,954	-	132,954	48,347	181,301
51		69	38,213	-	38,213	13,896	52,109
		00	27,955	-	27,955	10,165	38,120
51		-	1,463,916	-	1,463,916	532,333	1,996,249
51		-	4,322	-	4,322	1,572	5,893
51 51		-	50,769	-	50,769	18,462	69,231
51 51 51	.5				75,535	27,467	103,003
51 51 51 51	.6 6,7	'38	75,535	-			•
51 51 51 51 51	.5 .6 6,7	'38 -	75,535 20,897	-	20,897	8,359	29,255
51 51 51 51 51	.5 .6 6,7 .7	'38 - -	20,897	-	20,897	8,359 -	29,255
51 51 51 51 51 51	.5 .6 6,7 .7 .8 .9 23,6	'38 - - 33	20,897 - 94,740	-	20,897 - 94,740	8,359 - 37,896	29,255 132,636
51 51 51 51 51	.5 .6 6,7 .7 .8 .9 23,6	'38 - -	20,897	-	20,897	8,359 -	29,255
51 51 51 51 51 51	.5 .6 6,7 .7 .8 .9 23,6 .0 5,6	'38 - - 33	20,897 - 94,740	-	20,897 - 94,740	8,359 - 37,896	29,255 132,636
51 51 51 51 51 51 51	.5 .6 .7 .8 .9 .9 .0 .5,6	738 - - 33 594	20,897 - 94,740 29,582	-	20,897 - 94,740 29,582	8,359 - 37,896 11,833	29,255 132,636 41,415
51 51 51 51 51 51 51 52	.5 6, 6, 7, 7, 7, 8, 8, 9, 9, 23,6, 10, 5,6, 11, 12, 2, 3	38 - - 33 394 10	20,897 - 94,740 29,582 6,834	-	20,897 - 94,740 29,582 6,834	8,359 - 37,896 11,833 2,733	29,255 132,636 41,415 9,567
51 51 51 51 51 51 51 52 52	.55 6,6,6,7 6,7 8,8 9,9 23,6,0 5,6 1,1 1,2 2 5,3 1,3 1,4 1,4 1,4 1,4 1,4 1,4 1,4 1,4 1,4 1,4	38 - - 33 94 10 12 -	20,897 - 94,740 29,582 6,834 61,055	-	20,897 - 94,740 29,582 6,834 61,055	8,359 - 37,896 11,833 2,733 24,422	29,255 132,636 41,415 9,567 85,477

	Paid Benefits					Estimate of
Row	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
526	- quarter	697	- Iviculculu	697	279	976
527	-	1,273	-	1,273	509	1,782
528	430	4,534	-	4,534	1,814	6,348
529	15,265	759,115	-	759,115	303,646	1,062,761
530	47,356	438,199	-	438,199	175,279	613,478
531	-	7,511	-	7,511	3,004	10,515
532	-	1,017	-	1,017	452	1,469
533 534	12,121 34,025	166,237 86,410	-	166,237 86,410	73,883 38,405	240,120 124,815
535	34,023	29,792	-	29,792	13,241	43,033
536	-	-	-	-	-	· · · · · · · · · · · · · · · · · · ·
537	508	11,183	-	11,183	4,970	16,154
538	45,210	393,326	-	393,326	174,811	568,137
539	31,628	406,725		406,725	180,767	587,492
540	7,464	145,867 73,411		145,867	64,830	210,697
541 542	9,150 14,910	119,353	-	73,411 119,353	32,627 53,046	106,038 172,399
543	14,310	119,333		-	33,040	172,333
544	-	7,532		7,532	3,348	10,880
545	-	-	-	-	· -	,
546	567	4,488	-	4,488	1,995	6,483
547	-	-	-	-	-	
548	-	-	-	-	-	
549 550		20,151		20,151	10,076	30,227
551		202		202	101	303
552	6,000	60,558	_	60,558	30,279	90,837
553	275	7,354	-	7,354	3,677	11,031
554	77,852	337,587	-	337,587	168,793	506,380
555	110	2,833	-	2,833	1,417	4,250
556	-	3,550	-	3,550	1,775	5,324
557	300	22,174	-	22,174	11,087	33,260
558 559	243	243 377	-	243 377	121 189	364 566
560	3,937	13,692		13,692	6,846	20,538
561	10,716	229,484	-	229,484	114,742	344,225
562	41,293	291,823	-	291,823	145,912	437,735
563	-	534	-	534	267	801
564	-	625	-	625	313	938
565		-		-		
566 567	- 127	- 721	-	721	412	1,134
568	107	1,019		1,019	582	1,601
569	150	8,053	-	8,053	4,602	12,655
570	7,222	12,472	-	12,472	7,127	19,598
571	19,295	42,716	-	42,716	24,409	67,124
572	23,726	114,084	-	114,084	65,191	179,275
573	-	-	-	-	-	
574 575	26,477	659,663 24,720		659,663 24,720	376,951 14,126	1,036,614 38,846
576		24,720		24,720	17,120	30,840
577	92,668	422,818	-	422,818	241,610	664,428
578	19,399	139,614	-	139,614	79,779	219,393
579	-	-	-	-	-	
580	21,675	72,116	-	72,116	41,209	113,325
581	8,015	15,131	-	15,131	8,646	23,777
582 583	30	1,775 2,391	-	1,775 2,391	1,014 1,366	2,790 3,757
584	62,180	528,871		528,871	302,212	831,084
585	-	257	-	257	147	404
586	111,869	367,595	-	367,595	245,064	612,659
587	-	-	-	-	-	
588	949	3,127	-	3,127	2,085	5,212
589 590	- 6,442	- 8,993	-	- 8,993	- 5,996	14,989
590	36,999	105,683		105,683	70,456	176,139
592	2,555	10,503		103,003	7,002	17,504
593	148,143	402,720		402,720	268,480	671,200
594	-	-	-	-	-	
595	-	10,781	-	10,781	7,187	17,969
596		3,739	-	3,739	2,492	6,231
597	20,563	115,817	-	115,817	77,212	193,029
598 599	5,741 6,840	21,659 270,981	-	21,659 270,981	14,439 180,654	36,098 451,635
600	480	480	-	480	320	451,635
000		.00		.50	320	000

	Paid Benefits					Estimate of
Row	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
601	18,359	56,921	-	56,921	37,947	94,868
602	1,333	6,278	-	6,278	4,185	10,463
603	4,015	9,083	-	9,083	6,055	15,138
604	-	-	-	-	-	
605	220	1,268	-	1,268	1,014	2,282
606	-	-	-	-	-	
607	2,700	55,544	-	55,544	44,435	99,979
608 609	359,925 20	372,141	-	372,141	297,713	669,854
610	-	6,513	-	6,513	5,211	11,724
611	5,028	9,545		9,545	7,636	17,181
612	-	-	-	-	-	, -
613	66,153	169,512	-	169,512	135,610	305,121
614	3,929	21,240	-	21,240	16,992	38,231
615	21,488	59,313	-	59,313	47,450	106,763
616	-	-	-	-	-	
617	1 205	- 2 120	-	2 120	1 710	2.040
618 619	1,395 3,284	2,138 6,277	-	2,138 6,277	1,710 5,021	3,848 11,298
620		150	_	150	120	270
621	106,950	157,601	-	157,601	126,081	283,681
622	254	254	-	254	203	457
623	148	271	-	271	217	488
624	8,000	14,303	-	14,303	11,443	25,746
625	6,770	21,622	-	21,622	17,297	38,919
626	24,963	44,970	-	44,970	35,976	80,946
627	12,406	78,091	-	78,091	62,473	140,565
628	3,990	3,990	-	3,990	3,192	7,182
629 630	43,798	61,296		61,296	49,037	110,333
631	215	1,970		1,970	1,970	3,941
632	16,901	17,403	-	17,403	17,403	34,806
633	638	1,027	-	1,027	1,027	2,054
634	-	-	-	-	-	,
635	15,755	99,783	-	99,783	99,783	199,566
636	308	2,419	-	2,419	2,419	4,838
637	15,083	29,710	-	29,710	29,710	59,420
638	3,924	22,509	-	22,509	22,509	45,018
639	202	827	-	827	827	1,654
640 641				-		
642	-	-	-			
643	-	_	_	_		
644	6,736	24,271	-	24,271	32,362	56,633
645	215	991	-	991	1,321	2,312
646	-	-	-	-	-	
647	22,895	28,795	-	28,795	38,393	67,188
648	-	-	-	-	-	
649	245	245	-	245	327	572
650	20,699	32,645		32,645	43,526	76,171
651 652	<del>-</del>	650		650	867	1,517
653	-	-	-	- [	-	
654	5,029	6,068	-	6,068	8,091	14,159
655	2,134	2,608	-	2,608	3,477	6,085
656	148,143	300,479	-	300,479	400,639	701,118
657	-	-	-	-	-	
658	5,623	7,707	-	7,707	10,276	17,983
659	124,904	222,633	-	222,633	296,844	519,477
660	- 0.040	0.704	-	0.70:	-	22
661	8,819	9,794	-	9,794	13,058	22,852
662 663	-	-	-	- [	-	
664	- 8,997	16,995	-	16,995	22,660	39,655
665	-	10,993	-	10,333	22,000	33,033
666	273	3,841	-	3,841	5,121	8,962
667	2,160	2,160	-	2,160	2,880	5,040
668	351	351	-	351	468	819
	-	-	-	-	-	
669	31,005	47,109	-	47,109	62,812	109,921
670						
670 671	-	-	-	-	-	
670 671 672	12,375	12,375	-	12,375	16,500	28,875
670 671	-		-	- 12,375 35,392 14,169	16,500 47,189 18,892	28,875 82,581 33,061

	Paid Benefits					Estimate of
	Current	Cumulative		Incurred	Current	Cumulative Incurred
Row	Quarter	To Date	Medicaid	to Date	Annual Paid	in 12 Months
676	-	-	-	-	-	
677	11,589	11,589	-	11,589	15,452	27,042
678	773	773	-	773	1,031	1,804
679	2,100	2,250	-	2,250	3,000	5,250
680	-	-		-		
681 682	-	-	-	-	-	
683	- 1,980	- 1,980	-	1,980	3,960	5,940
684	1,560	1,560	-	1,500	3,500	3,940
685	595	595	-	595	1,190	1,785
686	253	253	-	253	506	760
687	-	-	_	-	-	
688	3,536	3,536	-	3,536	7,072	10,608
689	-	-	-	-	-	
690	-	-	-	-	-	
691	-	-	-	-	-	
692	350	350	-	350	700	1,050
693	7,898	11,728	-	11,728	23,457	35,185
694	10,780	10,780	-	10,780	21,560	32,340
695	-	-	-	-	-	
696	-	-	-		-	
697	8,176	8,176	-	8,176	16,352	24,528
698	-	-	-	-	-	
699 700	-	-	-	-	-	
						4 220
701 702	1,407	1,407	-	1,407	2,813	4,220
703	-		-	-	-	
704						
705	5,896	5,896		5,896	11,791	17,687
706	1,884	1,884	-	1,884	3,768	5,652
707	876	876		876	1,752	2,628
708	-	-	-	-		,
709	-	-	-	-	-	
710	-	-	-	-	-	
711	-	-	-	-	-	
712	-	-	-	-	-	
713	-	-	-	-	-	
714	-	-	-	-	-	
715	-	-	-	-	-	
716	-	-	-	-	-	
717	-	-	-	-	-	
718	-	-	-	-	-	
719 720	-		-		-	
721						
721	-	-	-		-	
723	*	-	-		-	
724	-	-		-	_	
725	-	-	-	-	-	
726	-	-	-	-	-	
727	-	_	-	-	-	
728	-	-	-	-	-	
729	-	-	-	-	-	
730	-	-	-	-	-	
731	-	-	-	-	-	
MedCare Invoice		5,037,116	-	5,037,116		
Vendor Invoice	1,014,343	9,064,534	-	9,064,534		
UNKNOWN	-	25,232	-	25,232		
Total	13,121,765	184,648,177	322,301	184,970,478		

# New York State Department of Health Quarterly Analysis of New York Medical Indemnity Fund Administrative Expense Summary

Exhibit 8

	<u>Dolla</u>	r Amount	<u>Provider</u>	<u>Basis</u>				
Prior Admin Expenses: (before 9/1/17)	\$	809.00	Alicare	Per member per month (pmpm)				
As of 9/1/17:		666.00 62.00	Alicare PCG	Per member per month (pmpm) Per member per month (pmpm)				
As of 9/1/18:		705.72 64.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)				
As of 9/1/19:		609.28 66.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)				
As of 9/1/20:		569.74 68.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)				
As of 9/1/21:		533.82 70.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)				
Years after 9/1/17								
Year 1:		728.00	Fiscal Year Average	<u>Fiscal Year</u>				
Year 2:		769.72	752.34	2018/19				
Year 3:		675.28	714.63	2019/20				
Year 4:		637.74	653.38	2020/21				
Year 5:		603.82	617.95	2021/22				
Average:		682.91						

Administrative expense details provided by MIF

## **New York State Department of Health** Benefit Payments Per Living Participant by Quarter By Category As of June 30, 2020

							-						our Quarters	Most Recent	
	20	16Q2	2016Q3	2016Q4	2017Q1	<u>2017Q2*</u> <u>2017Q3*</u>		2019Q3	2019Q4	2020Q1	2020Q2	Pri	or to 2017Q2	Four Quarters	% Change
Payments in Quarter	\$ 4,	703,249	\$ 5,435,722	\$ 5,087,847	\$ 5,873,047		\$	10,740,507	\$ 13,159,073	\$ 14,157,518	\$ 13,121,765	\$	21,099,865	\$ 51,178,863	142.6%
Number of Living Participants		400	422	437	455			628	669	697	719				
Average Payments Per Living Participant**	\$	11,758	\$ 12,881	\$ 11,643	\$ 12,908		\$	17,103	\$ 19,670	\$ 20,312	\$ 18,250	\$	12,310	\$ 18,864	53.2%
Average Payments per Participant															
Medical Treatment	\$	628	\$ 760	\$ 562	\$ 646		\$	914	\$ 1,167	\$ 1,105	\$ 635		649	955	47.2%
Hospital Based Care		1,024	898	1,242	1,217			459	613	658	495		1,095	556	-49.2%
Surgical Care		35	108	51	69			188	262	392	211		66	263	301.1%
Nursing Care		6,005	7,036	5,783	5,996			9,171	10,324	10,892	10,142		6,205	10,132	63.3%
Dental Care		24	29	29	21			13	30	22	2		25	17	-34.0%
Rehabilitation Care		725	708	613	613			573	551	621	280		665	506	-23.8%
Custodial Care		546	671	729	685			1,604	1,830	2,026	2,048		658	1,877	185.5%
Durable Med Equip		435	527	430	794			952	1,050	967	855		547	956	75.0%
Other Health Care Costs		31	37	22	20			711	822	788	857		27	795	2798.5%
Home Modification†		989	481	563	800			510	1,238	834	925		708	877	23.8%
Vehicle Modifications†		144	197	52	188			30	46	62	219		145	89	-38.5%
Prescription and Non-Prescriptive Drugs†		1,147	1,357	1,543	1,828			1,797	1,579	1,767	1,448		1,469	1,648	12.2%
Assistive Technology†		1	-	-	-			10	24	6	-		0	10	3043.7%
Other Payments†		25	70	24	31			171	133	171	132		37	152	305.1%

Source: MIF data provided by Alicare/PCG.

<sup>\*</sup>Payments from 2017Q2 and 2017Q3 excluded due to volatility as program changes were implemented

<sup>\*\*</sup>Payments calculated on a per living participant basis, not per participant receiving payments

<sup>†</sup>Categories not affected by Fair Health rates (as provided by MIF administration)